[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUKAMLvrOPsfUCZ5WDLIvuk2yAVynnmxRGq9-1xSStjE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"Children's Oncology Group",[4],443,false,78,111,337299,100,109,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Leukemia",96,{"name":18,"count":19},"Neuroblastoma",37,{"name":21,"count":19},"Sarcoma",{"name":23,"count":24},"Lymphoma",30,{"name":26,"count":27},"Unspecified Childhood Solid Tumor, Protocol Specific",22,{"name":29,"count":30},"Acute Lymphoblastic Leukemia",18,{"name":32,"count":33},"Recurrent Neuroblastoma",15,{"name":35,"count":36},"Brain and Central Nervous System Tumors",14,[38,43,48,52,56,61,66,71,76,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00352534","Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor","2014-12-31","Dactinomycin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT00107198","Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease","2015-10-06","Cyclophosphamide",{"nctId":49,"briefTitle":50,"date":51,"intervention":47},"NCT00379340","Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","2016-06-30",{"nctId":53,"briefTitle":54,"date":55,"intervention":42},"NCT00945009","Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor","2016-12-31",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT00392327","Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma\u002FPNET","2019-06-30","Carboplatin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT02339740","Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","2020-10-31","Arsenic Trioxide",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03057054","Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant","2022-06-30","Lactobacillus plantarum strain 299",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04158739","Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","2022-09-30","Cytarabine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04385277","Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","2023-06-30","Dinutuximab",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT02521493","Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","2024-06-30","Asparaginase",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,1268,1762,2285,2629,2829,3121,3184,3270,3524,3569,3732,3770,3834,3968,4092,4206,4316,4471,4602,4724,4770,4875,4941,5013,5071,5129,5175,5201,5227,5550,5624,5693,5757,5803,5858,5900,5922,5944,5966,6106,6148,6182,6216,6246,6287,6313,6339,6365,6387,6409,6439,6461,6487,6509,6527,6550,6568,6592,6610,6628,6646,6664,6682,6705,6723,6741,6759,6777,6795,6813,6831,6854,6872,6970,7042,7092,7122,7186,7212,7242,7264,7282,7323,7348,7375,7393,7416,7434,7463,7487,7510,7580,7608,7626,7644,7672,7695,7713,7731,7755,7797,7831,7857,7885,7907,7963,7985,8007,8031,8053,8071,8100,8121,8139,8157,8175,8193,8211,8229,8247,8265,8292,8319,8341,8365,8396,8422,8440,8461,8484,8502,8520,8545,8569,8587,8614,8638,8656,8681,8699,8717,8735,8753,8771,8794,8812,8830,8854,8872,8894,8918,8940,8961,8985,9010,9028,9046,9067,9085,9103,9121,9147,9169,9193,9211,9229,9247,9268,9286,9309,9601,9728,9865,9984,10089,10202,10287,10358,10424,10484,10538,10595,10643,10679,10713,10747,10773,10799,10821,10843,10865,10886,10904,10922,10945,10963,10981,10999,11021,11039,11057,11075,11093,11111,11129,11147,11165,11183],{"intervention":95,"totalTrials":11,"cells":96},"cyclophosphamide",{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":241,"PHASE3":599,"PHASE4":1236,"NA":1238},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102,118,142,161,174,187,201,213,230],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":110,"interventions":111},"NCT00002740","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and\u002For Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma","COMPLETED",[88],"2004-03","2005-09","1996-05",[18],[112,113,95,114,115,116,117],"filgrastim","carboplatin","doxorubicin hydrochloride","etoposide","mesna","vincristine sulfate",{"nctId":119,"briefTitle":120,"status":105,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":133},"NCT01175356","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",[88],"2016-09-28","2025-12-31","2011-12-21",99,[127,128,129,130,131,132],"Ganglioneuroblastoma","Localized Resectable Neuroblastoma","Localized Unresectable Neuroblastoma","Regional Neuroblastoma","Stage 4 Neuroblastoma","Stage 4S Neuroblastoma",[134,135,47,136,137,138,139,140,141],"Busulfan","Cisplatin","Doxorubicin Hydrochloride","Etoposide Phosphate","Isotretinoin","Melphalan","Topotecan Hydrochloride","Vincristine Sulfate",{"nctId":143,"briefTitle":144,"status":105,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":153},"NCT00866307","Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)",[88],"2014-06-30","2021-03-31","2009-02-23",104,[29,151,152],"Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia",[47,75,154,155,136,156,157,158,159,160,141],"Daunorubicin Hydrochloride","Dexamethasone","Mercaptopurine","Methotrexate","Pegaspargase","Prednisone","Thioguanine",{"nctId":162,"briefTitle":163,"status":105,"phases":164,"primaryCompletion":165,"start":166,"enrollment":27,"conditions":167,"interventions":172},"NCT01048892","Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features",[88],"2013-06","2009-09",[168,169,170,18,171,21],"Adrenocortical Carcinoma","Gastrointestinal Carcinoid Tumor","Kidney Cancer","Retinoblastoma",[173,95],"Seneca Valley virus-001",{"nctId":175,"briefTitle":176,"status":105,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":184},"NCT01606878","Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",[88],"2018-12-31","2013-04-29",46,[182,183,32],"Childhood Solid Neoplasm","Recurrent Childhood Anaplastic Large Cell Lymphoma",[185,47,186,136,140,141],"Crizotinib","Dexrazoxane Hydrochloride",{"nctId":188,"briefTitle":189,"status":105,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":198},"NCT00003141","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors",[88],"2007-12","2011-10","1998-03",94,[196,197,18,21],"Brain Tumors","Central Nervous System Tumors",[112,113,199,95,115,200,117],"cisplatin","thiotepa",{"nctId":202,"briefTitle":203,"status":105,"phases":204,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":208,"interventions":209},"NCT00003217","Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia",[88],"2004-10","2006-09",20,[15,23],[112,95,210,211,114,212,117],"cytarabine","dexamethasone","methotrexate",{"nctId":214,"briefTitle":215,"status":105,"phases":216,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":220,"interventions":226},"NCT01798004","Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma",[88],"2015-07-28","2013-04-09",150,[127,221,222,223,224,225,131,132],"Stage 1 Neuroblastoma","Stage 2 Neuroblastoma","Stage 2A Neuroblastoma","Stage 2B Neuroblastoma","Stage 3 Neuroblastoma",[134,135,47,136,227,228,139,229,140,141],"Etoposide","Filgrastim","Mesna",{"nctId":231,"briefTitle":232,"status":105,"phases":233,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":236,"interventions":237},"NCT00070200","Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma",[88],"2013-12",31,[18],[112,199,95,114,115,238,239,240,117],"isotretinoin","melphalan","topotecan hydrochloride",{"trials":242,"activeCount":598,"soonestReadout":46},[243,254,267,278,292,306,317,330,348,371,379,390,399,410,420,429,437,450,460,484,497,504,516,528,541,551,569,580,590],{"nctId":244,"briefTitle":245,"status":105,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT00002941","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma",[89],"2002-11","2007-03","1998-04",69,[23],[253,95,115,116],"carmustine",{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT02724579","Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","ACTIVE_NOT_RECRUITING",[89],"2028-03-31","2017-11-17",45,[263],"Medulloblastoma",[135,47,265,266,141],"Lomustine","Vincristine",{"nctId":268,"briefTitle":269,"status":105,"phases":270,"primaryCompletion":271,"completion":248,"start":272,"enrollment":235,"conditions":273,"interventions":276},"NCT00002594","Combination Chemotherapy Followed by Bone Marrow and\u002For Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors",[89],"2003-09","1994-09",[274,275],"Brain Tumor","Central Nervous System Tumor",[277,95,239],"Sargramostim",{"nctId":279,"briefTitle":280,"status":105,"phases":281,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":286},"NCT00003671","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia",[89],"2009-02","1998-12",59,[15],[287,95,210,288,211,289,290,212,291,117],"asparaginase","daunorubicin hydrochloride","leucovorin calcium","mercaptopurine","thioguanine",{"nctId":293,"briefTitle":294,"status":105,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT00066469","Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation",[89],"2009-10-01","2013-12-31","2004-04",55,[301],"Lymphoproliferative Disorder",[303,95,304,305],"rituximab","methylprednisolone","prednisone",{"nctId":307,"briefTitle":308,"status":105,"phases":309,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":313,"interventions":314},"NCT00022126","Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia",[89],"2005-01","2006-04",6,[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],"cyclosporine","pegaspargase",{"nctId":318,"briefTitle":319,"status":320,"phases":321,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":326},"NCT00072280","Surgery and\u002For Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma","TERMINATED",[89],"2008-03","2004-11",7,[21],[327,95,115,328,117,329,228],"dactinomycin","ifosfamide","MESNA",{"nctId":331,"briefTitle":332,"status":333,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":343},"NCT02981628","Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","RECRUITING",[89],"2026-12-31","2017-06-19",80,[339,340,341,342],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent B Lymphoblastic Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B Lymphoblastic Lymphoma",[344,345,47,75,346,347,157,158,266],"Asparaginase Erwinia chrysanthemi","Calaspargase Pegol","Inotuzumab Ozogamicin","Leucovorin Calcium",{"nctId":349,"briefTitle":350,"status":105,"phases":351,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":355,"interventions":369},"NCT00335556","Combination Chemotherapy, Radiation Therapy, and\u002For Surgery in Treating Patients With High-Risk Kidney Tumors",[89],"2015-12","2006-06",291,[356,357,358,359,360,361,362,363,364,365,366,367,368],"Childhood Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma","Clear Cell Sarcoma of the Kidney","Papillary Renal Cell Carcinoma","Rhabdoid Tumor of the Kidney","Stage I Renal Cell Cancer","Stage I Renal Wilms Tumor","Stage II Renal Cell Cancer","Stage II Renal Wilms Tumor","Stage III Renal Cell Cancer","Stage III Renal Wilms Tumor","Stage IV Renal Cell Cancer","Stage IV Renal Wilms Tumor",[136,370,47,227,60,42,141],"Irinotecan Hydrochloride",{"nctId":372,"briefTitle":373,"status":105,"phases":374,"primaryCompletion":205,"completion":248,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT00003846","Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors",[89],"1999-07",25,[35,18],[112,113,95,200,117],{"nctId":380,"briefTitle":381,"status":105,"phases":382,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":385,"interventions":386},"NCT00070174","Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy",[89],"2003-12",350,[15],[287,387,95,315,210,288,115,388,212,389],"busulfan","gemtuzumab ozogamicin","mitoxantrone hydrochloride",{"nctId":391,"briefTitle":392,"status":105,"phases":393,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT00003783","Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia",[89],"1999-03",36,[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],"idarubicin",{"nctId":400,"briefTitle":401,"status":105,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT00002756","Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia",[89],"2007-09","2012-03","1996-06",221,[15],[112,287,95,210,288,115,289,290,212,305,409,117],"therapeutic hydrocortisone",{"nctId":44,"briefTitle":45,"status":257,"phases":411,"primaryCompletion":46,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":419},[89],"2030-12-31","2006-01-02",188,[416,417,418],"Ann Arbor Stage I Childhood Hodgkin Lymphoma","Ann Arbor Stage II Childhood Hodgkin Lymphoma","Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma",[47,136,159,141],{"nctId":421,"briefTitle":422,"status":105,"phases":423,"primaryCompletion":424,"completion":322,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT00003573","Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma",[89],"2007-10","1998-11",53,[196,197],[112,199,95,115,117],{"nctId":430,"briefTitle":431,"status":105,"phases":432,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":435,"interventions":436},"NCT00002590","Combination Chemotherapy in Treating Children With Lymphoma",[89],"2001-03","1994-07",[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":438,"briefTitle":439,"status":105,"phases":440,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":449},"NCT02017964","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma",[89],"2018-03-31","2022-12-31","2013-12-24",26,[446,263,447,448],"Desmoplastic\u002FNodular Medulloblastoma","Medulloblastoma With Extensive Nodularity","Nevoid Basal Cell Carcinoma Syndrome",[60,47,227,157,141],{"nctId":451,"briefTitle":452,"status":105,"phases":453,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":456,"interventions":457},"NCT00061893","Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors",[89],"2008-04",38,[21],[458,95,114,115,328,459,117,329,228],"celecoxib","vinblastine sulfate",{"nctId":461,"briefTitle":462,"status":105,"phases":463,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":481},"NCT00057811","Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma",[89],"2009-10","2014-07","2004-06",97,[469,470,471,472,473,474,475,476,477,478,479,480],"Childhood Burkitt Lymphoma","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Stage I Childhood Large Cell Lymphoma","Stage I Childhood Small Noncleaved Cell Lymphoma","Stage II Childhood Large Cell Lymphoma","Stage II Childhood Small Noncleaved Cell Lymphoma","Stage III Childhood Large Cell Lymphoma","Stage III Childhood Small Noncleaved Cell Lymphoma","Stage IV Childhood Large Cell Lymphoma","Stage IV Childhood Small Noncleaved Cell Lymphoma","Untreated Childhood Acute Lymphoblastic Leukemia",[114,95,212,482,289,305,304,112,303,210,115,117,483],"rasburicase","hydrocortisone sodium succinate",{"nctId":485,"briefTitle":486,"status":105,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT00098839","Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)",[88,89],"2011-04","2005-02",134,[492],"Recurrent Childhood Acute Lymphoblastic Leukemia",[494,114,409,117,495,210,305,316,496,212,115,95,289,112],"L-asparaginase","epratuzumab","dexrazoxane hydrochloride",{"nctId":498,"briefTitle":499,"status":105,"phases":500,"primaryCompletion":424,"completion":404,"start":193,"enrollment":501,"conditions":502,"interventions":503},"NCT00003203","Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors",[89],168,[196,197,18],[112,113,199,95,117],{"nctId":505,"briefTitle":506,"status":105,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":513},"NCT00553202","Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5\u002F5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia",[89],"2016-06","2020-03-31","2008-01",158,[15],[514,387,95,315,212,304,515],"anti-thymocyte globulin","tacrolimus",{"nctId":517,"briefTitle":518,"status":105,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":522,"interventions":524},"NCT01824693","Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia",[89],"2017-12-31","2013-06-24",[523],"Juvenile Myelomonocytic Leukemia",[134,47,525,139,526,527],"Fludarabine Phosphate","Mycophenolate Mofetil","Tacrolimus",{"nctId":529,"briefTitle":530,"status":105,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":535,"interventions":536},"NCT00004010","Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease",[89],"2003-10","2008-06","1999-10",[23],[537,112,538,95,539,114,115,305,540,459,117],"bleomycin sulfate","ABVD regimen","dacarbazine","procarbazine hydrochloride",{"nctId":542,"briefTitle":543,"status":105,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT00027846","Observation or Radiation Therapy and\u002For Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma",[89],"2010-01-01","2016-03-31","2003-08",378,[274,275],[112,113,95,115,117,229],{"nctId":552,"briefTitle":553,"status":333,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":564},"NCT04322318","A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT",[89],"2027-07-01","2020-10-19",256,[559,560,561,562,563],"Anaplastic Kidney Wilms Tumor","Recurrent Kidney Wilms Tumor","Stage II Kidney Wilms Tumor","Stage III Kidney Wilms Tumor","Stage IV Kidney Wilms Tumor",[60,47,565,227,566,567,568,266],"Doxorubicin","Ifosfamide","Irinotecan","Topotecan",{"nctId":570,"briefTitle":571,"status":105,"phases":572,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":577},"NCT00017368","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma",[89],"2012-01","2001-04",42,[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],"sargramostim","etoposide phosphate",{"nctId":581,"briefTitle":582,"status":105,"phases":583,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":586,"interventions":587},"NCT00003955","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma",[89],"1999-09",77,[21],[327,112,588,578,95,589,117],"pegfilgrastim","irinotecan hydrochloride",{"nctId":591,"briefTitle":592,"status":105,"phases":593,"primaryCompletion":594,"completion":248,"start":595,"conditions":596,"interventions":597},"NCT00002785","Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia",[89],"2000-08","1996-07",[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],4,{"trials":600,"activeCount":33,"soonestReadout":51},[601,608,617,626,644,653,667,675,684,699,708,719,729,744,753,764,772,781,798,814,822,832,841,854,868,875,884,899,916,925,936,946,955,963,979,991,999,1008,1025,1034,1042,1049,1056,1068,1081,1090,1098,1111,1122,1139,1148,1157,1168,1177,1189,1198,1207,1215,1223],{"nctId":602,"briefTitle":603,"status":105,"phases":604,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":606,"interventions":607},"NCT00002744","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia",[90],1970,[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":609,"briefTitle":610,"status":105,"phases":611,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":615,"interventions":616},"NCT00006734","Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor",[90],"2006-08","2001-05",587,[21],[112,95,114,115,328,117],{"nctId":618,"briefTitle":619,"status":105,"phases":620,"primaryCompletion":621,"completion":442,"start":622,"enrollment":426,"conditions":623,"interventions":624},"NCT00033293","Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma",[90],"2013-12-10","2004-03-15",[128,129,130,131,132],[47,159,625],"Therapeutic Immune Globulin",{"nctId":627,"briefTitle":628,"status":257,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":642},"NCT04994132","A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma",[90],"2026-06-30","2021-09-14",118,[634,635,636,637,638,639,640,641],"Alveolar Rhabdomyosarcoma","Botryoid-Type Embryonal Rhabdomyosarcoma","Embryonal Rhabdomyosarcoma","Metastatic Embryonal Rhabdomyosarcoma","Metastatic Rhabdomyosarcoma","Solid Alveolar Rhabdomyosarcoma","Spindle Cell Rhabdomyosarcoma","Spindle Cell\u002FSclerosing Rhabdomyosarcoma",[47,42,141,643],"Vinorelbine Tartrate",{"nctId":645,"briefTitle":646,"status":647,"phases":648,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":651,"interventions":652},"NCT00334867","Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma","WITHDRAWN",[90],"2006-01","2005-12",[21],[95,496,114,115,328,240,117],{"nctId":654,"briefTitle":655,"status":105,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":666},"NCT00075582","Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma",[90],"2012-08-13","2021-09-30","2004-09-04",390,[662,663,664,665],"Adult Rhabdomyosarcoma","Embryonal Childhood Rhabdomyosarcoma","Embryonal-botryoid Childhood Rhabdomyosarcoma","Previously Untreated Childhood Rhabdomyosarcoma",[327,95,117],{"nctId":668,"briefTitle":669,"status":105,"phases":670,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":673,"interventions":674},"NCT00004188","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma",[90],"2001-02",495,[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":676,"briefTitle":677,"status":105,"phases":678,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT00002611","Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer",[90],"2002-06","1995-07",3031,[170],[327,112,95,114,115,117],{"nctId":685,"briefTitle":686,"status":105,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":696},"NCT01026220","Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma",[90],"2012-03-01","2022-03-31","2009-12-07",166,[693,694,695],"Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage IV Childhood Hodgkin Lymphoma",[537,114,697,698,95,579,305,112,328],"liposomal vincristine sulfate","vinorelbine tartrate",{"nctId":700,"briefTitle":701,"status":105,"phases":702,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT00002757","TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma",[90],"2001-06",1148,[15,23],[112,95,210,114,115,212,707,305,409,117],"prednisolone",{"nctId":709,"briefTitle":710,"status":333,"phases":711,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT06647953","Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma",[90],"2029-03-31","2025-03-21",110,[716],"Pleuropulmonary Blastoma",[47,42,718,565,566,568,266],"Dexrazoxane",{"nctId":720,"briefTitle":721,"status":105,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT00004228","Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma",[90],"2008-08","2015-03-31","2000-06",393,[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":730,"briefTitle":731,"status":105,"phases":732,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":735,"interventions":743},"NCT00003958","Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma",[90],"2002-09",702,[736,662,737,738,663,664,739,665,740,741,742],"Adult Malignant Mesenchymoma","Alveolar Childhood Rhabdomyosarcoma","Childhood Malignant Mesenchymoma","Nonmetastatic Childhood Soft Tissue Sarcoma","Stage I Adult Soft Tissue Sarcoma","Stage II Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma",[327,117,95,240,112,578],{"nctId":745,"briefTitle":746,"status":105,"phases":747,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":750,"interventions":752},"NCT00005578","Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease",[90],"1997-03",219,[751,23],"Cardiac Toxicity",[537,112,95,496,114,115,305,117],{"nctId":754,"briefTitle":755,"status":756,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":763},"NCT07466316","A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","NOT_YET_RECRUITING",[90],"2031-03-31","2026-06-22",342,[762],"Rhabdomyosarcoma",[47,42,370,141,643],{"nctId":765,"briefTitle":766,"status":105,"phases":767,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":770,"interventions":771},"NCT00005945","Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia",[90],"2007-11",3054,[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":773,"briefTitle":774,"status":105,"phases":775,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":780},"NCT00499616","Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma",[90],"2021-06-30","2007-10-08",464,[18],[113,95,114,115,240,138,228],{"nctId":782,"briefTitle":783,"status":257,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":792},"NCT03007147","Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[90],"2027-09-30","2017-08-08",475,[29,789,790,791],"B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia",[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],"Imatinib Mesylate","Levoleucovorin","Methylprednisolone","Prednisolone","Therapeutic Hydrocortisone",{"nctId":799,"briefTitle":800,"status":105,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":813},"NCT01096368","Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma",[90],"2021-12-31","2026-03-31","2010-05-07",479,[807,808,809,810,811,812],"Anaplastic Ependymoma","Brain Ependymoma","Cellular Ependymoma","Clear Cell Ependymoma","Ependymoma","Papillary Ependymoma",[60,135,47,227,228,229,266],{"nctId":49,"briefTitle":50,"status":257,"phases":815,"primaryCompletion":51,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":820},[90],"2026-11-18","2007-04-30",395,[562,563],[47,42,136,227,821],"Vincristine Sulfate Liposome",{"nctId":823,"briefTitle":824,"status":333,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT05304585","Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma",[90],"2030-06-30","2022-08-04",205,[636,830,641],"Fusion-Negative Alveolar Rhabdomyosarcoma",[47,42,266],{"nctId":833,"briefTitle":834,"status":105,"phases":835,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":838,"interventions":839},"NCT00671034","Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia",[90],"2011-02-01","2008-07-21",[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],"Calaspargase Pegol-mknl",{"nctId":842,"briefTitle":843,"status":105,"phases":844,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":852},"NCT00336024","Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma",[90],"2025-09-30","2007-10-22",91,[849,263,850,851],"Anaplastic Medulloblastoma","Supratentorial Embryonal Tumor, Not Otherwise Specified","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor",[60,135,47,227,228,347,157,853,141],"Thiotepa",{"nctId":855,"briefTitle":856,"status":105,"phases":857,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":860,"interventions":866},"NCT00025259","Chemotherapy With or Without Additional Chemotherapy and\u002For Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease",[90],"2012-08",1734,[861,862,693,863,864,865,694,695],"Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma","Childhood Mixed Cellularity Classical Hodgkin Lymphoma","Childhood Nodular Sclerosis Classical Hodgkin Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage II Childhood Hodgkin Lymphoma",[867,135,47,75,155,136,227,228,159,821],"Bleomycin Sulfate",{"nctId":57,"briefTitle":58,"status":257,"phases":869,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":874},[90],"2028-06-30","2007-05-23",379,[849,263],[60,135,47,228,138,141],{"nctId":876,"briefTitle":877,"status":105,"phases":878,"primaryCompletion":403,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT00006461","Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor",[90],"2000-10",82,[882,851],"Untreated Childhood Medulloblastoma",[199,95,117,115],{"nctId":885,"briefTitle":886,"status":105,"phases":887,"primaryCompletion":41,"completion":442,"start":888,"enrollment":889,"conditions":890,"interventions":898},"NCT00354835","Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma",[90],"2006-12-26",481,[662,891,892,893,894,762,21,895,896,897],"Childhood Alveolar Rhabdomyosarcoma","Childhood Botryoid-Type Embryonal Rhabdomyosarcoma","Childhood Embryonal Rhabdomyosarcoma","Localized Childhood Soft Tissue Sarcoma","Stage I Adult Soft Tissue Sarcoma AJCC v7","Stage II Adult Soft Tissue Sarcoma AJCC v7","Stage III Adult Soft Tissue Sarcoma AJCC v7",[47,42,370,141],{"nctId":900,"briefTitle":901,"status":257,"phases":902,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":914},"NCT06820957","Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body",[89,90],"2027-12-31","2025-11-10",437,[907,908,909,910,911,912,913],"CIC-Rearranged Sarcoma","Metastatic Ewing Sarcoma","Metastatic High Grade Sarcoma","Metastatic Undifferentiated Round Cell Sarcoma","Metastatic Undifferentiated Sarcoma, Not Otherwise Specified","Round Cell Sarcoma With EWSR1-non-ETS Fusion","Sarcoma With BCOR Genetic Alterations",[47,136,227,566,370,915,141],"Regorafenib",{"nctId":917,"briefTitle":918,"status":105,"phases":919,"primaryCompletion":546,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":924},"NCT00085735","Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma",[90],"2024-12-31","2004-04-30",549,[263],[135,47,265,141],{"nctId":926,"briefTitle":927,"status":105,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT00653068","Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid\u002FRhabdoid Tumor of the Central Nervous System",[90],"2016-09-27","2024-03-31","2009-02-10",70,[934],"Childhood Atypical Teratoid\u002FRhabdoid Tumor",[60,135,47,227,228,347,157,853,141],{"nctId":937,"briefTitle":938,"status":105,"phases":939,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT00554788","Combination Chemotherapy, Autologous Stem Cell Transplant, and\u002For Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma",[90],"2018-06-30","2008-05-06",60,[944],"Extraocular Retinoblastoma",[60,135,47,227,228,853,141],{"nctId":947,"briefTitle":948,"status":105,"phases":949,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":953,"interventions":954},"NCT00103285","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[90],"2013-12-30","2005-04-11",5377,[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":958,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":961,"interventions":962},"NCT00005977","Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia",[90],"2000-09",83,[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":964,"briefTitle":965,"status":105,"phases":966,"primaryCompletion":967,"completion":968,"start":248,"enrollment":969,"conditions":970,"interventions":977},"NCT00382109","Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission",[90],"2011-05","2017-06-30",146,[971,972,973,974,975,976],"B-cell Childhood Acute Lymphoblastic Leukemia","Childhood Acute Lymphoblastic Leukemia in Remission","Graft Versus Host Disease","L1 Childhood Acute Lymphoblastic Leukemia","L2 Childhood Acute Lymphoblastic Leukemia","T-cell Childhood Acute Lymphoblastic Leukemia",[200,95,515,212,978],"sirolimus",{"nctId":980,"briefTitle":981,"status":105,"phases":982,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":985,"interventions":990},"NCT00302003","Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma",[90],"2006-02",287,[986,987,988,989,864,865],"Childhood Favorable Prognosis Hodgkin Lymphoma","Childhood Lymphocyte Depletion Hodgkin Lymphoma","Childhood Mixed Cellularity Hodgkin Lymphoma","Childhood Nodular Sclerosis Hodgkin Lymphoma",[114,117,305,95,328,698,211,579,199,210,112],{"nctId":992,"briefTitle":993,"status":105,"phases":994,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":997,"interventions":998},"NCT00002610","Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors",[90],"1996-01",203,[170],[327,112,113,95,114,115,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":1002,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1007},"NCT00005585","Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia",[90],"2007-07","2000-04",838,[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1020},"NCT07072585","Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)",[89,90],"2035-09-01","2026-06-28",1708,[1016,1017,1018,791,1019],"Stage II T Lymphoblastic Leukemia\u002FLymphoma","Stage III T Lymphoblastic Leukemia\u002FLymphoma","Stage IV T Lymphoblastic Leukemia\u002FLymphoma","T Lymphoblastic Lymphoma",[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],"Bortezomib","Daratumumab","Mercaptopurine Oral Suspension","Nelarabine",{"nctId":1026,"briefTitle":1027,"status":105,"phases":1028,"primaryCompletion":206,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT00002995","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma",[90],"2011-01","1997-08",483,[21],[327,112,578,95,117],{"nctId":1035,"briefTitle":1036,"status":105,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":1040,"interventions":1041},"NCT00003119","Surgery in Treating Children With Neuroblastoma",[90],"2006-03",968,[18],[112,578,113,95,114,115],{"nctId":1043,"briefTitle":603,"status":105,"phases":1044,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":1047,"interventions":1048},"NCT00005596",[90],"2005-07",1076,[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":1051,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT00005603",[90],"2000-03",276,[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1057,"briefTitle":1058,"status":333,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT03126916","Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)",[90],"2030-09-30","2018-05-14",750,[127,1064,18],"Ganglioneuroblastoma, Nodular",[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],"Lorlatinib","Melphalan Hydrochloride",{"nctId":1069,"briefTitle":1070,"status":333,"phases":1071,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1080},"NCT06401330","A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)",[90],"2031-02-13","2025-04-15",1656,[1076,1077,1078,1079],"Stage I Mixed Cell Type Kidney Wilms Tumor","Stage II Mixed Cell Type Kidney Wilms Tumor","Stage III Mixed Cell Type Kidney Wilms Tumor","Stage IV Mixed Cell Type Kidney Wilms Tumor",[60,47,42,565,227,567,266],{"nctId":1082,"briefTitle":1083,"status":105,"phases":1084,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT00381680","Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia",[90],"2016-03",275,[971,974,975,1088],"Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia",[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":1093,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1097},"NCT00002812","Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia",[90],"1996-09",2078,[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":1101,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1109},"NCT03959085","Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",[90],"2032-03-31","2019-10-31",5951,[789,1106,1107,790,1108],"B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Testicular Leukemia",[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],"Blinatumomab",{"nctId":1112,"briefTitle":1113,"status":333,"phases":1114,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1120},"NCT05382338","A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss",[90],"2029-12-31","2023-02-20",225,[1119],"Childhood Medulloblastoma",[135,47,265,1121,266],"Sodium Thiosulfate",{"nctId":1123,"briefTitle":1124,"status":105,"phases":1125,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1138},"NCT01190930","Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma",[90],"2019-03-31","2010-08-11",9350,[29,1130,1131,1132,152,1133,1134,1135,1136,1137],"Adult B Lymphoblastic Lymphoma","Ann Arbor Stage I B Lymphoblastic Lymphoma","Ann Arbor Stage II B Lymphoblastic Lymphoma","Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Childhood B Lymphoblastic Lymphoma","Down Syndrome","Hypodiploid B Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive",[47,75,155,136,347,156,157,158,160,141],{"nctId":1140,"briefTitle":1141,"status":105,"phases":1142,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1146},"NCT00002875","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma",[90],"1996-12",421,[196,197],[112,199,95,1147,116,117],"lomustine",{"nctId":1149,"briefTitle":1150,"status":257,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT02176967","Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma",[90],"2026-09-30","2014-08-08",621,[127,128,129,18],[60,47,136,227],{"nctId":1158,"briefTitle":1159,"status":105,"phases":1160,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1167},"NCT01231906","Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma",[90],"2010-11-24",642,[1164,1165,1166],"Localized Extraskeletal Ewing Sarcoma","Peripheral Primitive Neuroectodermal Tumor of Bone","Peripheral Primitive Neuroectodermal Tumor of Soft Tissues",[47,718,136,227,566,140,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":1171,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1176},"NCT00075725","Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia",[90],"2010-12-31","2003-12-29",3154,[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":1180,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1187},"NCT00557193","Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[90],"2017-09-30","2008-01-15",218,[29,1185,1186],"Acute Undifferentiated Leukemia","Childhood T Acute Lymphoblastic Leukemia",[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],"Lestaurtinib",{"nctId":1190,"briefTitle":1191,"status":105,"phases":1192,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT00567567","Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma",[90],"2015-02-27","2007-11-05",665,[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":1199,"briefTitle":1200,"status":105,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT00085098","Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor",[90],"2009-05","2007-01",24,[274,275],[112,113,199,95,115],{"nctId":1208,"briefTitle":1209,"status":105,"phases":1210,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1214},"NCT00003093","Combination Chemotherapy in Treating Children With Neuroblastoma",[90],"1988-03",573,[18],[112,578,113,95,114,115],{"nctId":1216,"briefTitle":1217,"status":105,"phases":1218,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":1221,"interventions":1222},"NCT00354744","High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma",[90],"2010-01","2006-07",[21],[327,95,114,115,328,589,117,112],{"nctId":1224,"briefTitle":1225,"status":257,"phases":1226,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1232},"NCT05457556","Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome",[90],"2023-03-15",435,[29,1230,790,1231],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[134,47,1233,1234,139,157,526,1235,527,853],"Fludarabine","Lapine T-Lymphocyte Immune Globulin","Rituximab",{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":99},[1240,1251,1261],{"nctId":1241,"briefTitle":1242,"status":105,"phases":1243,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1250},"NCT00066482","Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors",[92],"2007-04","2004-07",19,[1248,1249],"Childhood Germ Cell Tumor","Extragonadal Germ Cell Tumor",[537,112,199,95,115,329],{"nctId":1252,"briefTitle":1253,"status":105,"phases":1254,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":1257,"interventions":1260},"NCT00618813","Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors",[92],"2010-03",35,[1258,1259],"Ewing Sarcoma of Bone","Localized Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor",[115,328,114,95,117,240,112],{"nctId":1262,"briefTitle":1263,"status":105,"phases":1264,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":1266,"interventions":1267},"NCT00096135","Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes",[92],"2013-09",[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"intervention":117,"totalTrials":1269,"cells":1270},93,{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1335,"PHASE3":1450,"PHASE4":1726,"NA":1728},{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":99},[1275,1282,1286,1292,1296,1300,1309,1313,1317,1321,1325,1331],{"nctId":1276,"briefTitle":1277,"status":105,"phases":1278,"primaryCompletion":310,"completion":108,"start":1279,"enrollment":207,"conditions":1280,"interventions":1281},"NCT00006095","Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy",[88],"2000-07",[26],[589,117],{"nctId":103,"briefTitle":104,"status":105,"phases":1283,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":1284,"interventions":1285},[88],[18],[112,113,95,114,115,116,117],{"nctId":1287,"briefTitle":1288,"status":105,"phases":1289,"primaryCompletion":532,"completion":248,"start":584,"enrollment":235,"conditions":1290,"interventions":1291},"NCT00003935","Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma",[88],[196,197],[115,117],{"nctId":119,"briefTitle":120,"status":105,"phases":1293,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":1294,"interventions":1295},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":143,"briefTitle":144,"status":105,"phases":1297,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":1298,"interventions":1299},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":1301,"briefTitle":1302,"status":105,"phases":1303,"primaryCompletion":1304,"completion":1029,"start":1305,"enrollment":575,"conditions":1306,"interventions":1307},"NCT00138216","Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors",[88],"2009-06","2005-10",[35,26],[589,1308,117],"temozolomide",{"nctId":175,"briefTitle":176,"status":105,"phases":1310,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":1311,"interventions":1312},[88],[182,183,32],[185,47,186,136,140,141],{"nctId":188,"briefTitle":189,"status":105,"phases":1314,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":1315,"interventions":1316},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"nctId":202,"briefTitle":203,"status":105,"phases":1318,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":1319,"interventions":1320},[88],[15,23],[112,95,210,211,114,212,117],{"nctId":214,"briefTitle":215,"status":105,"phases":1322,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":1323,"interventions":1324},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":1326,"briefTitle":1327,"status":105,"phases":1328,"primaryCompletion":671,"completion":311,"start":283,"enrollment":324,"conditions":1329,"interventions":1330},"NCT00003625","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma",[88],[196,197],[315,115,117],{"nctId":231,"briefTitle":232,"status":105,"phases":1332,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":1333,"interventions":1334},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":1336,"activeCount":1449,"soonestReadout":46},[1337,1358,1362,1366,1370,1374,1378,1382,1386,1390,1394,1398,1402,1406,1410,1414,1418,1422,1426,1433,1437,1441,1445],{"nctId":1338,"briefTitle":1339,"status":257,"phases":1340,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":1342,"interventions":1355},"NCT05761171","A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia",[89],"2024-01-08",[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],"Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia",[345,75,525,1356,157,796,159,1357,141],"Hydrocortisone Sodium Succinate","Revumenib",{"nctId":255,"briefTitle":256,"status":257,"phases":1359,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":1360,"interventions":1361},[89],[263],[135,47,265,266,141],{"nctId":279,"briefTitle":280,"status":105,"phases":1363,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":1364,"interventions":1365},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":1367,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":1368,"interventions":1369},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":318,"briefTitle":319,"status":320,"phases":1371,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":1372,"interventions":1373},[89],[21],[327,95,115,328,117,329,228],{"nctId":349,"briefTitle":350,"status":105,"phases":1375,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":1376,"interventions":1377},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":372,"briefTitle":373,"status":105,"phases":1379,"primaryCompletion":205,"completion":248,"start":375,"enrollment":376,"conditions":1380,"interventions":1381},[89],[35,18],[112,113,95,200,117],{"nctId":391,"briefTitle":392,"status":105,"phases":1383,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":1384,"interventions":1385},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":1387,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":1388,"interventions":1389},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":44,"briefTitle":45,"status":257,"phases":1391,"primaryCompletion":46,"completion":412,"start":413,"enrollment":414,"conditions":1392,"interventions":1393},[89],[416,417,418],[47,136,159,141],{"nctId":421,"briefTitle":422,"status":105,"phases":1395,"primaryCompletion":424,"completion":322,"start":425,"enrollment":426,"conditions":1396,"interventions":1397},[89],[196,197],[112,199,95,115,117],{"nctId":430,"briefTitle":431,"status":105,"phases":1399,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":1400,"interventions":1401},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":438,"briefTitle":439,"status":105,"phases":1403,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1404,"interventions":1405},[89],[446,263,447,448],[60,47,227,157,141],{"nctId":451,"briefTitle":452,"status":105,"phases":1407,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":1408,"interventions":1409},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":461,"briefTitle":462,"status":105,"phases":1411,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":1412,"interventions":1413},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":1415,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":1416,"interventions":1417},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":498,"briefTitle":499,"status":105,"phases":1419,"primaryCompletion":424,"completion":404,"start":193,"enrollment":501,"conditions":1420,"interventions":1421},[89],[196,197,18],[112,113,199,95,117],{"nctId":529,"briefTitle":530,"status":105,"phases":1423,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":1424,"interventions":1425},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":1427,"briefTitle":1428,"status":105,"phases":1429,"primaryCompletion":725,"completion":311,"start":1094,"enrollment":1430,"conditions":1431,"interventions":1432},"NCT00002804","Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma",[89],43,[21],[112,114,328,116,117],{"nctId":542,"briefTitle":543,"status":105,"phases":1434,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":1435,"interventions":1436},[89],[274,275],[112,113,95,115,117,229],{"nctId":570,"briefTitle":571,"status":105,"phases":1438,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":1439,"interventions":1440},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"nctId":581,"briefTitle":582,"status":105,"phases":1442,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":1443,"interventions":1444},[89],[21],[327,112,588,578,95,589,117],{"nctId":591,"briefTitle":592,"status":105,"phases":1446,"primaryCompletion":594,"completion":248,"start":595,"conditions":1447,"interventions":1448},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],3,{"trials":1451,"activeCount":1725,"soonestReadout":41},[1452,1456,1460,1464,1468,1472,1476,1480,1484,1488,1492,1496,1500,1504,1508,1515,1527,1534,1538,1542,1546,1550,1554,1564,1568,1572,1576,1580,1584,1588,1592,1596,1604,1608,1612,1616,1625,1629,1633,1640,1644,1648,1652,1669,1673,1677,1685,1689,1693,1697,1701,1712,1716],{"nctId":602,"briefTitle":603,"status":105,"phases":1453,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":1454,"interventions":1455},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":609,"briefTitle":610,"status":105,"phases":1457,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":1458,"interventions":1459},[90],[21],[112,95,114,115,328,117],{"nctId":627,"briefTitle":628,"status":257,"phases":1461,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":1462,"interventions":1463},[90],[634,635,636,637,638,639,640,641],[47,42,141,643],{"nctId":645,"briefTitle":646,"status":647,"phases":1465,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":1466,"interventions":1467},[90],[21],[95,496,114,115,328,240,117],{"nctId":654,"briefTitle":655,"status":105,"phases":1469,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":1470,"interventions":1471},[90],[662,663,664,665],[327,95,117],{"nctId":668,"briefTitle":669,"status":105,"phases":1473,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":1474,"interventions":1475},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":676,"briefTitle":677,"status":105,"phases":1477,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":1478,"interventions":1479},[90],[170],[327,112,95,114,115,117],{"nctId":700,"briefTitle":701,"status":105,"phases":1481,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":1482,"interventions":1483},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":720,"briefTitle":721,"status":105,"phases":1485,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":1486,"interventions":1487},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":730,"briefTitle":731,"status":105,"phases":1489,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":1490,"interventions":1491},[90],[736,662,737,738,663,664,739,665,740,741,742],[327,117,95,240,112,578],{"nctId":745,"briefTitle":746,"status":105,"phases":1493,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":1494,"interventions":1495},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":754,"briefTitle":755,"status":756,"phases":1497,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":1498,"interventions":1499},[90],[762],[47,42,370,141,643],{"nctId":765,"briefTitle":766,"status":105,"phases":1501,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":1502,"interventions":1503},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":1505,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":1506,"interventions":1507},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":1511,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":1513,"interventions":1514},"NCT01230983","Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma",[90],"2001-09",[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1516,"briefTitle":1517,"status":105,"phases":1518,"primaryCompletion":424,"start":394,"enrollment":1519,"conditions":1520,"interventions":1524},"NCT00003994","Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer",[90],277,[1521,1522,1523],"Childhood Hepatoblastoma","Recurrent Childhood Liver Cancer","Stage I Childhood Liver Cancer",[199,117,1525,1526,113],"fluorouracil","amifostine trihydrate",{"nctId":1528,"briefTitle":1529,"status":105,"phases":1530,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":1532,"interventions":1533},"NCT00002816","Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia",[90],120,[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":1535,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":1536,"interventions":1537},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":842,"briefTitle":843,"status":105,"phases":1539,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":1540,"interventions":1541},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":57,"briefTitle":58,"status":257,"phases":1543,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":1544,"interventions":1545},[90],[849,263],[60,135,47,228,138,141],{"nctId":876,"briefTitle":877,"status":105,"phases":1547,"primaryCompletion":403,"start":879,"enrollment":880,"conditions":1548,"interventions":1549},[90],[882,851],[199,95,117,115],{"nctId":885,"briefTitle":886,"status":105,"phases":1551,"primaryCompletion":41,"completion":442,"start":888,"enrollment":889,"conditions":1552,"interventions":1553},[90],[662,891,892,893,894,762,21,895,896,897],[47,42,370,141],{"nctId":1555,"briefTitle":1556,"status":105,"phases":1557,"primaryCompletion":545,"completion":1558,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1563},"NCT00079417","Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma",[90],"2017-03-31","2005-12-26",28,[1562],"Intraocular Retinoblastoma",[60,141],{"nctId":900,"briefTitle":901,"status":257,"phases":1565,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":1566,"interventions":1567},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"nctId":917,"briefTitle":918,"status":105,"phases":1569,"primaryCompletion":546,"completion":920,"start":921,"enrollment":922,"conditions":1570,"interventions":1571},[90],[263],[135,47,265,141],{"nctId":926,"briefTitle":927,"status":105,"phases":1573,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":1574,"interventions":1575},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":937,"briefTitle":938,"status":105,"phases":1577,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":1578,"interventions":1579},[90],[944],[60,135,47,227,228,853,141],{"nctId":947,"briefTitle":948,"status":105,"phases":1581,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":1582,"interventions":1583},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":1585,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":1586,"interventions":1587},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":980,"briefTitle":981,"status":105,"phases":1589,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":1590,"interventions":1591},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":992,"briefTitle":993,"status":105,"phases":1593,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":1594,"interventions":1595},[90],[170],[327,112,113,95,114,115,117],{"nctId":1597,"briefTitle":1598,"status":105,"phases":1599,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1603},"NCT00002618","Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma",[90],"1994-12",242,[23],[112,210,114,289,290,212,305,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":1605,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":1606,"interventions":1607},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":1609,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1610,"interventions":1611},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1026,"briefTitle":1027,"status":105,"phases":1613,"primaryCompletion":206,"completion":1029,"start":1030,"enrollment":1031,"conditions":1614,"interventions":1615},[90],[21],[327,112,578,95,117],{"nctId":1617,"briefTitle":1618,"status":105,"phases":1619,"primaryCompletion":983,"completion":1620,"start":1621,"enrollment":1622,"conditions":1623,"interventions":1624},"NCT00002944","Combination Chemotherapy in Treating Children With Progressive Brain Tumors",[90],"2012-04","1997-04",428,[196,197],[113,1147,540,291,117],{"nctId":1043,"briefTitle":603,"status":105,"phases":1626,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":1627,"interventions":1628},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":1630,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":1631,"interventions":1632},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":39,"briefTitle":40,"status":257,"phases":1634,"primaryCompletion":41,"completion":803,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1639},[90],"2006-11-06",808,[1638,561,562],"Stage I Kidney Wilms Tumor",[42,136,141],{"nctId":1057,"briefTitle":1058,"status":333,"phases":1641,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1642,"interventions":1643},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1082,"briefTitle":1083,"status":105,"phases":1645,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":1646,"interventions":1647},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":1649,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":1650,"interventions":1651},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1653,"briefTitle":1654,"status":257,"phases":1655,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":1658,"interventions":1664},"NCT03533582","Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery",[90],"2018-05-24",537,[1659,1660,1661,1662,1663],"Childhood Hepatocellular Carcinoma","Childhood Malignant Liver Neoplasm","Fibrolamellar Carcinoma","Hepatoblastoma","Hepatocellular Malignant Neoplasm, Not Otherwise Specified",[60,135,565,227,1665,1666,567,1667,1668,141],"Fluorouracil","Gemcitabine","Oxaliplatin","Sorafenib",{"nctId":1099,"briefTitle":1100,"status":333,"phases":1670,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1671,"interventions":1672},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":1674,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":1675,"interventions":1676},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1678,"briefTitle":1679,"status":105,"phases":1680,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1684},"NCT00002827","Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease",[90],"1996-10",294,[751,23],[537,112,496,114,115,117],{"nctId":1140,"briefTitle":1141,"status":105,"phases":1686,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":1687,"interventions":1688},[90],[196,197],[112,199,95,1147,116,117],{"nctId":1158,"briefTitle":1159,"status":105,"phases":1690,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":1691,"interventions":1692},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":1694,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":1695,"interventions":1696},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":1698,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":1699,"interventions":1700},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":53,"briefTitle":54,"status":257,"phases":1702,"primaryCompletion":55,"start":1703,"enrollment":1704,"conditions":1705,"interventions":1711},[90],"2009-07-13",249,[1706,1707,1708,1709,360,1638,561,562,563,1710],"Adult Kidney Wilms Tumor","Beckwith-Wiedemann Syndrome","Childhood Kidney Wilms Tumor","Diffuse Hyperplastic Perilobar Nephroblastomatosis","Stage V Kidney Wilms Tumor",[42,136,141],{"nctId":1216,"briefTitle":1217,"status":105,"phases":1713,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":1714,"interventions":1715},[90],[21],[327,95,114,115,328,589,117,112],{"nctId":1717,"briefTitle":1718,"status":105,"phases":1719,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":1723,"interventions":1724},"NCT00059839","Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma",[90],"2009-12","2003-11",129,[23],[114,290,212,305,459,117],11,{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730,1738,1742,1746,1755],{"nctId":1731,"briefTitle":1732,"status":647,"phases":1733,"primaryCompletion":1734,"start":1735,"enrollment":99,"conditions":1736,"interventions":1737},"NCT00900445","Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia",[],"2009-08-17","2008-03-24",[29,480],[154,796,159,141],{"nctId":1252,"briefTitle":1253,"status":105,"phases":1739,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":1740,"interventions":1741},[92],[1258,1259],[115,328,114,95,117,240,112],{"nctId":1262,"briefTitle":1263,"status":105,"phases":1743,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":1744,"interventions":1745},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":1747,"briefTitle":1748,"status":105,"phases":1749,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":1752,"interventions":1753},"NCT01225874","Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL",[92],"1999-12",3762,[15],[1754,210,288,211,212,316,305,117],"SC-PEG E. coli L-asparaginase",{"nctId":1756,"briefTitle":1757,"status":105,"phases":1758,"primaryCompletion":1255,"completion":234,"start":1245,"enrollment":1759,"conditions":1760,"interventions":1761},"NCT00077207","Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and\u002For Symptomatic Low-Grade Glioma",[92],66,[274,275],[113,1308,117],{"intervention":115,"totalTrials":1763,"cells":1764},79,{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1810,"PHASE3":1961,"PHASE4":2269,"NA":2271},{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[1769,1773,1780,1784,1794,1798,1802,1806],{"nctId":103,"briefTitle":104,"status":105,"phases":1770,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":1771,"interventions":1772},[88],[18],[112,113,95,114,115,116,117],{"nctId":1774,"briefTitle":1775,"status":105,"phases":1776,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":1777,"interventions":1778},"NCT00742924","Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma",[88],[21],[199,496,114,115,328,289,212,1779,112,229],"zoledronic acid",{"nctId":1287,"briefTitle":1288,"status":105,"phases":1781,"primaryCompletion":532,"completion":248,"start":584,"enrollment":235,"conditions":1782,"interventions":1783},[88],[196,197],[115,117],{"nctId":1785,"briefTitle":1786,"status":105,"phases":1787,"primaryCompletion":205,"completion":108,"start":425,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT00003597","Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors",[88],16,[1790],"Cancer",[1792,113,115,328,1793],"recombinant human thrombopoietin","G-CSF",{"nctId":188,"briefTitle":189,"status":105,"phases":1795,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":1796,"interventions":1797},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"nctId":214,"briefTitle":215,"status":105,"phases":1799,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":1800,"interventions":1801},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":1326,"briefTitle":1327,"status":105,"phases":1803,"primaryCompletion":671,"completion":311,"start":283,"enrollment":324,"conditions":1804,"interventions":1805},[88],[196,197],[315,115,117],{"nctId":231,"briefTitle":232,"status":105,"phases":1807,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":1808,"interventions":1809},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":1811,"activeCount":598,"soonestReadout":555},[1812,1816,1823,1831,1835,1839,1843,1847,1851,1855,1859,1870,1874,1878,1882,1886,1890,1909,1918,1922,1937,1941,1953,1957],{"nctId":244,"briefTitle":245,"status":105,"phases":1813,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":1814,"interventions":1815},[89],[23],[253,95,115,116],{"nctId":1817,"briefTitle":1818,"status":105,"phases":1819,"primaryCompletion":282,"completion":282,"start":1820,"enrollment":149,"conditions":1821,"interventions":1822},"NCT00047320","Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors",[89],"2004-01",[274,197,1248],[113,115,328,200],{"nctId":1824,"briefTitle":1825,"status":105,"phases":1826,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":1828,"interventions":1829},"NCT00002805","Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[89],115,[15],[112,1830,210,115,212,389,409],"cladribine",{"nctId":318,"briefTitle":319,"status":320,"phases":1832,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":1833,"interventions":1834},[89],[21],[327,95,115,328,117,329,228],{"nctId":349,"briefTitle":350,"status":105,"phases":1836,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":1837,"interventions":1838},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":380,"briefTitle":381,"status":105,"phases":1840,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":1841,"interventions":1842},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":391,"briefTitle":392,"status":105,"phases":1844,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":1845,"interventions":1846},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":1848,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":1849,"interventions":1850},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":421,"briefTitle":422,"status":105,"phases":1852,"primaryCompletion":424,"completion":322,"start":425,"enrollment":426,"conditions":1853,"interventions":1854},[89],[196,197],[112,199,95,115,117],{"nctId":430,"briefTitle":431,"status":105,"phases":1856,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":1857,"interventions":1858},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":1860,"briefTitle":1861,"status":105,"phases":1862,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1869},"NCT01602666","Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors",[89],"2024-09-30","2012-06-27",262,[1867,1868],"Central Nervous System Nongerminomatous Germ Cell Tumor","Childhood Germinoma",[60,227,566],{"nctId":438,"briefTitle":439,"status":105,"phases":1871,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":1872,"interventions":1873},[89],[446,263,447,448],[60,47,227,157,141],{"nctId":451,"briefTitle":452,"status":105,"phases":1875,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":1876,"interventions":1877},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":461,"briefTitle":462,"status":105,"phases":1879,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":1880,"interventions":1881},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":1883,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":1884,"interventions":1885},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":529,"briefTitle":530,"status":105,"phases":1887,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":1888,"interventions":1889},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":1891,"briefTitle":1892,"status":333,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1897,"interventions":1907},"NCT04684368","A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT",[89],"2029-12-21","2021-07-13",160,[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],"Choriocarcinoma","Embryonal Carcinoma","Immature Teratoma","Malignant Teratoma","Mixed Germ Cell Tumor","Pineal Region Germ Cell Tumor","Pineal Region Immature Teratoma","Pineal Region Yolk Sac Tumor","Suprasellar Germ Cell Tumor",[60,227,228,566,229,1908,853],"Pegfilgrastim",{"nctId":1910,"briefTitle":1911,"status":105,"phases":1912,"primaryCompletion":205,"completion":403,"start":1004,"enrollment":1913,"conditions":1914,"interventions":1917},"NCT00003811","Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors",[89],27,[1248,1915,1249,1916],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Ovarian Cancer",[537,1526,199,115],{"nctId":542,"briefTitle":543,"status":105,"phases":1919,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":1920,"interventions":1921},[89],[274,275],[112,113,95,115,117,229],{"nctId":1923,"briefTitle":1924,"status":333,"phases":1925,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":1928,"conditions":1929,"interventions":1936},"NCT06368817","A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma",[89],"2033-11-04","2024-10-22",240,[1930,1931,1932,1933,1934,1935],"Basal Ganglia Germinoma","Diabetes Insipidus","Germinoma","Pineal Region Germinoma","Suprasellar Germinoma","Thalamic Germinoma",[60,227],{"nctId":552,"briefTitle":553,"status":333,"phases":1938,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":1939,"interventions":1940},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"nctId":1942,"briefTitle":1943,"status":333,"phases":1944,"primaryCompletion":259,"completion":259,"start":1945,"enrollment":444,"conditions":1946,"interventions":1952},"NCT05504291","A Study to Give Treatment Inside the Eye to Treat Retinoblastoma",[89],"2022-11-04",[1947,1948,1949,1950,1951],"Bilateral Retinoblastoma","Childhood Intraocular Retinoblastoma","Group D Retinoblastoma","Stage I Retinoblastoma","Unilateral Retinoblastoma",[60,227,139,266],{"nctId":570,"briefTitle":571,"status":105,"phases":1954,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":1955,"interventions":1956},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"nctId":591,"briefTitle":592,"status":105,"phases":1958,"primaryCompletion":594,"completion":248,"start":595,"conditions":1959,"interventions":1960},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":1962,"activeCount":2268,"soonestReadout":51},[1963,2002,2006,2015,2019,2023,2027,2040,2044,2056,2063,2067,2071,2075,2079,2083,2087,2091,2095,2099,2103,2112,2138,2142,2164,2172,2176,2180,2184,2193,2197,2201,2205,2209,2217,2221,2233,2237,2241,2245,2249,2256,2260,2264],{"nctId":1964,"briefTitle":1965,"status":333,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":1970,"interventions":2001},"NCT03067181","Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors",[90],"2027-06-30","2017-05-25",1780,[1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000],"Childhood Extracranial Germ Cell Tumor","Extragonadal Embryonal Carcinoma","Germ Cell Tumor","Malignant Germ Cell Tumor","Malignant Ovarian Teratoma","Stage I Ovarian Choriocarcinoma","Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage I Testicular Choriocarcinoma AJCC v6 and v7","Stage I Testicular Embryonal Carcinoma AJCC v6 and v7","Stage I Testicular Seminoma AJCC v6 and v7","Stage I Testicular Yolk Sac Tumor AJCC v6 and v7","Stage II Ovarian Choriocarcinoma","Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage II Testicular Choriocarcinoma AJCC v6 and v7","Stage II Testicular Embryonal Carcinoma AJCC v6 and v7","Stage II Testicular Yolk Sac Tumor AJCC v6 and v7","Stage III Ovarian Choriocarcinoma","Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage III Testicular Choriocarcinoma AJCC v6 and v7","Stage III Testicular Embryonal Carcinoma AJCC v6 and v7","Stage III Testicular Yolk Sac Tumor AJCC v6 and v7","Stage IV Ovarian Choriocarcinoma","Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7","Testicular Mixed Choriocarcinoma and Embryonal Carcinoma","Testicular Mixed Choriocarcinoma and Teratoma","Testicular Mixed Choriocarcinoma and Yolk Sac Tumor",[867,60,135,227],{"nctId":609,"briefTitle":610,"status":105,"phases":2003,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":2004,"interventions":2005},[90],[21],[112,95,114,115,328,117],{"nctId":82,"briefTitle":83,"status":257,"phases":2007,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":2010,"interventions":2013},[90],"2015-12-23",280,[1230,1135,1231,2011,2012],"Myeloid Leukemia Associated With Down Syndrome","Myeloproliferative Neoplasm",[85,344,75,154,227,2014,160],"Mitoxantrone Hydrochloride",{"nctId":645,"briefTitle":646,"status":647,"phases":2016,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":2017,"interventions":2018},[90],[21],[95,496,114,115,328,240,117],{"nctId":668,"briefTitle":669,"status":105,"phases":2020,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":2021,"interventions":2022},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":676,"briefTitle":677,"status":105,"phases":2024,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":2025,"interventions":2026},[90],[170],[327,112,95,114,115,117],{"nctId":2028,"briefTitle":2029,"status":105,"phases":2030,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":2033,"interventions":2038},"NCT00304070","Cisplatin-Based Chemotherapy and\u002For Surgery in Treating Young Patients With Adrenocortical Tumor",[90],"2015-12-31","2007-05-03",[2034,2035,2036,2037],"Stage I Adrenal Cortical Carcinoma AJCC v7","Stage II Adrenal Cortical Carcinoma AJCC v7","Stage III Adrenal Cortical Carcinoma AJCC v7","Stage IV Adrenal Cortical Carcinoma AJCC v7",[135,136,227,228,2039,1908],"Mitotane",{"nctId":700,"briefTitle":701,"status":105,"phases":2041,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":2042,"interventions":2043},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":2045,"briefTitle":2046,"status":105,"phases":2047,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":2051,"interventions":2054},"NCT00134030","Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma",[90],"2015-01-31","2005-11-14",1334,[2052,2053],"Localized Osteosarcoma","Metastatic Osteosarcoma",[135,136,227,566,157,2055],"Peginterferon Alfa-2b",{"nctId":2057,"briefTitle":2058,"status":105,"phases":2059,"primaryCompletion":206,"completion":206,"start":205,"enrollment":2060,"conditions":2061,"interventions":2062},"NCT00078988","High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas",[90],1,[274,275],[112,113,115,238,200],{"nctId":745,"briefTitle":746,"status":105,"phases":2064,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":2065,"interventions":2066},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":773,"briefTitle":774,"status":105,"phases":2068,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":2069,"interventions":2070},[90],[18],[113,95,114,115,240,138,228],{"nctId":782,"briefTitle":783,"status":257,"phases":2072,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":2073,"interventions":2074},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":799,"briefTitle":800,"status":105,"phases":2076,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":2077,"interventions":2078},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":49,"briefTitle":50,"status":257,"phases":2080,"primaryCompletion":51,"completion":816,"start":817,"enrollment":818,"conditions":2081,"interventions":2082},[90],[562,563],[47,42,136,227,821],{"nctId":1528,"briefTitle":1529,"status":105,"phases":2084,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":2085,"interventions":2086},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":842,"briefTitle":843,"status":105,"phases":2088,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":2089,"interventions":2090},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":855,"briefTitle":856,"status":105,"phases":2092,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":2093,"interventions":2094},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":876,"briefTitle":877,"status":105,"phases":2096,"primaryCompletion":403,"start":879,"enrollment":880,"conditions":2097,"interventions":2098},[90],[882,851],[199,95,117,115],{"nctId":900,"briefTitle":901,"status":257,"phases":2100,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":2101,"interventions":2102},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"nctId":2104,"briefTitle":2105,"status":105,"phases":2106,"primaryCompletion":2107,"completion":2108,"start":650,"enrollment":2109,"conditions":2110,"interventions":2111},"NCT00335738","Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma",[90],"2011-09","2020-09-30",331,[1562],[697,113,115],{"nctId":2113,"briefTitle":2114,"status":105,"phases":2115,"primaryCompletion":2116,"completion":776,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2137},"NCT00053352","Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors",[90],"2013-10-01","2003-11-03",302,[2120,1971,2121,2122,2123,2124,2125,2126,2127,2128,2129,2130,2131,2132,2133,2134,2135,2136],"Childhood Embryonal Tumor","Childhood Extragonadal Germ Cell Tumor","Childhood Malignant Ovarian Germ Cell Tumor","Childhood Malignant Testicular Germ Cell Tumor","Childhood Teratoma","Ovarian Embryonal Carcinoma","Ovarian Yolk Sac Tumor","Stage II Malignant Testicular Germ Cell Tumor","Stage IIA Ovarian Germ Cell Tumor","Stage IIB Ovarian Germ Cell Tumor","Stage IIC Ovarian Germ Cell Tumor","Stage III Malignant Testicular Germ Cell Tumor","Stage IIIA Ovarian Germ Cell Tumor","Stage IIIB Ovarian Germ Cell Tumor","Stage IIIC Ovarian Germ Cell Tumor","Testicular Choriocarcinoma and Yolk Sac Tumor","Testicular Embryonal Carcinoma",[199,115,537],{"nctId":926,"briefTitle":927,"status":105,"phases":2139,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":2140,"interventions":2141},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":2143,"briefTitle":2144,"status":105,"phases":2145,"primaryCompletion":2146,"completion":802,"start":248,"enrollment":828,"conditions":2147,"interventions":2163},"NCT00369317","Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes",[90],"2013-12-01",[2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162],"Childhood Acute Basophilic Leukemia","Childhood Acute Eosinophilic Leukemia","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Childhood Myelodysplastic Syndromes","de Novo Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies",[287,288,210,291,115],{"nctId":2165,"briefTitle":2166,"status":105,"phases":2167,"primaryCompletion":2168,"completion":776,"start":2169,"enrollment":24,"conditions":2170,"interventions":2171},"NCT00072384","Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma",[90],"2013-02-01","2007-04-16",[1562],[697,113,115,112],{"nctId":937,"briefTitle":938,"status":105,"phases":2173,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":2174,"interventions":2175},[90],[944],[60,135,47,227,228,853,141],{"nctId":956,"briefTitle":957,"status":105,"phases":2177,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":2178,"interventions":2179},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":992,"briefTitle":993,"status":105,"phases":2181,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":2182,"interventions":2183},[90],[170],[327,112,113,95,114,115,117],{"nctId":2185,"briefTitle":2186,"status":105,"phases":2187,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":2189,"interventions":2190},"NCT00070187","Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma",[89,90],"2005-06",[23],[2191,112,2192,253,315,210,115,239],"aldesleukin","recombinant interferon gamma",{"nctId":1035,"briefTitle":1036,"status":105,"phases":2194,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":2195,"interventions":2196},[90],[18],[112,578,113,95,114,115],{"nctId":1069,"briefTitle":1070,"status":333,"phases":2198,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":2199,"interventions":2200},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":1082,"briefTitle":1083,"status":105,"phases":2202,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":2203,"interventions":2204},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1653,"briefTitle":1654,"status":257,"phases":2206,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":2207,"interventions":2208},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"nctId":2210,"briefTitle":2211,"status":105,"phases":2212,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":2215,"interventions":2216},"NCT00372593","Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia",[90],"2013-08",1070,[15],[287,210,288,115,388,389],{"nctId":1678,"briefTitle":1679,"status":105,"phases":2218,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":2219,"interventions":2220},[90],[751,23],[537,112,496,114,115,117],{"nctId":2222,"briefTitle":2223,"status":333,"phases":2224,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":2228,"interventions":2229},"NCT04293562","A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and\u002For Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations",[90],"2029-06-30","2020-07-21",1186,[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],"Gemtuzumab Ozogamicin","Gilteritinib Fumarate","Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":1149,"briefTitle":1150,"status":257,"phases":2234,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":2235,"interventions":2236},[90],[127,128,129,18],[60,47,136,227],{"nctId":1158,"briefTitle":1159,"status":105,"phases":2238,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":2239,"interventions":2240},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":2242,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":2243,"interventions":2244},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":2246,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":2247,"interventions":2248},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":2250,"briefTitle":2251,"status":105,"phases":2252,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT00003937","Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma",[90],253,[751,21],[199,496,114,115,328,212],{"nctId":1199,"briefTitle":1200,"status":105,"phases":2257,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":2258,"interventions":2259},[90],[274,275],[112,113,199,95,115],{"nctId":1208,"briefTitle":1209,"status":105,"phases":2261,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":2262,"interventions":2263},[90],[18],[112,578,113,95,114,115],{"nctId":1216,"briefTitle":1217,"status":105,"phases":2265,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":2266,"interventions":2267},[90],[21],[327,95,114,115,328,589,117,112],9,{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[2273,2277,2281],{"nctId":1241,"briefTitle":1242,"status":105,"phases":2274,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":2275,"interventions":2276},[92],[1248,1249],[537,112,199,95,115,329],{"nctId":1252,"briefTitle":1253,"status":105,"phases":2278,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":2279,"interventions":2280},[92],[1258,1259],[115,328,114,95,117,240,112],{"nctId":1262,"briefTitle":1263,"status":105,"phases":2282,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":2283,"interventions":2284},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"intervention":210,"totalTrials":942,"cells":2286},{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2366,"PHASE3":2459,"PHASE4":2617,"NA":2619},{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":2365,"soonestReadout":74},[2291,2302,2311,2328,2332,2339,2353,2361],{"nctId":2292,"briefTitle":2293,"status":647,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":99,"conditions":2297,"interventions":2301},"NCT07498465","A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia",[88],"2028-11-12","2026-09-10",[29,1230,2298,2299,2300,790],"Childhood Acute Lymphoblastic Leukemia","Childhood Acute Myeloid Leukemia","Childhood Mixed Phenotype Acute Leukemia",[75,157,1357,797],{"nctId":2303,"briefTitle":2304,"status":105,"phases":2305,"primaryCompletion":206,"completion":404,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT00028899","Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes",[88],"2002-07",47,[15,2309],"Myelodysplastic Syndromes",[287,210,388,389],{"nctId":2312,"briefTitle":2313,"status":105,"phases":2314,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":2318,"interventions":2325},"NCT03792256","Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)",[88],"2023-09-30","2019-04-11",12,[2319,2320,2321,2322,2323,2324],"Leukemia, Lymphocytic","Lymphoblastic Lymphoma","T-cell Lymphoma","T-cell Leukemia","Recurrent Disease","Acute Leukemia",[2326,75,157,2327,565,796,266,158,2327,159],"Palbociclib","Hydrocortisone",{"nctId":143,"briefTitle":144,"status":105,"phases":2329,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":2330,"interventions":2331},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":2333,"briefTitle":2334,"status":105,"phases":2335,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":2337,"interventions":2338},"NCT00004056","Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia",[88],"2002-10",[15],[112,287,210,288,239,291],{"nctId":2340,"briefTitle":2341,"status":333,"phases":2342,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":2344,"interventions":2351},"NCT06247787","A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy",[88],"2025-02-04",[2345,2346,2347,2348,2349,2350],"Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Myelodysplastic Syndrome","Recurrent Juvenile Myelomonocytic Leukemia","Refractory Childhood Acute Myeloid Leukemia","Refractory Childhood Myelodysplastic Syndrome","Refractory Juvenile Myelomonocytic Leukemia",[75,1233,1356,2352,347,157],"Imetelstat",{"nctId":72,"briefTitle":73,"status":257,"phases":2354,"primaryCompletion":74,"completion":803,"start":2355,"enrollment":1788,"conditions":2356,"interventions":2359},[88],"2020-01-22",[2357,2358],"Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[75,2360],"Flotetuzumab",{"nctId":202,"briefTitle":203,"status":105,"phases":2362,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":2363,"interventions":2364},[88],[15,23],[112,95,210,211,114,212,117],2,{"trials":2367,"activeCount":2365,"soonestReadout":335},[2368,2372,2376,2380,2384,2388,2396,2404,2408,2412,2416,2427,2431,2439,2443,2447,2455],{"nctId":1338,"briefTitle":1339,"status":257,"phases":2369,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":2370,"interventions":2371},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":279,"briefTitle":280,"status":105,"phases":2373,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":2374,"interventions":2375},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":2377,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":2378,"interventions":2379},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":1824,"briefTitle":1825,"status":105,"phases":2381,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":2382,"interventions":2383},[89],[15],[112,1830,210,115,212,389,409],{"nctId":331,"briefTitle":332,"status":333,"phases":2385,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":2386,"interventions":2387},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"nctId":2389,"briefTitle":2390,"status":105,"phases":2391,"primaryCompletion":1255,"completion":1255,"start":2392,"enrollment":36,"conditions":2393,"interventions":2394},"NCT00469859","Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88,89],"2007-06",[15],[210,398,2395],"lestaurtinib",{"nctId":2397,"briefTitle":2398,"status":105,"phases":2399,"primaryCompletion":178,"completion":79,"start":2400,"enrollment":455,"conditions":2401,"interventions":2403},"NCT02642965","Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88,89],"2016-05-02",[2402,2345,2160],"Acute Myeloid Leukemia Post Cytotoxic Therapy",[75,228,525,2232],{"nctId":380,"briefTitle":381,"status":105,"phases":2405,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":2406,"interventions":2407},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":391,"briefTitle":392,"status":105,"phases":2409,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":2410,"interventions":2411},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":2413,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":2414,"interventions":2415},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":2417,"briefTitle":2418,"status":647,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":2422,"interventions":2425},"NCT05320380","A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat",[88,89],"2023-09-01","2023-08-01",[2357,339,1348,2423,2358,341,1354,2424],"Recurrent T Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia",[2426,75,525,1356,2232,157,796],"Anti-CD123 ADC IMGN632",{"nctId":430,"briefTitle":431,"status":105,"phases":2428,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":2429,"interventions":2430},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":2432,"briefTitle":2433,"status":105,"phases":2434,"primaryCompletion":858,"completion":858,"start":248,"enrollment":2435,"conditions":2436,"interventions":2437},"NCT00372619","Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[88,89],74,[15],[2438,210,212],"clofarabine",{"nctId":461,"briefTitle":462,"status":105,"phases":2440,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":2441,"interventions":2442},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":2444,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":2445,"interventions":2446},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":2448,"briefTitle":2449,"status":105,"phases":2450,"primaryCompletion":723,"completion":234,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2454},"NCT00470275","Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma",[89],"2007-05",10,[21],[210],{"nctId":591,"briefTitle":592,"status":105,"phases":2456,"primaryCompletion":594,"completion":248,"start":595,"conditions":2457,"interventions":2458},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":2460,"activeCount":324,"soonestReadout":64},[2461,2465,2473,2479,2483,2494,2498,2502,2506,2510,2514,2518,2522,2526,2530,2534,2538,2542,2546,2550,2554,2558,2562,2566,2570,2574,2584,2588,2592,2596,2600,2604,2608],{"nctId":602,"briefTitle":603,"status":105,"phases":2462,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":2463,"interventions":2464},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":62,"briefTitle":63,"status":257,"phases":2466,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":2468,"interventions":2470},[90],"2015-07-21",[2469],"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA",[65,75,155,2471,2014,2472],"Idarubicin","Tretinoin",{"nctId":2474,"briefTitle":2475,"status":647,"phases":2476,"primaryCompletion":768,"completion":768,"start":1038,"enrollment":99,"conditions":2477,"interventions":2478},"NCT00411281","Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder",[90],[15],[210],{"nctId":82,"briefTitle":83,"status":257,"phases":2480,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":2481,"interventions":2482},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":2484,"briefTitle":2485,"status":105,"phases":2486,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":2490,"interventions":2493},"NCT00866918","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia",[90],"2015-06-30","2009-03-09",106,[2491,2492],"Childhood Acute Promyelocytic Leukemia With PML-RARA","Myeloid Neoplasm",[65,75,2471,156,157,2014,2472],{"nctId":700,"briefTitle":701,"status":105,"phases":2495,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":2496,"interventions":2497},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":720,"briefTitle":721,"status":105,"phases":2499,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":2500,"interventions":2501},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":2503,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":2504,"interventions":2505},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":2507,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":2508,"interventions":2509},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":2511,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":2512,"interventions":2513},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1528,"briefTitle":1529,"status":105,"phases":2515,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":2516,"interventions":2517},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":2519,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":2520,"interventions":2521},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":855,"briefTitle":856,"status":105,"phases":2523,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":2524,"interventions":2525},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":2143,"briefTitle":2144,"status":105,"phases":2527,"primaryCompletion":2146,"completion":802,"start":248,"enrollment":828,"conditions":2528,"interventions":2529},[90],[2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162],[287,288,210,291,115],{"nctId":947,"briefTitle":948,"status":105,"phases":2531,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":2532,"interventions":2533},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":2535,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":2536,"interventions":2537},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":980,"briefTitle":981,"status":105,"phases":2539,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":2540,"interventions":2541},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":1597,"briefTitle":1598,"status":105,"phases":2543,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":2544,"interventions":2545},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":2547,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":2548,"interventions":2549},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":2551,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":2552,"interventions":2553},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":2185,"briefTitle":2186,"status":105,"phases":2555,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":2556,"interventions":2557},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"nctId":1043,"briefTitle":603,"status":105,"phases":2559,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":2560,"interventions":2561},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":2563,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":2564,"interventions":2565},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":2567,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":2568,"interventions":2569},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":2571,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":2572,"interventions":2573},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":2575,"briefTitle":2576,"status":333,"phases":2577,"primaryCompletion":2578,"completion":2579,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT07022678","Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia",[90],"2032-01-15","2033-01-15","2026-05-26",556,[1230,2357],[75],{"nctId":1099,"briefTitle":1100,"status":333,"phases":2585,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":2586,"interventions":2587},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":2210,"briefTitle":2211,"status":105,"phases":2589,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":2590,"interventions":2591},[90],[15],[287,210,288,115,388,389],{"nctId":1123,"briefTitle":1124,"status":105,"phases":2593,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":2594,"interventions":2595},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":2222,"briefTitle":2223,"status":333,"phases":2597,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":2598,"interventions":2599},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"nctId":1169,"briefTitle":1170,"status":105,"phases":2601,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":2602,"interventions":2603},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":2605,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":2606,"interventions":2607},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":2609,"briefTitle":2610,"status":105,"phases":2611,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2616},"NCT00003593","Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome",[90],"1999-06",254,[15,2309,2615],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[287,210,288,212,409,291],{"trials":2618,"activeCount":99},[],{"trials":2620,"activeCount":99},[2621,2625],{"nctId":1262,"briefTitle":1263,"status":105,"phases":2622,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":2623,"interventions":2624},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":1747,"briefTitle":1748,"status":105,"phases":2626,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":2627,"interventions":2628},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":113,"totalTrials":575,"cells":2630},{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2662,"PHASE3":2727,"PHASE4":2821,"NA":2823},{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[2635,2639,2647,2651,2658],{"nctId":103,"briefTitle":104,"status":105,"phases":2636,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":2637,"interventions":2638},[88],[18],[112,113,95,114,115,116,117],{"nctId":2640,"briefTitle":2641,"status":105,"phases":2642,"primaryCompletion":310,"completion":108,"start":671,"enrollment":2643,"conditions":2644,"interventions":2645},"NCT00005602","Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas",[88],13,[35],[113,2646],"cereport",{"nctId":1785,"briefTitle":1786,"status":105,"phases":2648,"primaryCompletion":205,"completion":108,"start":425,"enrollment":1788,"conditions":2649,"interventions":2650},[88],[1790],[1792,113,115,328,1793],{"nctId":2652,"briefTitle":2653,"status":105,"phases":2654,"primaryCompletion":2107,"completion":404,"start":353,"enrollment":444,"conditions":2655,"interventions":2657},"NCT00352495","Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma",[88],[35,2656],"Neurofibromatosis Type 1",[113,459],{"nctId":188,"briefTitle":189,"status":105,"phases":2659,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":2660,"interventions":2661},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"trials":2663,"activeCount":598,"soonestReadout":555},[2664,2679,2683,2687,2691,2695,2699,2703,2707,2711,2715,2719,2723],{"nctId":2665,"briefTitle":2666,"status":105,"phases":2667,"primaryCompletion":688,"completion":940,"start":1194,"enrollment":207,"conditions":2668,"interventions":2677},"NCT00467051","Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors",[89],[1971,2669,2122,2123,2670,2125,2126,2671,2672,2673,2674,2136,1998,2000,2675,2676],"Childhood Extragonadal Malignant Germ Cell Tumor","Ovarian Choriocarcinoma","Recurrent Childhood Malignant Germ Cell Tumor","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Ovarian Germ Cell Tumor","Testicular Choriocarcinoma","Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor","Testicular Yolk Sac Tumor",[60,228,566,2678],"Paclitaxel",{"nctId":1817,"briefTitle":1818,"status":105,"phases":2680,"primaryCompletion":282,"completion":282,"start":1820,"enrollment":149,"conditions":2681,"interventions":2682},[89],[274,197,1248],[113,115,328,200],{"nctId":349,"briefTitle":350,"status":105,"phases":2684,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":2685,"interventions":2686},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":372,"briefTitle":373,"status":105,"phases":2688,"primaryCompletion":205,"completion":248,"start":375,"enrollment":376,"conditions":2689,"interventions":2690},[89],[35,18],[112,113,95,200,117],{"nctId":1860,"briefTitle":1861,"status":105,"phases":2692,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":1865,"conditions":2693,"interventions":2694},[89],[1867,1868],[60,227,566],{"nctId":438,"briefTitle":439,"status":105,"phases":2696,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":2697,"interventions":2698},[89],[446,263,447,448],[60,47,227,157,141],{"nctId":498,"briefTitle":499,"status":105,"phases":2700,"primaryCompletion":424,"completion":404,"start":193,"enrollment":501,"conditions":2701,"interventions":2702},[89],[196,197,18],[112,113,199,95,117],{"nctId":1891,"briefTitle":1892,"status":333,"phases":2704,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":2705,"interventions":2706},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":542,"briefTitle":543,"status":105,"phases":2708,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":2709,"interventions":2710},[89],[274,275],[112,113,95,115,117,229],{"nctId":1923,"briefTitle":1924,"status":333,"phases":2712,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":1928,"conditions":2713,"interventions":2714},[89],[1930,1931,1932,1933,1934,1935],[60,227],{"nctId":552,"briefTitle":553,"status":333,"phases":2716,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":2717,"interventions":2718},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"nctId":1942,"briefTitle":1943,"status":333,"phases":2720,"primaryCompletion":259,"completion":259,"start":1945,"enrollment":444,"conditions":2721,"interventions":2722},[89],[1947,1948,1949,1950,1951],[60,227,139,266],{"nctId":570,"briefTitle":571,"status":105,"phases":2724,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":2725,"interventions":2726},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":2728,"activeCount":312,"soonestReadout":59},[2729,2733,2737,2741,2745,2749,2753,2757,2761,2765,2769,2773,2777,2781,2785,2789,2793,2797,2801,2805,2809,2813,2817],{"nctId":1964,"briefTitle":1965,"status":333,"phases":2730,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":2731,"interventions":2732},[90],[1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000],[867,60,135,227],{"nctId":668,"briefTitle":669,"status":105,"phases":2734,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":2735,"interventions":2736},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":2057,"briefTitle":2058,"status":105,"phases":2738,"primaryCompletion":206,"completion":206,"start":205,"enrollment":2060,"conditions":2739,"interventions":2740},[90],[274,275],[112,113,115,238,200],{"nctId":773,"briefTitle":774,"status":105,"phases":2742,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":2743,"interventions":2744},[90],[18],[113,95,114,115,240,138,228],{"nctId":1516,"briefTitle":1517,"status":105,"phases":2746,"primaryCompletion":424,"start":394,"enrollment":1519,"conditions":2747,"interventions":2748},[90],[1521,1522,1523],[199,117,1525,1526,113],{"nctId":799,"briefTitle":800,"status":105,"phases":2750,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":2751,"interventions":2752},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":842,"briefTitle":843,"status":105,"phases":2754,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":2755,"interventions":2756},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":57,"briefTitle":58,"status":257,"phases":2758,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":2759,"interventions":2760},[90],[849,263],[60,135,47,228,138,141],{"nctId":1555,"briefTitle":1556,"status":105,"phases":2762,"primaryCompletion":545,"completion":1558,"start":1559,"enrollment":1560,"conditions":2763,"interventions":2764},[90],[1562],[60,141],{"nctId":2104,"briefTitle":2105,"status":105,"phases":2766,"primaryCompletion":2107,"completion":2108,"start":650,"enrollment":2109,"conditions":2767,"interventions":2768},[90],[1562],[697,113,115],{"nctId":926,"briefTitle":927,"status":105,"phases":2770,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":2771,"interventions":2772},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":2165,"briefTitle":2166,"status":105,"phases":2774,"primaryCompletion":2168,"completion":776,"start":2169,"enrollment":24,"conditions":2775,"interventions":2776},[90],[1562],[697,113,115,112],{"nctId":937,"briefTitle":938,"status":105,"phases":2778,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":2779,"interventions":2780},[90],[944],[60,135,47,227,228,853,141],{"nctId":992,"briefTitle":993,"status":105,"phases":2782,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":2783,"interventions":2784},[90],[170],[327,112,113,95,114,115,117],{"nctId":1035,"briefTitle":1036,"status":105,"phases":2786,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":2787,"interventions":2788},[90],[18],[112,578,113,95,114,115],{"nctId":1617,"briefTitle":1618,"status":105,"phases":2790,"primaryCompletion":983,"completion":1620,"start":1621,"enrollment":1622,"conditions":2791,"interventions":2792},[90],[196,197],[113,1147,540,291,117],{"nctId":1057,"briefTitle":1058,"status":333,"phases":2794,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":2795,"interventions":2796},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1069,"briefTitle":1070,"status":333,"phases":2798,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":2799,"interventions":2800},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":1653,"briefTitle":1654,"status":257,"phases":2802,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":2803,"interventions":2804},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"nctId":1149,"briefTitle":1150,"status":257,"phases":2806,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":2807,"interventions":2808},[90],[127,128,129,18],[60,47,136,227],{"nctId":1190,"briefTitle":1191,"status":105,"phases":2810,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":2811,"interventions":2812},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":1199,"briefTitle":1200,"status":105,"phases":2814,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":2815,"interventions":2816},[90],[274,275],[112,113,199,95,115],{"nctId":1208,"briefTitle":1209,"status":105,"phases":2818,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":2819,"interventions":2820},[90],[18],[112,578,113,95,114,115],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[2825],{"nctId":1756,"briefTitle":1757,"status":105,"phases":2826,"primaryCompletion":1255,"completion":234,"start":1245,"enrollment":1759,"conditions":2827,"interventions":2828},[92],[274,275],[113,1308,117],{"intervention":114,"totalTrials":2830,"cells":2831},62,{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2868,"PHASE3":2910,"PHASE4":3113,"NA":3115},{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[2836,2840,2844,2848,2852,2856,2860,2864],{"nctId":103,"briefTitle":104,"status":105,"phases":2837,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":2838,"interventions":2839},[88],[18],[112,113,95,114,115,116,117],{"nctId":1774,"briefTitle":1775,"status":105,"phases":2841,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":2842,"interventions":2843},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":119,"briefTitle":120,"status":105,"phases":2845,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":2846,"interventions":2847},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":143,"briefTitle":144,"status":105,"phases":2849,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":2850,"interventions":2851},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":175,"briefTitle":176,"status":105,"phases":2853,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":2854,"interventions":2855},[88],[182,183,32],[185,47,186,136,140,141],{"nctId":202,"briefTitle":203,"status":105,"phases":2857,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":2858,"interventions":2859},[88],[15,23],[112,95,210,211,114,212,117],{"nctId":214,"briefTitle":215,"status":105,"phases":2861,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":2862,"interventions":2863},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":2865,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":2866,"interventions":2867},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":2869,"activeCount":2060,"soonestReadout":46},[2870,2874,2878,2882,2886,2890,2894,2898,2902,2906],{"nctId":307,"briefTitle":308,"status":105,"phases":2871,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":2872,"interventions":2873},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":349,"briefTitle":350,"status":105,"phases":2875,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":2876,"interventions":2877},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":44,"briefTitle":45,"status":257,"phases":2879,"primaryCompletion":46,"completion":412,"start":413,"enrollment":414,"conditions":2880,"interventions":2881},[89],[416,417,418],[47,136,159,141],{"nctId":430,"briefTitle":431,"status":105,"phases":2883,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":2884,"interventions":2885},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":451,"briefTitle":452,"status":105,"phases":2887,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":2888,"interventions":2889},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":461,"briefTitle":462,"status":105,"phases":2891,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":2892,"interventions":2893},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":2895,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":2896,"interventions":2897},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":529,"briefTitle":530,"status":105,"phases":2899,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":2900,"interventions":2901},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":1427,"briefTitle":1428,"status":105,"phases":2903,"primaryCompletion":725,"completion":311,"start":1094,"enrollment":1430,"conditions":2904,"interventions":2905},[89],[21],[112,114,328,116,117],{"nctId":570,"briefTitle":571,"status":105,"phases":2907,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":2908,"interventions":2909},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":2911,"activeCount":3112,"soonestReadout":41},[2912,2916,2920,2924,2928,2932,2936,2940,2944,2948,2952,2956,2960,2964,2968,2972,2976,2980,2984,2988,2992,2996,3000,3004,3008,3012,3044,3048,3052,3056,3060,3064,3068,3072,3076,3080,3084,3088,3092,3096,3100,3104,3108],{"nctId":602,"briefTitle":603,"status":105,"phases":2913,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":2914,"interventions":2915},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":609,"briefTitle":610,"status":105,"phases":2917,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":2918,"interventions":2919},[90],[21],[112,95,114,115,328,117],{"nctId":645,"briefTitle":646,"status":647,"phases":2921,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":2922,"interventions":2923},[90],[21],[95,496,114,115,328,240,117],{"nctId":668,"briefTitle":669,"status":105,"phases":2925,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":2926,"interventions":2927},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":676,"briefTitle":677,"status":105,"phases":2929,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":2930,"interventions":2931},[90],[170],[327,112,95,114,115,117],{"nctId":685,"briefTitle":686,"status":105,"phases":2933,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":2934,"interventions":2935},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":2028,"briefTitle":2029,"status":105,"phases":2937,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":2938,"interventions":2939},[90],[2034,2035,2036,2037],[135,136,227,228,2039,1908],{"nctId":700,"briefTitle":701,"status":105,"phases":2941,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":2942,"interventions":2943},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":2045,"briefTitle":2046,"status":105,"phases":2945,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":2946,"interventions":2947},[90],[2052,2053],[135,136,227,566,157,2055],{"nctId":720,"briefTitle":721,"status":105,"phases":2949,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":2950,"interventions":2951},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":745,"briefTitle":746,"status":105,"phases":2953,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":2954,"interventions":2955},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":765,"briefTitle":766,"status":105,"phases":2957,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":2958,"interventions":2959},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":773,"briefTitle":774,"status":105,"phases":2961,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":2962,"interventions":2963},[90],[18],[113,95,114,115,240,138,228],{"nctId":1509,"briefTitle":1510,"status":105,"phases":2965,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":2966,"interventions":2967},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":49,"briefTitle":50,"status":257,"phases":2969,"primaryCompletion":51,"completion":816,"start":817,"enrollment":818,"conditions":2970,"interventions":2971},[90],[562,563],[47,42,136,227,821],{"nctId":833,"briefTitle":834,"status":105,"phases":2973,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":2974,"interventions":2975},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":855,"briefTitle":856,"status":105,"phases":2977,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":2978,"interventions":2979},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":900,"briefTitle":901,"status":257,"phases":2981,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":2982,"interventions":2983},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"nctId":947,"briefTitle":948,"status":105,"phases":2985,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":2986,"interventions":2987},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":2989,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":2990,"interventions":2991},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":980,"briefTitle":981,"status":105,"phases":2993,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":2994,"interventions":2995},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":992,"briefTitle":993,"status":105,"phases":2997,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":2998,"interventions":2999},[90],[170],[327,112,113,95,114,115,117],{"nctId":1597,"briefTitle":1598,"status":105,"phases":3001,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":3002,"interventions":3003},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":3005,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":3006,"interventions":3007},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1035,"briefTitle":1036,"status":105,"phases":3009,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":3010,"interventions":3011},[90],[18],[112,578,113,95,114,115],{"nctId":3013,"briefTitle":3014,"status":105,"phases":3015,"primaryCompletion":3016,"completion":689,"start":3017,"enrollment":3018,"conditions":3019,"interventions":3043},"NCT00346164","Observation, Radiation Therapy, Combination Chemotherapy, and\u002For Surgery in Treating Young Patients With Soft Tissue Sarcoma",[90],"2014-09-05","2007-02-05",588,[3020,3021,3022,3023,3024,3025,3026,3027,3028,3029,736,3030,3031,3032,3033,3034,3035,3036,3037,738,3038,3039,3040,3041,739,740,741,742,3042],"Adult Alveolar Soft-part Sarcoma","Adult Angiosarcoma","Adult Epithelioid Sarcoma","Adult Extraskeletal Chondrosarcoma","Adult Extraskeletal Osteosarcoma","Adult Fibrosarcoma","Adult Leiomyosarcoma","Adult Liposarcoma","Adult Malignant Fibrous Histiocytoma","Adult Malignant Hemangiopericytoma","Adult Neurofibrosarcoma","Adult Synovial Sarcoma","Childhood Alveolar Soft-part Sarcoma","Childhood Angiosarcoma","Childhood Epithelioid Sarcoma","Childhood Fibrosarcoma","Childhood Leiomyosarcoma","Childhood Liposarcoma","Childhood Neurofibrosarcoma","Childhood Synovial Sarcoma","Dermatofibrosarcoma Protuberans","Metastatic Childhood Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[114,328],{"nctId":1050,"briefTitle":1001,"status":105,"phases":3045,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":3046,"interventions":3047},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":39,"briefTitle":40,"status":257,"phases":3049,"primaryCompletion":41,"completion":803,"start":1635,"enrollment":1636,"conditions":3050,"interventions":3051},[90],[1638,561,562],[42,136,141],{"nctId":1057,"briefTitle":1058,"status":333,"phases":3053,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":3054,"interventions":3055},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1082,"briefTitle":1083,"status":105,"phases":3057,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":3058,"interventions":3059},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":3061,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":3062,"interventions":3063},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":3065,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":3066,"interventions":3067},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":3069,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":3070,"interventions":3071},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1678,"briefTitle":1679,"status":105,"phases":3073,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":3074,"interventions":3075},[90],[751,23],[537,112,496,114,115,117],{"nctId":1149,"briefTitle":1150,"status":257,"phases":3077,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":3078,"interventions":3079},[90],[127,128,129,18],[60,47,136,227],{"nctId":1158,"briefTitle":1159,"status":105,"phases":3081,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":3082,"interventions":3083},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":3085,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":3086,"interventions":3087},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":3089,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":3090,"interventions":3091},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":2250,"briefTitle":2251,"status":105,"phases":3093,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":3094,"interventions":3095},[90],[751,21],[199,496,114,115,328,212],{"nctId":1208,"briefTitle":1209,"status":105,"phases":3097,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":3098,"interventions":3099},[90],[18],[112,578,113,95,114,115],{"nctId":53,"briefTitle":54,"status":257,"phases":3101,"primaryCompletion":55,"start":1703,"enrollment":1704,"conditions":3102,"interventions":3103},[90],[1706,1707,1708,1709,360,1638,561,562,563,1710],[42,136,141],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3105,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":3106,"interventions":3107},[90],[21],[327,95,114,115,328,589,117,112],{"nctId":1717,"briefTitle":1718,"status":105,"phases":3109,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":3110,"interventions":3111},[90],[23],[114,290,212,305,459,117],8,{"trials":3114,"activeCount":99},[],{"trials":3116,"activeCount":99},[3117],{"nctId":1252,"briefTitle":1253,"status":105,"phases":3118,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":3119,"interventions":3120},[92],[1258,1259],[115,328,114,95,117,240,112],{"intervention":266,"totalTrials":1725,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3131,"PHASE3":3149,"PHASE4":3171,"NA":3173},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[3127],{"nctId":2312,"briefTitle":2313,"status":105,"phases":3128,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":3129,"interventions":3130},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"trials":3132,"activeCount":598,"soonestReadout":335},[3133,3137,3141,3145],{"nctId":255,"briefTitle":256,"status":257,"phases":3134,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":3135,"interventions":3136},[89],[263],[135,47,265,266,141],{"nctId":331,"briefTitle":332,"status":333,"phases":3138,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":3139,"interventions":3140},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"nctId":552,"briefTitle":553,"status":333,"phases":3142,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":3143,"interventions":3144},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"nctId":1942,"briefTitle":1943,"status":333,"phases":3146,"primaryCompletion":259,"completion":259,"start":1945,"enrollment":444,"conditions":3147,"interventions":3148},[89],[1947,1948,1949,1950,1951],[60,227,139,266],{"trials":3150,"activeCount":598,"soonestReadout":712},[3151,3155,3159,3163,3167],{"nctId":709,"briefTitle":710,"status":333,"phases":3152,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":3153,"interventions":3154},[90],[716],[47,42,718,565,566,568,266],{"nctId":799,"briefTitle":800,"status":105,"phases":3156,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":3157,"interventions":3158},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":823,"briefTitle":824,"status":333,"phases":3160,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":3161,"interventions":3162},[90],[636,830,641],[47,42,266],{"nctId":1069,"briefTitle":1070,"status":333,"phases":3164,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":3165,"interventions":3166},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":1112,"briefTitle":1113,"status":333,"phases":3168,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":3169,"interventions":3170},[90],[1119],[135,47,265,1121,266],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":2060,"soonestReadout":1152},[3175],{"nctId":3176,"briefTitle":3177,"status":257,"phases":3178,"primaryCompletion":1152,"completion":1152,"start":3179,"enrollment":960,"conditions":3180,"interventions":3183},"NCT05359237","Vincristine Pharmacokinetics in Infants",[],"2022-11-16",[3181,3182],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm",[266],{"intervention":42,"totalTrials":30,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3190,"PHASE3":3204,"PHASE4":3266,"NA":3268},{"trials":3187,"activeCount":99},[],{"trials":3189,"activeCount":99},[],{"trials":3191,"activeCount":99},[3192,3196,3200],{"nctId":318,"briefTitle":319,"status":320,"phases":3193,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":3194,"interventions":3195},[89],[21],[327,95,115,328,117,329,228],{"nctId":349,"briefTitle":350,"status":105,"phases":3197,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":3198,"interventions":3199},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":581,"briefTitle":582,"status":105,"phases":3201,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":3202,"interventions":3203},[89],[21],[327,112,588,578,95,589,117],{"trials":3205,"activeCount":3112,"soonestReadout":41},[3206,3210,3214,3218,3222,3226,3230,3234,3238,3242,3246,3250,3254,3258,3262],{"nctId":627,"briefTitle":628,"status":257,"phases":3207,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3208,"interventions":3209},[90],[634,635,636,637,638,639,640,641],[47,42,141,643],{"nctId":654,"briefTitle":655,"status":105,"phases":3211,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":3212,"interventions":3213},[90],[662,663,664,665],[327,95,117],{"nctId":676,"briefTitle":677,"status":105,"phases":3215,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":3216,"interventions":3217},[90],[170],[327,112,95,114,115,117],{"nctId":709,"briefTitle":710,"status":333,"phases":3219,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":3220,"interventions":3221},[90],[716],[47,42,718,565,566,568,266],{"nctId":730,"briefTitle":731,"status":105,"phases":3223,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":3224,"interventions":3225},[90],[736,662,737,738,663,664,739,665,740,741,742],[327,117,95,240,112,578],{"nctId":754,"briefTitle":755,"status":756,"phases":3227,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":3228,"interventions":3229},[90],[762],[47,42,370,141,643],{"nctId":49,"briefTitle":50,"status":257,"phases":3231,"primaryCompletion":51,"completion":816,"start":817,"enrollment":818,"conditions":3232,"interventions":3233},[90],[562,563],[47,42,136,227,821],{"nctId":823,"briefTitle":824,"status":333,"phases":3235,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":3236,"interventions":3237},[90],[636,830,641],[47,42,266],{"nctId":885,"briefTitle":886,"status":105,"phases":3239,"primaryCompletion":41,"completion":442,"start":888,"enrollment":889,"conditions":3240,"interventions":3241},[90],[662,891,892,893,894,762,21,895,896,897],[47,42,370,141],{"nctId":992,"briefTitle":993,"status":105,"phases":3243,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":3244,"interventions":3245},[90],[170],[327,112,113,95,114,115,117],{"nctId":1026,"briefTitle":1027,"status":105,"phases":3247,"primaryCompletion":206,"completion":1029,"start":1030,"enrollment":1031,"conditions":3248,"interventions":3249},[90],[21],[327,112,578,95,117],{"nctId":39,"briefTitle":40,"status":257,"phases":3251,"primaryCompletion":41,"completion":803,"start":1635,"enrollment":1636,"conditions":3252,"interventions":3253},[90],[1638,561,562],[42,136,141],{"nctId":1069,"briefTitle":1070,"status":333,"phases":3255,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":3256,"interventions":3257},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":53,"briefTitle":54,"status":257,"phases":3259,"primaryCompletion":55,"start":1703,"enrollment":1704,"conditions":3260,"interventions":3261},[90],[1706,1707,1708,1709,360,1638,561,562,563,1710],[42,136,141],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3263,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":3264,"interventions":3265},[90],[21],[327,95,114,115,328,589,117,112],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":99},[],{"intervention":212,"totalTrials":3271,"cells":3272},57,{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3301,"PHASE3":3375,"PHASE4":3502,"NA":3504},{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":2060,"soonestReadout":259},[3277,3281,3285,3289,3293,3297],{"nctId":2292,"briefTitle":2293,"status":647,"phases":3278,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":99,"conditions":3279,"interventions":3280},[88],[29,1230,2298,2299,2300,790],[75,157,1357,797],{"nctId":2312,"briefTitle":2313,"status":105,"phases":3282,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":3283,"interventions":3284},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"nctId":1774,"briefTitle":1775,"status":105,"phases":3286,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":3287,"interventions":3288},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":143,"briefTitle":144,"status":105,"phases":3290,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":3291,"interventions":3292},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":2340,"briefTitle":2341,"status":333,"phases":3294,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":3295,"interventions":3296},[88],[2345,2346,2347,2348,2349,2350],[75,1233,1356,2352,347,157],{"nctId":202,"briefTitle":203,"status":105,"phases":3298,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":3299,"interventions":3300},[88],[15,23],[112,95,210,211,114,212,117],{"trials":3302,"activeCount":2365,"soonestReadout":335},[3303,3311,3315,3319,3323,3327,3331,3335,3339,3343,3347,3351,3355,3359,3363,3367,3371],{"nctId":3304,"briefTitle":3305,"status":105,"phases":3306,"primaryCompletion":3307,"completion":206,"start":1030,"enrollment":1560,"conditions":3308,"interventions":3310},"NCT00003019","Vinblastine and Methotrexate in Treating Children With Desmoid Tumors",[89],"2003-07",[3309],"Desmoid Tumor",[212,459],{"nctId":1338,"briefTitle":1339,"status":257,"phases":3312,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":3313,"interventions":3314},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":279,"briefTitle":280,"status":105,"phases":3316,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":3317,"interventions":3318},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":3320,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":3321,"interventions":3322},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":1824,"briefTitle":1825,"status":105,"phases":3324,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":3325,"interventions":3326},[89],[15],[112,1830,210,115,212,389,409],{"nctId":331,"briefTitle":332,"status":333,"phases":3328,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":3329,"interventions":3330},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"nctId":380,"briefTitle":381,"status":105,"phases":3332,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":3333,"interventions":3334},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":391,"briefTitle":392,"status":105,"phases":3336,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":3337,"interventions":3338},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":3340,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":3341,"interventions":3342},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":2417,"briefTitle":2418,"status":647,"phases":3344,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":3345,"interventions":3346},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"nctId":430,"briefTitle":431,"status":105,"phases":3348,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":3349,"interventions":3350},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":438,"briefTitle":439,"status":105,"phases":3352,"primaryCompletion":441,"completion":442,"start":443,"enrollment":444,"conditions":3353,"interventions":3354},[89],[446,263,447,448],[60,47,227,157,141],{"nctId":2432,"briefTitle":2433,"status":105,"phases":3356,"primaryCompletion":858,"completion":858,"start":248,"enrollment":2435,"conditions":3357,"interventions":3358},[88,89],[15],[2438,210,212],{"nctId":461,"briefTitle":462,"status":105,"phases":3360,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":3361,"interventions":3362},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":3364,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":3365,"interventions":3366},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":505,"briefTitle":506,"status":105,"phases":3368,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":3369,"interventions":3370},[89],[15],[514,387,95,315,212,304,515],{"nctId":591,"briefTitle":592,"status":105,"phases":3372,"primaryCompletion":594,"completion":248,"start":595,"conditions":3373,"interventions":3374},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":3376,"activeCount":3501,"soonestReadout":630},[3377,3381,3385,3389,3393,3397,3401,3405,3409,3413,3417,3421,3425,3429,3433,3437,3441,3445,3449,3453,3457,3461,3465,3469,3473,3477,3481,3485,3489,3493,3497],{"nctId":602,"briefTitle":603,"status":105,"phases":3378,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":3379,"interventions":3380},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":2484,"briefTitle":2485,"status":105,"phases":3382,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":3383,"interventions":3384},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"nctId":700,"briefTitle":701,"status":105,"phases":3386,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":3387,"interventions":3388},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":2045,"briefTitle":2046,"status":105,"phases":3390,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":3391,"interventions":3392},[90],[2052,2053],[135,136,227,566,157,2055],{"nctId":720,"briefTitle":721,"status":105,"phases":3394,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":3395,"interventions":3396},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":3398,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":3399,"interventions":3400},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":3402,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":3403,"interventions":3404},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":3406,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":3407,"interventions":3408},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1528,"briefTitle":1529,"status":105,"phases":3410,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":3411,"interventions":3412},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":3414,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":3415,"interventions":3416},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":842,"briefTitle":843,"status":105,"phases":3418,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":3419,"interventions":3420},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":926,"briefTitle":927,"status":105,"phases":3422,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":3423,"interventions":3424},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":947,"briefTitle":948,"status":105,"phases":3426,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":3427,"interventions":3428},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":3430,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":3431,"interventions":3432},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":964,"briefTitle":965,"status":105,"phases":3434,"primaryCompletion":967,"completion":968,"start":248,"enrollment":969,"conditions":3435,"interventions":3436},[90],[971,972,973,974,975,976],[200,95,515,212,978],{"nctId":1597,"briefTitle":1598,"status":105,"phases":3438,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":3439,"interventions":3440},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":3442,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":3443,"interventions":3444},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":3446,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":3447,"interventions":3448},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1043,"briefTitle":603,"status":105,"phases":3450,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":3451,"interventions":3452},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":3454,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":3455,"interventions":3456},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":3458,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":3459,"interventions":3460},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":3462,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":3463,"interventions":3464},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":3466,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":3467,"interventions":3468},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":3470,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":3471,"interventions":3472},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":2222,"briefTitle":2223,"status":333,"phases":3474,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":3475,"interventions":3476},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"nctId":1169,"briefTitle":1170,"status":105,"phases":3478,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":3479,"interventions":3480},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":3482,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":3483,"interventions":3484},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":2250,"briefTitle":2251,"status":105,"phases":3486,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":3487,"interventions":3488},[90],[751,21],[199,496,114,115,328,212],{"nctId":1717,"briefTitle":1718,"status":105,"phases":3490,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":3491,"interventions":3492},[90],[23],[114,290,212,305,459,117],{"nctId":2609,"briefTitle":2610,"status":105,"phases":3494,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":3495,"interventions":3496},[90],[15,2309,2615],[287,210,288,212,409,291],{"nctId":1224,"briefTitle":1225,"status":257,"phases":3498,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":3499,"interventions":3500},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],5,{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[3506,3510,3520],{"nctId":1262,"briefTitle":1263,"status":105,"phases":3507,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":3508,"interventions":3509},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":3511,"briefTitle":3512,"status":105,"phases":3513,"primaryCompletion":3514,"completion":3515,"start":3516,"enrollment":3517,"conditions":3518,"interventions":3519},"NCT00268528","Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission",[],"2012-03-05","2020-06-30","2005-05-30",720,[972],[156,157],{"nctId":1747,"briefTitle":1748,"status":105,"phases":3521,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":3522,"interventions":3523},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":345,"totalTrials":312,"cells":3525},{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3540,"PHASE4":3565,"NA":3567},{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[],{"trials":3531,"activeCount":2365,"soonestReadout":335},[3532,3536],{"nctId":1338,"briefTitle":1339,"status":257,"phases":3533,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":3534,"interventions":3535},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":331,"briefTitle":332,"status":333,"phases":3537,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":3538,"interventions":3539},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"trials":3541,"activeCount":598,"soonestReadout":785},[3542,3553,3557,3561],{"nctId":3543,"briefTitle":3544,"status":257,"phases":3545,"primaryCompletion":870,"completion":3546,"start":3547,"enrollment":3548,"conditions":3549,"interventions":3552},"NCT05602194","Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma",[90],"2028-12-30","2023-08-14",440,[789,3550,3551,2320,790,791],"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like",[345,158],{"nctId":782,"briefTitle":783,"status":257,"phases":3554,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":3555,"interventions":3556},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1009,"briefTitle":1010,"status":756,"phases":3558,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":3559,"interventions":3560},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1099,"briefTitle":1100,"status":333,"phases":3562,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":3563,"interventions":3564},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"trials":3566,"activeCount":99},[],{"trials":3568,"activeCount":99},[],{"intervention":135,"totalTrials":3570,"cells":3571},34,{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3596,"PHASE3":3618,"PHASE4":3724,"NA":3726},{"trials":3573,"activeCount":99},[],{"trials":3575,"activeCount":99},[3576,3580,3584,3588,3592],{"nctId":1774,"briefTitle":1775,"status":105,"phases":3577,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":3578,"interventions":3579},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":119,"briefTitle":120,"status":105,"phases":3581,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":3582,"interventions":3583},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":188,"briefTitle":189,"status":105,"phases":3585,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":3586,"interventions":3587},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"nctId":214,"briefTitle":215,"status":105,"phases":3589,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":3590,"interventions":3591},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":3593,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":3594,"interventions":3595},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":3597,"activeCount":2060,"soonestReadout":259},[3598,3602,3606,3610,3614],{"nctId":255,"briefTitle":256,"status":257,"phases":3599,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":3600,"interventions":3601},[89],[263],[135,47,265,266,141],{"nctId":421,"briefTitle":422,"status":105,"phases":3603,"primaryCompletion":424,"completion":322,"start":425,"enrollment":426,"conditions":3604,"interventions":3605},[89],[196,197],[112,199,95,115,117],{"nctId":498,"briefTitle":499,"status":105,"phases":3607,"primaryCompletion":424,"completion":404,"start":193,"enrollment":501,"conditions":3608,"interventions":3609},[89],[196,197,18],[112,113,199,95,117],{"nctId":1910,"briefTitle":1911,"status":105,"phases":3611,"primaryCompletion":205,"completion":403,"start":1004,"enrollment":1913,"conditions":3612,"interventions":3613},[89],[1248,1915,1249,1916],[537,1526,199,115],{"nctId":570,"briefTitle":571,"status":105,"phases":3615,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":3616,"interventions":3617},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":3619,"activeCount":3501,"soonestReadout":59},[3620,3624,3628,3644,3648,3652,3656,3660,3664,3668,3672,3676,3680,3684,3688,3692,3696,3700,3704,3708,3712,3716,3720],{"nctId":1964,"briefTitle":1965,"status":333,"phases":3621,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":3622,"interventions":3623},[90],[1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000],[867,60,135,227],{"nctId":668,"briefTitle":669,"status":105,"phases":3625,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":3626,"interventions":3627},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":3629,"briefTitle":3630,"status":105,"phases":3631,"primaryCompletion":41,"completion":74,"start":3632,"enrollment":9,"conditions":3633,"interventions":3642},"NCT00274937","Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer",[90],"2006-02-20",[3634,3635,3636,3637,3638,3639,3640,3641],"Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7",[3643,135,1665],"Amifostine",{"nctId":2028,"briefTitle":2029,"status":105,"phases":3645,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":3646,"interventions":3647},[90],[2034,2035,2036,2037],[135,136,227,228,2039,1908],{"nctId":2045,"briefTitle":2046,"status":105,"phases":3649,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":3650,"interventions":3651},[90],[2052,2053],[135,136,227,566,157,2055],{"nctId":1516,"briefTitle":1517,"status":105,"phases":3653,"primaryCompletion":424,"start":394,"enrollment":1519,"conditions":3654,"interventions":3655},[90],[1521,1522,1523],[199,117,1525,1526,113],{"nctId":799,"briefTitle":800,"status":105,"phases":3657,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":3658,"interventions":3659},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":842,"briefTitle":843,"status":105,"phases":3661,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":3662,"interventions":3663},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":855,"briefTitle":856,"status":105,"phases":3665,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":3666,"interventions":3667},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":57,"briefTitle":58,"status":257,"phases":3669,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":3670,"interventions":3671},[90],[849,263],[60,135,47,228,138,141],{"nctId":876,"briefTitle":877,"status":105,"phases":3673,"primaryCompletion":403,"start":879,"enrollment":880,"conditions":3674,"interventions":3675},[90],[882,851],[199,95,117,115],{"nctId":917,"briefTitle":918,"status":105,"phases":3677,"primaryCompletion":546,"completion":920,"start":921,"enrollment":922,"conditions":3678,"interventions":3679},[90],[263],[135,47,265,141],{"nctId":2113,"briefTitle":2114,"status":105,"phases":3681,"primaryCompletion":2116,"completion":776,"start":2117,"enrollment":2118,"conditions":3682,"interventions":3683},[90],[2120,1971,2121,2122,2123,2124,2125,2126,2127,2128,2129,2130,2131,2132,2133,2134,2135,2136],[199,115,537],{"nctId":926,"briefTitle":927,"status":105,"phases":3685,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":3686,"interventions":3687},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":937,"briefTitle":938,"status":105,"phases":3689,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":3690,"interventions":3691},[90],[944],[60,135,47,227,228,853,141],{"nctId":980,"briefTitle":981,"status":105,"phases":3693,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":3694,"interventions":3695},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":1057,"briefTitle":1058,"status":333,"phases":3697,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":3698,"interventions":3699},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1653,"briefTitle":1654,"status":257,"phases":3701,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":3702,"interventions":3703},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"nctId":1112,"briefTitle":1113,"status":333,"phases":3705,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":3706,"interventions":3707},[90],[1119],[135,47,265,1121,266],{"nctId":1140,"briefTitle":1141,"status":105,"phases":3709,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":3710,"interventions":3711},[90],[196,197],[112,199,95,1147,116,117],{"nctId":1190,"briefTitle":1191,"status":105,"phases":3713,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":3714,"interventions":3715},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":2250,"briefTitle":2251,"status":105,"phases":3717,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":3718,"interventions":3719},[90],[751,21],[199,496,114,115,328,212],{"nctId":1199,"briefTitle":1200,"status":105,"phases":3721,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":3722,"interventions":3723},[90],[274,275],[112,113,199,95,115],{"trials":3725,"activeCount":99},[],{"trials":3727,"activeCount":99},[3728],{"nctId":1241,"briefTitle":1242,"status":105,"phases":3729,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":3730,"interventions":3731},[92],[1248,1249],[537,112,199,95,115,329],{"intervention":565,"totalTrials":312,"cells":3733},{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3742,"PHASE3":3748,"PHASE4":3766,"NA":3768},{"trials":3735,"activeCount":99},[],{"trials":3737,"activeCount":99},[3738],{"nctId":2312,"briefTitle":2313,"status":105,"phases":3739,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":3740,"interventions":3741},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"trials":3743,"activeCount":2060,"soonestReadout":555},[3744],{"nctId":552,"briefTitle":553,"status":333,"phases":3745,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":3746,"interventions":3747},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"trials":3749,"activeCount":598,"soonestReadout":335},[3750,3754,3758,3762],{"nctId":709,"briefTitle":710,"status":333,"phases":3751,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":3752,"interventions":3753},[90],[716],[47,42,718,565,566,568,266],{"nctId":782,"briefTitle":783,"status":257,"phases":3755,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":3756,"interventions":3757},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1069,"briefTitle":1070,"status":333,"phases":3759,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":3760,"interventions":3761},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":1653,"briefTitle":1654,"status":257,"phases":3763,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":3764,"interventions":3765},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"intervention":567,"totalTrials":312,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3791,"PHASE3":3820,"PHASE4":3830,"NA":3832},{"trials":3773,"activeCount":99},[],{"trials":3775,"activeCount":99},[3776],{"nctId":3777,"briefTitle":3778,"status":105,"phases":3779,"primaryCompletion":658,"completion":1863,"start":3780,"enrollment":24,"conditions":3781,"interventions":3788},"NCT03323034","Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma",[88],"2018-01-11",[3782,3783,3784,3785,3786,3787],"Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Primary Central Nervous System Neoplasm","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Primary Central Nervous System Neoplasm",[567,3789,3790],"Pevonedistat","Temozolomide",{"trials":3792,"activeCount":1449,"soonestReadout":79},[3793,3799,3816],{"nctId":77,"briefTitle":78,"status":257,"phases":3794,"primaryCompletion":79,"completion":785,"start":3795,"enrollment":3796,"conditions":3797,"interventions":3798},[89],"2020-12-31",41,[1064,18],[80,567,138,277,3790],{"nctId":3800,"briefTitle":3801,"status":333,"phases":3802,"primaryCompletion":3803,"completion":3803,"start":3804,"enrollment":3805,"conditions":3806,"interventions":3814},"NCT06620302","Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma",[88,89],"2031-12-30","2025-06-12",81,[3807,3808,3809,3810,3783,3811,3812,3813,3786],"Childhood Fibrolamellar Carcinoma","Recurrent Childhood Fibrolamellar Carcinoma","Recurrent Childhood Malignant Solid Neoplasm","Recurrent Fibrolamellar Carcinoma","Refractory Childhood Fibrolamellar Carcinoma","Refractory Childhood Malignant Solid Neoplasm","Refractory Fibrolamellar Carcinoma",[3815,567],"Bcl-XL Proteolysis Targeting Chimera DT2216",{"nctId":552,"briefTitle":553,"status":333,"phases":3817,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":3818,"interventions":3819},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"trials":3821,"activeCount":2365,"soonestReadout":335},[3822,3826],{"nctId":1069,"briefTitle":1070,"status":333,"phases":3823,"primaryCompletion":1072,"completion":1072,"start":1073,"enrollment":1074,"conditions":3824,"interventions":3825},[90],[1076,1077,1078,1079],[60,47,42,565,227,567,266],{"nctId":1653,"briefTitle":1654,"status":257,"phases":3827,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":3828,"interventions":3829},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[],{"intervention":288,"totalTrials":24,"cells":3835},{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3848,"PHASE3":3878,"PHASE4":3952,"NA":3954},{"trials":3837,"activeCount":99},[],{"trials":3839,"activeCount":99},[3840,3844],{"nctId":143,"briefTitle":144,"status":105,"phases":3841,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":3842,"interventions":3843},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":2333,"briefTitle":2334,"status":105,"phases":3845,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":3846,"interventions":3847},[88],[15],[112,287,210,288,239,291],{"trials":3849,"activeCount":99},[3850,3854,3858,3862,3866,3870,3874],{"nctId":279,"briefTitle":280,"status":105,"phases":3851,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":3852,"interventions":3853},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":3855,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":3856,"interventions":3857},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":380,"briefTitle":381,"status":105,"phases":3859,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":3860,"interventions":3861},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":391,"briefTitle":392,"status":105,"phases":3863,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":3864,"interventions":3865},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":3867,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":3868,"interventions":3869},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":430,"briefTitle":431,"status":105,"phases":3871,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":3872,"interventions":3873},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":591,"briefTitle":592,"status":105,"phases":3875,"primaryCompletion":594,"completion":248,"start":595,"conditions":3876,"interventions":3877},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":3879,"activeCount":3501,"soonestReadout":84},[3880,3884,3888,3892,3896,3900,3904,3908,3912,3916,3920,3924,3928,3932,3936,3940,3944,3948],{"nctId":602,"briefTitle":603,"status":105,"phases":3881,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":3882,"interventions":3883},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":82,"briefTitle":83,"status":257,"phases":3885,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":3886,"interventions":3887},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":720,"briefTitle":721,"status":105,"phases":3889,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":3890,"interventions":3891},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":3893,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":3894,"interventions":3895},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":3897,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":3898,"interventions":3899},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":833,"briefTitle":834,"status":105,"phases":3901,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":3902,"interventions":3903},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":2143,"briefTitle":2144,"status":105,"phases":3905,"primaryCompletion":2146,"completion":802,"start":248,"enrollment":828,"conditions":3906,"interventions":3907},[90],[2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162],[287,288,210,291,115],{"nctId":1000,"briefTitle":1001,"status":105,"phases":3909,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":3910,"interventions":3911},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":3913,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":3914,"interventions":3915},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1043,"briefTitle":603,"status":105,"phases":3917,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":3918,"interventions":3919},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":3921,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":3922,"interventions":3923},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1091,"briefTitle":1092,"status":105,"phases":3925,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":3926,"interventions":3927},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":3929,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":3930,"interventions":3931},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":2210,"briefTitle":2211,"status":105,"phases":3933,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":3934,"interventions":3935},[90],[15],[287,210,288,115,388,389],{"nctId":2222,"briefTitle":2223,"status":333,"phases":3937,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":3938,"interventions":3939},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"nctId":1169,"briefTitle":1170,"status":105,"phases":3941,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":3942,"interventions":3943},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":3945,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":3946,"interventions":3947},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":2609,"briefTitle":2610,"status":105,"phases":3949,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":3950,"interventions":3951},[90],[15,2309,2615],[287,210,288,212,409,291],{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[3956,3960,3964],{"nctId":1731,"briefTitle":1732,"status":647,"phases":3957,"primaryCompletion":1734,"start":1735,"enrollment":99,"conditions":3958,"interventions":3959},[],[29,480],[154,796,159,141],{"nctId":1262,"briefTitle":1263,"status":105,"phases":3961,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":3962,"interventions":3963},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":1747,"briefTitle":1748,"status":105,"phases":3965,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":3966,"interventions":3967},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":328,"totalTrials":1913,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3982,"PHASE3":4026,"PHASE4":4084,"NA":4086},{"trials":3971,"activeCount":99},[],{"trials":3973,"activeCount":99},[3974,3978],{"nctId":1774,"briefTitle":1775,"status":105,"phases":3975,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":3976,"interventions":3977},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":1785,"briefTitle":1786,"status":105,"phases":3979,"primaryCompletion":205,"completion":108,"start":425,"enrollment":1788,"conditions":3980,"interventions":3981},[88],[1790],[1792,113,115,328,1793],{"trials":3983,"activeCount":2365,"soonestReadout":555},[3984,3988,3992,3998,4002,4006,4010,4014,4018,4022],{"nctId":2665,"briefTitle":2666,"status":105,"phases":3985,"primaryCompletion":688,"completion":940,"start":1194,"enrollment":207,"conditions":3986,"interventions":3987},[89],[1971,2669,2122,2123,2670,2125,2126,2671,2672,2673,2674,2136,1998,2000,2675,2676],[60,228,566,2678],{"nctId":1817,"briefTitle":1818,"status":105,"phases":3989,"primaryCompletion":282,"completion":282,"start":1820,"enrollment":149,"conditions":3990,"interventions":3991},[89],[274,197,1248],[113,115,328,200],{"nctId":3993,"briefTitle":3994,"status":105,"phases":3995,"primaryCompletion":1045,"completion":404,"start":613,"enrollment":1759,"conditions":3996,"interventions":3997},"NCT00006760","Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma",[89],[23],[112,328,698],{"nctId":318,"briefTitle":319,"status":320,"phases":3999,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":4000,"interventions":4001},[89],[21],[327,95,115,328,117,329,228],{"nctId":1860,"briefTitle":1861,"status":105,"phases":4003,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":1865,"conditions":4004,"interventions":4005},[89],[1867,1868],[60,227,566],{"nctId":451,"briefTitle":452,"status":105,"phases":4007,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":4008,"interventions":4009},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":1891,"briefTitle":1892,"status":333,"phases":4011,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":4012,"interventions":4013},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":1427,"briefTitle":1428,"status":105,"phases":4015,"primaryCompletion":725,"completion":311,"start":1094,"enrollment":1430,"conditions":4016,"interventions":4017},[89],[21],[112,114,328,116,117],{"nctId":552,"briefTitle":553,"status":333,"phases":4019,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":4020,"interventions":4021},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"nctId":570,"briefTitle":571,"status":105,"phases":4023,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":4024,"interventions":4025},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":4027,"activeCount":1449,"soonestReadout":785},[4028,4032,4036,4040,4044,4048,4052,4056,4060,4064,4068,4072,4076,4080],{"nctId":609,"briefTitle":610,"status":105,"phases":4029,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":4030,"interventions":4031},[90],[21],[112,95,114,115,328,117],{"nctId":645,"briefTitle":646,"status":647,"phases":4033,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":4034,"interventions":4035},[90],[21],[95,496,114,115,328,240,117],{"nctId":685,"briefTitle":686,"status":105,"phases":4037,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":4038,"interventions":4039},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":2045,"briefTitle":2046,"status":105,"phases":4041,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":4042,"interventions":4043},[90],[2052,2053],[135,136,227,566,157,2055],{"nctId":709,"briefTitle":710,"status":333,"phases":4045,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":4046,"interventions":4047},[90],[716],[47,42,718,565,566,568,266],{"nctId":782,"briefTitle":783,"status":257,"phases":4049,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4050,"interventions":4051},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1528,"briefTitle":1529,"status":105,"phases":4053,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":4054,"interventions":4055},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":900,"briefTitle":901,"status":257,"phases":4057,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":4058,"interventions":4059},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"nctId":956,"briefTitle":957,"status":105,"phases":4061,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":4062,"interventions":4063},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":980,"briefTitle":981,"status":105,"phases":4065,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":4066,"interventions":4067},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":3013,"briefTitle":3014,"status":105,"phases":4069,"primaryCompletion":3016,"completion":689,"start":3017,"enrollment":3018,"conditions":4070,"interventions":4071},[90],[3020,3021,3022,3023,3024,3025,3026,3027,3028,3029,736,3030,3031,3032,3033,3034,3035,3036,3037,738,3038,3039,3040,3041,739,740,741,742,3042],[114,328],{"nctId":1158,"briefTitle":1159,"status":105,"phases":4073,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":4074,"interventions":4075},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"nctId":2250,"briefTitle":2251,"status":105,"phases":4077,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":4078,"interventions":4079},[90],[751,21],[199,496,114,115,328,212],{"nctId":1216,"briefTitle":1217,"status":105,"phases":4081,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":4082,"interventions":4083},[90],[21],[327,95,114,115,328,589,117,112],{"trials":4085,"activeCount":99},[],{"trials":4087,"activeCount":99},[4088],{"nctId":1252,"briefTitle":1253,"status":105,"phases":4089,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":4090,"interventions":4091},[92],[1258,1259],[115,328,114,95,117,240,112],{"intervention":316,"totalTrials":376,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4106,"PHASE3":4128,"PHASE4":4194,"NA":4196},{"trials":4095,"activeCount":99},[],{"trials":4097,"activeCount":99},[4098,4102],{"nctId":2312,"briefTitle":2313,"status":105,"phases":4099,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":4100,"interventions":4101},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"nctId":143,"briefTitle":144,"status":105,"phases":4103,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":4104,"interventions":4105},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"trials":4107,"activeCount":2060,"soonestReadout":335},[4108,4112,4116,4120,4124],{"nctId":307,"briefTitle":308,"status":105,"phases":4109,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":4110,"interventions":4111},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":331,"briefTitle":332,"status":333,"phases":4113,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":4114,"interventions":4115},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"nctId":430,"briefTitle":431,"status":105,"phases":4117,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":4118,"interventions":4119},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":485,"briefTitle":486,"status":105,"phases":4121,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":4122,"interventions":4123},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":591,"briefTitle":592,"status":105,"phases":4125,"primaryCompletion":594,"completion":248,"start":595,"conditions":4126,"interventions":4127},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":4129,"activeCount":598,"soonestReadout":785},[4130,4134,4138,4142,4146,4150,4154,4158,4162,4166,4170,4174,4178,4182,4186,4190],{"nctId":602,"briefTitle":603,"status":105,"phases":4131,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":4132,"interventions":4133},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":3543,"briefTitle":3544,"status":257,"phases":4135,"primaryCompletion":870,"completion":3546,"start":3547,"enrollment":3548,"conditions":4136,"interventions":4137},[90],[789,3550,3551,2320,790,791],[345,158],{"nctId":765,"briefTitle":766,"status":105,"phases":4139,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":4140,"interventions":4141},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":4143,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4144,"interventions":4145},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1528,"briefTitle":1529,"status":105,"phases":4147,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":4148,"interventions":4149},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":4151,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":4152,"interventions":4153},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":947,"briefTitle":948,"status":105,"phases":4155,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":4156,"interventions":4157},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":1000,"briefTitle":1001,"status":105,"phases":4159,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":4160,"interventions":4161},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":4163,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":4164,"interventions":4165},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1043,"briefTitle":603,"status":105,"phases":4167,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":4168,"interventions":4169},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":4171,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":4172,"interventions":4173},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":4175,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":4176,"interventions":4177},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4179,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4180,"interventions":4181},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":4183,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":4184,"interventions":4185},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":4187,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":4188,"interventions":4189},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":4191,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":4192,"interventions":4193},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"trials":4195,"activeCount":99},[],{"trials":4197,"activeCount":99},[4198,4202],{"nctId":1262,"briefTitle":1263,"status":105,"phases":4199,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":4200,"interventions":4201},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":1747,"briefTitle":1748,"status":105,"phases":4203,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":4204,"interventions":4205},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":291,"totalTrials":1204,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4220,"PHASE3":4234,"PHASE4":4312,"NA":4314},{"trials":4209,"activeCount":99},[],{"trials":4211,"activeCount":99},[4212,4216],{"nctId":143,"briefTitle":144,"status":105,"phases":4213,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":4214,"interventions":4215},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":2333,"briefTitle":2334,"status":105,"phases":4217,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":4218,"interventions":4219},[88],[15],[112,287,210,288,239,291],{"trials":4221,"activeCount":99},[4222,4226,4230],{"nctId":279,"briefTitle":280,"status":105,"phases":4223,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":4224,"interventions":4225},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":4227,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":4228,"interventions":4229},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":430,"briefTitle":431,"status":105,"phases":4231,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":4232,"interventions":4233},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"trials":4235,"activeCount":598,"soonestReadout":84},[4236,4240,4244,4248,4252,4256,4260,4264,4268,4272,4276,4280,4284,4288,4292,4296,4300,4304,4308],{"nctId":602,"briefTitle":603,"status":105,"phases":4237,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":4238,"interventions":4239},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":82,"briefTitle":83,"status":257,"phases":4241,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":4242,"interventions":4243},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":720,"briefTitle":721,"status":105,"phases":4245,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":4246,"interventions":4247},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":4249,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":4250,"interventions":4251},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":4253,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4254,"interventions":4255},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1528,"briefTitle":1529,"status":105,"phases":4257,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":4258,"interventions":4259},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":4261,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":4262,"interventions":4263},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":2143,"briefTitle":2144,"status":105,"phases":4265,"primaryCompletion":2146,"completion":802,"start":248,"enrollment":828,"conditions":4266,"interventions":4267},[90],[2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162],[287,288,210,291,115],{"nctId":947,"briefTitle":948,"status":105,"phases":4269,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":4270,"interventions":4271},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":1000,"briefTitle":1001,"status":105,"phases":4273,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":4274,"interventions":4275},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":4277,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":4278,"interventions":4279},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1617,"briefTitle":1618,"status":105,"phases":4281,"primaryCompletion":983,"completion":1620,"start":1621,"enrollment":1622,"conditions":4282,"interventions":4283},[90],[196,197],[113,1147,540,291,117],{"nctId":1043,"briefTitle":603,"status":105,"phases":4285,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":4286,"interventions":4287},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":4289,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":4290,"interventions":4291},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1091,"briefTitle":1092,"status":105,"phases":4293,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":4294,"interventions":4295},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4297,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4298,"interventions":4299},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":4301,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":4302,"interventions":4303},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":4305,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":4306,"interventions":4307},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":2609,"briefTitle":2610,"status":105,"phases":4309,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":4310,"interventions":4311},[90],[15,2309,2615],[287,210,288,212,409,291],{"trials":4313,"activeCount":99},[],{"trials":4315,"activeCount":99},[],{"intervention":305,"totalTrials":3570,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4330,"PHASE3":4372,"PHASE4":4459,"NA":4461},{"trials":4319,"activeCount":99},[],{"trials":4321,"activeCount":99},[4322,4326],{"nctId":2312,"briefTitle":2313,"status":105,"phases":4323,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":4324,"interventions":4325},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"nctId":143,"briefTitle":144,"status":105,"phases":4327,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":4328,"interventions":4329},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"trials":4331,"activeCount":2365,"soonestReadout":46},[4332,4336,4340,4344,4348,4352,4356,4360,4364,4368],{"nctId":1338,"briefTitle":1339,"status":257,"phases":4333,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":4334,"interventions":4335},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":293,"briefTitle":294,"status":105,"phases":4337,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":4338,"interventions":4339},[89],[301],[303,95,304,305],{"nctId":391,"briefTitle":392,"status":105,"phases":4341,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":4342,"interventions":4343},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":4345,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":4346,"interventions":4347},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":44,"briefTitle":45,"status":257,"phases":4349,"primaryCompletion":46,"completion":412,"start":413,"enrollment":414,"conditions":4350,"interventions":4351},[89],[416,417,418],[47,136,159,141],{"nctId":430,"briefTitle":431,"status":105,"phases":4353,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":4354,"interventions":4355},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":461,"briefTitle":462,"status":105,"phases":4357,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":4358,"interventions":4359},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":4361,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":4362,"interventions":4363},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":529,"briefTitle":530,"status":105,"phases":4365,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":4366,"interventions":4367},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":591,"briefTitle":592,"status":105,"phases":4369,"primaryCompletion":594,"completion":248,"start":595,"conditions":4370,"interventions":4371},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":4373,"activeCount":2365,"soonestReadout":1102},[4374,4378,4382,4386,4390,4394,4398,4402,4406,4410,4414,4418,4422,4431,4435,4439,4443,4447,4451,4455],{"nctId":602,"briefTitle":603,"status":105,"phases":4375,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":4376,"interventions":4377},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":618,"briefTitle":619,"status":105,"phases":4379,"primaryCompletion":621,"completion":442,"start":622,"enrollment":426,"conditions":4380,"interventions":4381},[90],[128,129,130,131,132],[47,159,625],{"nctId":685,"briefTitle":686,"status":105,"phases":4383,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":4384,"interventions":4385},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":700,"briefTitle":701,"status":105,"phases":4387,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":4388,"interventions":4389},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":720,"briefTitle":721,"status":105,"phases":4391,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":4392,"interventions":4393},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":745,"briefTitle":746,"status":105,"phases":4395,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":4396,"interventions":4397},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":1509,"briefTitle":1510,"status":105,"phases":4399,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":4400,"interventions":4401},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":833,"briefTitle":834,"status":105,"phases":4403,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":4404,"interventions":4405},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":855,"briefTitle":856,"status":105,"phases":4407,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":4408,"interventions":4409},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":980,"briefTitle":981,"status":105,"phases":4411,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":4412,"interventions":4413},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":1597,"briefTitle":1598,"status":105,"phases":4415,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":4416,"interventions":4417},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":4419,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":4420,"interventions":4421},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":4423,"briefTitle":4424,"status":105,"phases":4425,"primaryCompletion":4426,"completion":1029,"start":4427,"enrollment":880,"conditions":4428,"interventions":4429},"NCT00031824","Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease",[90],"2005-05","2002-04",[973],[315,4430,305,515],"hydroxychloroquine",{"nctId":1050,"briefTitle":1001,"status":105,"phases":4432,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":4433,"interventions":4434},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":4436,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":4437,"interventions":4438},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":4440,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":4441,"interventions":4442},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4444,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4445,"interventions":4446},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":4448,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":4449,"interventions":4450},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":4452,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":4453,"interventions":4454},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":1717,"briefTitle":1718,"status":105,"phases":4456,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":4457,"interventions":4458},[90],[23],[114,290,212,305,459,117],{"trials":4460,"activeCount":99},[],{"trials":4462,"activeCount":99},[4463,4467],{"nctId":1731,"briefTitle":1732,"status":647,"phases":4464,"primaryCompletion":1734,"start":1735,"enrollment":99,"conditions":4465,"interventions":4466},[],[29,480],[154,796,159,141],{"nctId":1747,"briefTitle":1748,"status":105,"phases":4468,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":4469,"interventions":4470},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":211,"totalTrials":4472,"cells":4473},29,{"EARLY_PHASE1":4474,"PHASE1":4476,"PHASE2":4486,"PHASE3":4504,"PHASE4":4590,"NA":4592},{"trials":4475,"activeCount":99},[],{"trials":4477,"activeCount":99},[4478,4482],{"nctId":143,"briefTitle":144,"status":105,"phases":4479,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":4480,"interventions":4481},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"nctId":202,"briefTitle":203,"status":105,"phases":4483,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":4484,"interventions":4485},[88],[15,23],[112,95,210,211,114,212,117],{"trials":4487,"activeCount":99},[4488,4492,4496,4500],{"nctId":279,"briefTitle":280,"status":105,"phases":4489,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":4490,"interventions":4491},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":4493,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":4494,"interventions":4495},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":391,"briefTitle":392,"status":105,"phases":4497,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":4498,"interventions":4499},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":591,"briefTitle":592,"status":105,"phases":4501,"primaryCompletion":594,"completion":248,"start":595,"conditions":4502,"interventions":4503},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":4505,"activeCount":598,"soonestReadout":64},[4506,4510,4514,4518,4522,4526,4530,4534,4538,4542,4546,4550,4554,4558,4562,4566,4570,4574,4578,4582,4586],{"nctId":602,"briefTitle":603,"status":105,"phases":4507,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":4508,"interventions":4509},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":62,"briefTitle":63,"status":257,"phases":4511,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":4512,"interventions":4513},[90],[2469],[65,75,155,2471,2014,2472],{"nctId":720,"briefTitle":721,"status":105,"phases":4515,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":4516,"interventions":4517},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":4519,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":4520,"interventions":4521},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":4523,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4524,"interventions":4525},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1528,"briefTitle":1529,"status":105,"phases":4527,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":4528,"interventions":4529},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":833,"briefTitle":834,"status":105,"phases":4531,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":4532,"interventions":4533},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":855,"briefTitle":856,"status":105,"phases":4535,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":4536,"interventions":4537},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":947,"briefTitle":948,"status":105,"phases":4539,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":4540,"interventions":4541},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":4543,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":4544,"interventions":4545},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":980,"briefTitle":981,"status":105,"phases":4547,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":4548,"interventions":4549},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":1000,"briefTitle":1001,"status":105,"phases":4551,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":4552,"interventions":4553},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1009,"briefTitle":1010,"status":756,"phases":4555,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":4556,"interventions":4557},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1043,"briefTitle":603,"status":105,"phases":4559,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":4560,"interventions":4561},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":4563,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":4564,"interventions":4565},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":4567,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":4568,"interventions":4569},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":4571,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":4572,"interventions":4573},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4575,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4576,"interventions":4577},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":4579,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":4580,"interventions":4581},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":4583,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":4584,"interventions":4585},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":4587,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":4588,"interventions":4589},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"trials":4591,"activeCount":99},[],{"trials":4593,"activeCount":99},[4594,4598],{"nctId":1262,"briefTitle":1263,"status":105,"phases":4595,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":4596,"interventions":4597},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":1747,"briefTitle":1748,"status":105,"phases":4599,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":4600,"interventions":4601},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":289,"totalTrials":1913,"cells":4603},{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4616,"PHASE3":4650,"PHASE4":4716,"NA":4718},{"trials":4605,"activeCount":99},[],{"trials":4607,"activeCount":2060,"soonestReadout":259},[4608,4612],{"nctId":1774,"briefTitle":1775,"status":105,"phases":4609,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":4610,"interventions":4611},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":2340,"briefTitle":2341,"status":333,"phases":4613,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":4614,"interventions":4615},[88],[2345,2346,2347,2348,2349,2350],[75,1233,1356,2352,347,157],{"trials":4617,"activeCount":2060,"soonestReadout":335},[4618,4622,4626,4630,4634,4638,4642,4646],{"nctId":279,"briefTitle":280,"status":105,"phases":4619,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":4620,"interventions":4621},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":331,"briefTitle":332,"status":333,"phases":4623,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":4624,"interventions":4625},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"nctId":391,"briefTitle":392,"status":105,"phases":4627,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":4628,"interventions":4629},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":4631,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":4632,"interventions":4633},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":430,"briefTitle":431,"status":105,"phases":4635,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":4636,"interventions":4637},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":461,"briefTitle":462,"status":105,"phases":4639,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":4640,"interventions":4641},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":4643,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":4644,"interventions":4645},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":591,"briefTitle":592,"status":105,"phases":4647,"primaryCompletion":594,"completion":248,"start":595,"conditions":4648,"interventions":4649},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":4651,"activeCount":2365,"soonestReadout":785},[4652,4656,4660,4664,4668,4672,4676,4680,4684,4688,4692,4696,4700,4704,4708,4712],{"nctId":720,"briefTitle":721,"status":105,"phases":4653,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":4654,"interventions":4655},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":4657,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4658,"interventions":4659},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":4661,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":4662,"interventions":4663},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1528,"briefTitle":1529,"status":105,"phases":4665,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":4666,"interventions":4667},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":842,"briefTitle":843,"status":105,"phases":4669,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":4670,"interventions":4671},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":926,"briefTitle":927,"status":105,"phases":4673,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":4674,"interventions":4675},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":947,"briefTitle":948,"status":105,"phases":4677,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":4678,"interventions":4679},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":956,"briefTitle":957,"status":105,"phases":4681,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":4682,"interventions":4683},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":1597,"briefTitle":1598,"status":105,"phases":4685,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":4686,"interventions":4687},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":4689,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":4690,"interventions":4691},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1043,"briefTitle":603,"status":105,"phases":4693,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":4694,"interventions":4695},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":4697,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":4698,"interventions":4699},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4701,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4702,"interventions":4703},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":4705,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":4706,"interventions":4707},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":4709,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":4710,"interventions":4711},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":4713,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":4714,"interventions":4715},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"trials":4717,"activeCount":99},[],{"trials":4719,"activeCount":99},[4720],{"nctId":1262,"briefTitle":1263,"status":105,"phases":4721,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":4722,"interventions":4723},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"intervention":796,"totalTrials":3112,"cells":4725},{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4734,"PHASE3":4744,"PHASE4":4762,"NA":4764},{"trials":4727,"activeCount":99},[],{"trials":4729,"activeCount":99},[4730],{"nctId":2312,"briefTitle":2313,"status":105,"phases":4731,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":4732,"interventions":4733},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"trials":4735,"activeCount":2060,"soonestReadout":903},[4736,4740],{"nctId":1338,"briefTitle":1339,"status":257,"phases":4737,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":4738,"interventions":4739},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":2417,"briefTitle":2418,"status":647,"phases":4741,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":4742,"interventions":4743},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"trials":4745,"activeCount":1449,"soonestReadout":785},[4746,4750,4754,4758],{"nctId":700,"briefTitle":701,"status":105,"phases":4747,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":4748,"interventions":4749},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":782,"briefTitle":783,"status":257,"phases":4751,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":4752,"interventions":4753},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1009,"briefTitle":1010,"status":756,"phases":4755,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":4756,"interventions":4757},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1099,"briefTitle":1100,"status":333,"phases":4759,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":4760,"interventions":4761},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"trials":4763,"activeCount":99},[],{"trials":4765,"activeCount":99},[4766],{"nctId":1731,"briefTitle":1732,"status":647,"phases":4767,"primaryCompletion":1734,"start":1735,"enrollment":99,"conditions":4768,"interventions":4769},[],[29,480],[154,796,159,141],{"intervention":589,"totalTrials":2643,"cells":4771},{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4799,"PHASE3":4853,"PHASE4":4871,"NA":4873},{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[4776,4780,4789,4795],{"nctId":1276,"briefTitle":1277,"status":105,"phases":4777,"primaryCompletion":310,"completion":108,"start":1279,"enrollment":207,"conditions":4778,"interventions":4779},[88],[26],[589,117],{"nctId":4781,"briefTitle":4782,"status":105,"phases":4783,"primaryCompletion":689,"completion":920,"start":4784,"enrollment":4785,"conditions":4786,"interventions":4787},"NCT02975882","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",[88],"2017-08-15",33,[182,3783,3784,3786,3787],[370,4788,3790],"Sirolimus Albumin-bound Nanoparticles",{"nctId":4790,"briefTitle":4791,"status":105,"phases":4792,"primaryCompletion":108,"completion":206,"start":879,"enrollment":324,"conditions":4793,"interventions":4794},"NCT00008424","Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants",[88],[26],[589],{"nctId":1301,"briefTitle":1302,"status":105,"phases":4796,"primaryCompletion":1304,"completion":1029,"start":1305,"enrollment":575,"conditions":4797,"interventions":4798},[88],[35,26],[589,1308,117],{"trials":4800,"activeCount":2060,"soonestReadout":4831},[4801,4827,4838,4842,4849],{"nctId":4802,"briefTitle":4803,"status":105,"phases":4804,"primaryCompletion":424,"start":534,"enrollment":4805,"conditions":4806,"interventions":4826},"NCT00004078","Irinotecan in Treating Children With Refractory Solid Tumors",[89],181,[4807,4808,4809,4810,4811,4812,4813,4814,4815,4816,4817,4818,4819,4820,4821,4822,4823,4824,32,4825,26],"Childhood Central Nervous System Germ Cell Tumor","Childhood Choroid Plexus Tumor","Childhood Craniopharyngioma","Childhood Grade I Meningioma","Childhood Grade II Meningioma","Childhood Grade III Meningioma","Childhood Infratentorial Ependymoma","Childhood Oligodendroglioma","Childhood Supratentorial Ependymoma","Previously Treated Childhood Rhabdomyosarcoma","Recurrent Childhood Cerebellar Astrocytoma","Recurrent Childhood Cerebral Astrocytoma","Recurrent Childhood Ependymoma","Recurrent Childhood Medulloblastoma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Recurrent Childhood Visual Pathway Glioma","Recurrent Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Recurrent Osteosarcoma",[589],{"nctId":4828,"briefTitle":4829,"status":257,"phases":4830,"primaryCompletion":4831,"completion":712,"start":4832,"enrollment":194,"conditions":4833,"interventions":4836},"NCT03794349","Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma",[89],"2025-03-31","2019-07-08",[4834,32,4835],"High Risk Neuroblastoma","Refractory Neuroblastoma",[80,4837,370,277,3790],"Eflornithine Hydrochloride",{"nctId":349,"briefTitle":350,"status":105,"phases":4839,"primaryCompletion":352,"start":353,"enrollment":354,"conditions":4840,"interventions":4841},[89],[356,357,358,359,360,361,362,363,364,365,366,367,368],[136,370,47,227,60,42,141],{"nctId":4843,"briefTitle":4844,"status":105,"phases":4845,"primaryCompletion":4846,"completion":234,"start":311,"enrollment":284,"conditions":4847,"interventions":4848},"NCT00311584","Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma",[89],"2009-03",[18],[589,1308],{"nctId":581,"briefTitle":582,"status":105,"phases":4850,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":4851,"interventions":4852},[89],[21],[327,112,588,578,95,589,117],{"trials":4854,"activeCount":2365,"soonestReadout":903},[4855,4859,4863,4867],{"nctId":754,"briefTitle":755,"status":756,"phases":4856,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":4857,"interventions":4858},[90],[762],[47,42,370,141,643],{"nctId":885,"briefTitle":886,"status":105,"phases":4860,"primaryCompletion":41,"completion":442,"start":888,"enrollment":889,"conditions":4861,"interventions":4862},[90],[662,891,892,893,894,762,21,895,896,897],[47,42,370,141],{"nctId":900,"briefTitle":901,"status":257,"phases":4864,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":4865,"interventions":4866},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"nctId":1216,"briefTitle":1217,"status":105,"phases":4868,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":4869,"interventions":4870},[90],[21],[327,95,114,115,328,589,117,112],{"trials":4872,"activeCount":99},[],{"trials":4874,"activeCount":99},[],{"intervention":853,"totalTrials":2643,"cells":4876},{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4885,"PHASE3":4903,"PHASE4":4937,"NA":4939},{"trials":4878,"activeCount":99},[],{"trials":4880,"activeCount":99},[4881],{"nctId":188,"briefTitle":189,"status":105,"phases":4882,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":4883,"interventions":4884},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"trials":4886,"activeCount":2060,"soonestReadout":1894},[4887,4891,4895,4899],{"nctId":1817,"briefTitle":1818,"status":105,"phases":4888,"primaryCompletion":282,"completion":282,"start":1820,"enrollment":149,"conditions":4889,"interventions":4890},[89],[274,197,1248],[113,115,328,200],{"nctId":372,"briefTitle":373,"status":105,"phases":4892,"primaryCompletion":205,"completion":248,"start":375,"enrollment":376,"conditions":4893,"interventions":4894},[89],[35,18],[112,113,95,200,117],{"nctId":1891,"briefTitle":1892,"status":333,"phases":4896,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":4897,"interventions":4898},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":570,"briefTitle":571,"status":105,"phases":4900,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":4901,"interventions":4902},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":4904,"activeCount":2365,"soonestReadout":630},[4905,4909,4913,4917,4921,4925,4929,4933],{"nctId":2057,"briefTitle":2058,"status":105,"phases":4906,"primaryCompletion":206,"completion":206,"start":205,"enrollment":2060,"conditions":4907,"interventions":4908},[90],[274,275],[112,113,115,238,200],{"nctId":842,"briefTitle":843,"status":105,"phases":4910,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":4911,"interventions":4912},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":926,"briefTitle":927,"status":105,"phases":4914,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":4915,"interventions":4916},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":937,"briefTitle":938,"status":105,"phases":4918,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":4919,"interventions":4920},[90],[944],[60,135,47,227,228,853,141],{"nctId":964,"briefTitle":965,"status":105,"phases":4922,"primaryCompletion":967,"completion":968,"start":248,"enrollment":969,"conditions":4923,"interventions":4924},[90],[971,972,973,974,975,976],[200,95,515,212,978],{"nctId":1057,"briefTitle":1058,"status":333,"phases":4926,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":4927,"interventions":4928},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":4930,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":4931,"interventions":4932},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":1224,"briefTitle":1225,"status":257,"phases":4934,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":4935,"interventions":4936},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":4938,"activeCount":99},[],{"trials":4940,"activeCount":99},[],{"intervention":578,"totalTrials":2317,"cells":4942},{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4947,"PHASE3":4987,"PHASE4":5009,"NA":5011},{"trials":4944,"activeCount":99},[],{"trials":4946,"activeCount":99},[],{"trials":4948,"activeCount":2365,"soonestReadout":79},[4949,4953,4957,4961,4970,4979,4983],{"nctId":77,"briefTitle":78,"status":257,"phases":4950,"primaryCompletion":79,"completion":785,"start":3795,"enrollment":3796,"conditions":4951,"interventions":4952},[89],[1064,18],[80,567,138,277,3790],{"nctId":268,"briefTitle":269,"status":105,"phases":4954,"primaryCompletion":271,"completion":248,"start":272,"enrollment":235,"conditions":4955,"interventions":4956},[89],[274,275],[277,95,239],{"nctId":4828,"briefTitle":4829,"status":257,"phases":4958,"primaryCompletion":4831,"completion":712,"start":4832,"enrollment":194,"conditions":4959,"interventions":4960},[89],[4834,32,4835],[80,4837,370,277,3790],{"nctId":4962,"briefTitle":4963,"status":105,"phases":4964,"primaryCompletion":297,"completion":4965,"start":2107,"enrollment":4966,"conditions":4967,"interventions":4968},"NCT01334515","Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma",[89],"2019-09-30",52,[32],[4969,238,578],"hu14.18-IL2 fusion protein",{"nctId":4971,"briefTitle":4972,"status":105,"phases":4973,"primaryCompletion":4974,"completion":234,"start":1245,"enrollment":4975,"conditions":4976,"interventions":4978},"NCT00066365","Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma",[89],"2010-07",49,[4977,21],"Metastatic Cancer",[578],{"nctId":570,"briefTitle":571,"status":105,"phases":4980,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":4981,"interventions":4982},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"nctId":581,"briefTitle":582,"status":105,"phases":4984,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":4985,"interventions":4986},[89],[21],[327,112,588,578,95,589,117],{"trials":4988,"activeCount":2060,"soonestReadout":1060},[4989,4993,4997,5001,5005],{"nctId":730,"briefTitle":731,"status":105,"phases":4990,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":4991,"interventions":4992},[90],[736,662,737,738,663,664,739,665,740,741,742],[327,117,95,240,112,578],{"nctId":1026,"briefTitle":1027,"status":105,"phases":4994,"primaryCompletion":206,"completion":1029,"start":1030,"enrollment":1031,"conditions":4995,"interventions":4996},[90],[21],[327,112,578,95,117],{"nctId":1035,"briefTitle":1036,"status":105,"phases":4998,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":4999,"interventions":5000},[90],[18],[112,578,113,95,114,115],{"nctId":1057,"briefTitle":1058,"status":333,"phases":5002,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":5003,"interventions":5004},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1208,"briefTitle":1209,"status":105,"phases":5006,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":5007,"interventions":5008},[90],[18],[112,578,113,95,114,115],{"trials":5010,"activeCount":99},[],{"trials":5012,"activeCount":99},[],{"intervention":138,"totalTrials":1725,"cells":5014},{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5027,"PHASE3":5041,"PHASE4":5067,"NA":5069},{"trials":5016,"activeCount":99},[],{"trials":5018,"activeCount":99},[5019,5023],{"nctId":119,"briefTitle":120,"status":105,"phases":5020,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":5021,"interventions":5022},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":5024,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":5025,"interventions":5026},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":5028,"activeCount":2060,"soonestReadout":79},[5029,5033,5037],{"nctId":77,"briefTitle":78,"status":257,"phases":5030,"primaryCompletion":79,"completion":785,"start":3795,"enrollment":3796,"conditions":5031,"interventions":5032},[89],[1064,18],[80,567,138,277,3790],{"nctId":4962,"briefTitle":4963,"status":105,"phases":5034,"primaryCompletion":297,"completion":4965,"start":2107,"enrollment":4966,"conditions":5035,"interventions":5036},[89],[32],[4969,238,578],{"nctId":570,"briefTitle":571,"status":105,"phases":5038,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":5039,"interventions":5040},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":5042,"activeCount":2365,"soonestReadout":59},[5043,5047,5051,5055,5059,5063],{"nctId":668,"briefTitle":669,"status":105,"phases":5044,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":5045,"interventions":5046},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":2057,"briefTitle":2058,"status":105,"phases":5048,"primaryCompletion":206,"completion":206,"start":205,"enrollment":2060,"conditions":5049,"interventions":5050},[90],[274,275],[112,113,115,238,200],{"nctId":773,"briefTitle":774,"status":105,"phases":5052,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":5053,"interventions":5054},[90],[18],[113,95,114,115,240,138,228],{"nctId":57,"briefTitle":58,"status":257,"phases":5056,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":5057,"interventions":5058},[90],[849,263],[60,135,47,228,138,141],{"nctId":1057,"briefTitle":1058,"status":333,"phases":5060,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":5061,"interventions":5062},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":5064,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":5065,"interventions":5066},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"intervention":496,"totalTrials":1725,"cells":5072},{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5085,"PHASE3":5091,"PHASE4":5125,"NA":5127},{"trials":5074,"activeCount":99},[],{"trials":5076,"activeCount":99},[5077,5081],{"nctId":1774,"briefTitle":1775,"status":105,"phases":5078,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":5079,"interventions":5080},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":175,"briefTitle":176,"status":105,"phases":5082,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":5083,"interventions":5084},[88],[182,183,32],[185,47,186,136,140,141],{"trials":5086,"activeCount":99},[5087],{"nctId":485,"briefTitle":486,"status":105,"phases":5088,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":5089,"interventions":5090},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"trials":5092,"activeCount":1449,"soonestReadout":785},[5093,5097,5101,5105,5109,5113,5117,5121],{"nctId":645,"briefTitle":646,"status":647,"phases":5094,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":5095,"interventions":5096},[90],[21],[95,496,114,115,328,240,117],{"nctId":745,"briefTitle":746,"status":105,"phases":5098,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":5099,"interventions":5100},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":782,"briefTitle":783,"status":257,"phases":5102,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5103,"interventions":5104},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":5106,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":5107,"interventions":5108},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1057,"briefTitle":1058,"status":333,"phases":5110,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":5111,"interventions":5112},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1678,"briefTitle":1679,"status":105,"phases":5114,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":5115,"interventions":5116},[90],[751,23],[537,112,496,114,115,117],{"nctId":2222,"briefTitle":2223,"status":333,"phases":5118,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":5119,"interventions":5120},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"nctId":2250,"briefTitle":2251,"status":105,"phases":5122,"primaryCompletion":107,"completion":533,"start":584,"enrollment":2253,"conditions":5123,"interventions":5124},[90],[751,21],[199,496,114,115,328,212],{"trials":5126,"activeCount":99},[],{"trials":5128,"activeCount":99},[],{"intervention":2014,"totalTrials":3112,"cells":5130},{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5139,"PHASE3":5149,"PHASE4":5171,"NA":5173},{"trials":5132,"activeCount":99},[],{"trials":5134,"activeCount":99},[5135],{"nctId":2303,"briefTitle":2304,"status":105,"phases":5136,"primaryCompletion":206,"completion":404,"start":2306,"enrollment":2307,"conditions":5137,"interventions":5138},[88],[15,2309],[287,210,388,389],{"trials":5140,"activeCount":99},[5141,5145],{"nctId":1824,"briefTitle":1825,"status":105,"phases":5142,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":5143,"interventions":5144},[89],[15],[112,1830,210,115,212,389,409],{"nctId":380,"briefTitle":381,"status":105,"phases":5146,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":5147,"interventions":5148},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"trials":5150,"activeCount":1449,"soonestReadout":64},[5151,5155,5159,5163,5167],{"nctId":62,"briefTitle":63,"status":257,"phases":5152,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":5153,"interventions":5154},[90],[2469],[65,75,155,2471,2014,2472],{"nctId":82,"briefTitle":83,"status":257,"phases":5156,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":5157,"interventions":5158},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":2484,"briefTitle":2485,"status":105,"phases":5160,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":5161,"interventions":5162},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"nctId":2210,"briefTitle":2211,"status":105,"phases":5164,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":5165,"interventions":5166},[90],[15],[287,210,288,115,388,389],{"nctId":2222,"briefTitle":2223,"status":333,"phases":5168,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":5169,"interventions":5170},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"trials":5172,"activeCount":99},[],{"trials":5174,"activeCount":99},[],{"intervention":344,"totalTrials":1449,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5187,"PHASE4":5197,"NA":5199},{"trials":5178,"activeCount":99},[],{"trials":5180,"activeCount":99},[],{"trials":5182,"activeCount":2060,"soonestReadout":335},[5183],{"nctId":331,"briefTitle":332,"status":333,"phases":5184,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":5185,"interventions":5186},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"trials":5188,"activeCount":2365,"soonestReadout":84},[5189,5193],{"nctId":82,"briefTitle":83,"status":257,"phases":5190,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":5191,"interventions":5192},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":2222,"briefTitle":2223,"status":333,"phases":5194,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":5195,"interventions":5196},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"trials":5198,"activeCount":99},[],{"trials":5200,"activeCount":99},[],{"intervention":80,"totalTrials":1449,"cells":5202},{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5217,"PHASE4":5223,"NA":5225},{"trials":5204,"activeCount":99},[],{"trials":5206,"activeCount":99},[],{"trials":5208,"activeCount":2365,"soonestReadout":79},[5209,5213],{"nctId":77,"briefTitle":78,"status":257,"phases":5210,"primaryCompletion":79,"completion":785,"start":3795,"enrollment":3796,"conditions":5211,"interventions":5212},[89],[1064,18],[80,567,138,277,3790],{"nctId":4828,"briefTitle":4829,"status":257,"phases":5214,"primaryCompletion":4831,"completion":712,"start":4832,"enrollment":194,"conditions":5215,"interventions":5216},[89],[4834,32,4835],[80,4837,370,277,3790],{"trials":5218,"activeCount":2060,"soonestReadout":1060},[5219],{"nctId":1057,"briefTitle":1058,"status":333,"phases":5220,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":5221,"interventions":5222},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"trials":5224,"activeCount":99},[],{"trials":5226,"activeCount":99},[],{"intervention":112,"totalTrials":932,"cells":5228},{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5261,"PHASE3":5367,"PHASE4":5534,"NA":5536},{"trials":5230,"activeCount":99},[],{"trials":5232,"activeCount":99},[5233,5237,5241,5245,5249,5253,5257],{"nctId":103,"briefTitle":104,"status":105,"phases":5234,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":5235,"interventions":5236},[88],[18],[112,113,95,114,115,116,117],{"nctId":1774,"briefTitle":1775,"status":105,"phases":5238,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":5239,"interventions":5240},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":2333,"briefTitle":2334,"status":105,"phases":5242,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":5243,"interventions":5244},[88],[15],[112,287,210,288,239,291],{"nctId":188,"briefTitle":189,"status":105,"phases":5246,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":5247,"interventions":5248},[88],[196,197,18,21],[112,113,199,95,115,200,117],{"nctId":202,"briefTitle":203,"status":105,"phases":5250,"primaryCompletion":205,"completion":206,"start":193,"enrollment":207,"conditions":5251,"interventions":5252},[88],[15,23],[112,95,210,211,114,212,117],{"nctId":214,"briefTitle":215,"status":105,"phases":5254,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":5255,"interventions":5256},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":5258,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":5259,"interventions":5260},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":5262,"activeCount":2060,"soonestReadout":1894},[5263,5267,5271,5275,5279,5283,5287,5294,5301,5305,5309,5313,5317,5321,5325,5329,5333,5337,5341,5345,5349,5353,5357,5361],{"nctId":2665,"briefTitle":2666,"status":105,"phases":5264,"primaryCompletion":688,"completion":940,"start":1194,"enrollment":207,"conditions":5265,"interventions":5266},[89],[1971,2669,2122,2123,2670,2125,2126,2671,2672,2673,2674,2136,1998,2000,2675,2676],[60,228,566,2678],{"nctId":1824,"briefTitle":1825,"status":105,"phases":5268,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":5269,"interventions":5270},[89],[15],[112,1830,210,115,212,389,409],{"nctId":3993,"briefTitle":3994,"status":105,"phases":5272,"primaryCompletion":1045,"completion":404,"start":613,"enrollment":1759,"conditions":5273,"interventions":5274},[89],[23],[112,328,698],{"nctId":318,"briefTitle":319,"status":320,"phases":5276,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":5277,"interventions":5278},[89],[21],[327,95,115,328,117,329,228],{"nctId":2397,"briefTitle":2398,"status":105,"phases":5280,"primaryCompletion":178,"completion":79,"start":2400,"enrollment":455,"conditions":5281,"interventions":5282},[88,89],[2402,2345,2160],[75,228,525,2232],{"nctId":372,"briefTitle":373,"status":105,"phases":5284,"primaryCompletion":205,"completion":248,"start":375,"enrollment":376,"conditions":5285,"interventions":5286},[89],[35,18],[112,113,95,200,117],{"nctId":5288,"briefTitle":5289,"status":105,"phases":5290,"primaryCompletion":5291,"completion":248,"start":193,"enrollment":1531,"conditions":5292,"interventions":5293},"NCT00003178","Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia",[89],"2004-12",[15],[112,1830,398],{"nctId":5295,"briefTitle":5296,"status":105,"phases":5297,"primaryCompletion":403,"start":1245,"enrollment":4785,"conditions":5298,"interventions":5299},"NCT00070304","Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma",[89],[23],[112,5300,698],"gemcitabine hydrochloride",{"nctId":391,"briefTitle":392,"status":105,"phases":5302,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":5303,"interventions":5304},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":5306,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":5307,"interventions":5308},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":421,"briefTitle":422,"status":105,"phases":5310,"primaryCompletion":424,"completion":322,"start":425,"enrollment":426,"conditions":5311,"interventions":5312},[89],[196,197],[112,199,95,115,117],{"nctId":430,"briefTitle":431,"status":105,"phases":5314,"primaryCompletion":433,"completion":248,"start":434,"enrollment":406,"conditions":5315,"interventions":5316},[89],[23],[112,95,210,288,114,115,289,212,316,305,291,117],{"nctId":451,"briefTitle":452,"status":105,"phases":5318,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":5319,"interventions":5320},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":461,"briefTitle":462,"status":105,"phases":5322,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":5323,"interventions":5324},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":485,"briefTitle":486,"status":105,"phases":5326,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":5327,"interventions":5328},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":498,"briefTitle":499,"status":105,"phases":5330,"primaryCompletion":424,"completion":404,"start":193,"enrollment":501,"conditions":5331,"interventions":5332},[89],[196,197,18],[112,113,199,95,117],{"nctId":529,"briefTitle":530,"status":105,"phases":5334,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":5335,"interventions":5336},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":1891,"briefTitle":1892,"status":333,"phases":5338,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":5339,"interventions":5340},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":1427,"briefTitle":1428,"status":105,"phases":5342,"primaryCompletion":725,"completion":311,"start":1094,"enrollment":1430,"conditions":5343,"interventions":5344},[89],[21],[112,114,328,116,117],{"nctId":542,"briefTitle":543,"status":105,"phases":5346,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":5347,"interventions":5348},[89],[274,275],[112,113,95,115,117,229],{"nctId":570,"briefTitle":571,"status":105,"phases":5350,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":5351,"interventions":5352},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"nctId":581,"briefTitle":582,"status":105,"phases":5354,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":5355,"interventions":5356},[89],[21],[327,112,588,578,95,589,117],{"nctId":591,"briefTitle":592,"status":105,"phases":5358,"primaryCompletion":594,"completion":248,"start":595,"conditions":5359,"interventions":5360},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"nctId":5362,"briefTitle":5363,"status":320,"phases":5364,"primaryCompletion":424,"start":1305,"enrollment":324,"conditions":5365,"interventions":5366},"NCT00107471","Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma",[88,89],[196,197],[112,240],{"trials":5368,"activeCount":2365,"soonestReadout":59},[5369,5373,5385,5389,5393,5397,5401,5405,5409,5413,5417,5421,5425,5429,5433,5437,5441,5445,5449,5453,5457,5468,5472,5476,5486,5490,5494,5498,5502,5506,5510,5514,5518,5522,5526,5530],{"nctId":609,"briefTitle":610,"status":105,"phases":5370,"primaryCompletion":612,"completion":79,"start":613,"enrollment":614,"conditions":5371,"interventions":5372},[90],[21],[112,95,114,115,328,117],{"nctId":5374,"briefTitle":5375,"status":105,"phases":5376,"primaryCompletion":5377,"completion":689,"start":5378,"enrollment":1913,"conditions":5379,"interventions":5384},"NCT00450450","Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases",[90],"2013-06-01","2007-12-31",[972,5380,5381,2158,5382,2159,523,5383,492,2161],"Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Chronic Phase Chronic Myelogenous Leukemia","Previously Treated Myelodysplastic Syndromes",[112],{"nctId":668,"briefTitle":669,"status":105,"phases":5386,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":5387,"interventions":5388},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":676,"briefTitle":677,"status":105,"phases":5390,"primaryCompletion":679,"completion":547,"start":680,"enrollment":681,"conditions":5391,"interventions":5392},[90],[170],[327,112,95,114,115,117],{"nctId":685,"briefTitle":686,"status":105,"phases":5394,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":5395,"interventions":5396},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":2028,"briefTitle":2029,"status":105,"phases":5398,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":5399,"interventions":5400},[90],[2034,2035,2036,2037],[135,136,227,228,2039,1908],{"nctId":700,"briefTitle":701,"status":105,"phases":5402,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":5403,"interventions":5404},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":2057,"briefTitle":2058,"status":105,"phases":5406,"primaryCompletion":206,"completion":206,"start":205,"enrollment":2060,"conditions":5407,"interventions":5408},[90],[274,275],[112,113,115,238,200],{"nctId":730,"briefTitle":731,"status":105,"phases":5410,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":5411,"interventions":5412},[90],[736,662,737,738,663,664,739,665,740,741,742],[327,117,95,240,112,578],{"nctId":745,"briefTitle":746,"status":105,"phases":5414,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":5415,"interventions":5416},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":773,"briefTitle":774,"status":105,"phases":5418,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":5419,"interventions":5420},[90],[18],[113,95,114,115,240,138,228],{"nctId":782,"briefTitle":783,"status":257,"phases":5422,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5423,"interventions":5424},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":799,"briefTitle":800,"status":105,"phases":5426,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":5427,"interventions":5428},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":842,"briefTitle":843,"status":105,"phases":5430,"primaryCompletion":55,"completion":845,"start":846,"enrollment":847,"conditions":5431,"interventions":5432},[90],[849,263,850,851],[60,135,47,227,228,347,157,853,141],{"nctId":855,"briefTitle":856,"status":105,"phases":5434,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":5435,"interventions":5436},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":57,"briefTitle":58,"status":257,"phases":5438,"primaryCompletion":59,"completion":870,"start":871,"enrollment":872,"conditions":5439,"interventions":5440},[90],[849,263],[60,135,47,228,138,141],{"nctId":926,"briefTitle":927,"status":105,"phases":5442,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":5443,"interventions":5444},[90],[934],[60,135,47,227,228,347,157,853,141],{"nctId":2165,"briefTitle":2166,"status":105,"phases":5446,"primaryCompletion":2168,"completion":776,"start":2169,"enrollment":24,"conditions":5447,"interventions":5448},[90],[1562],[697,113,115,112],{"nctId":937,"briefTitle":938,"status":105,"phases":5450,"primaryCompletion":940,"completion":920,"start":941,"enrollment":942,"conditions":5451,"interventions":5452},[90],[944],[60,135,47,227,228,853,141],{"nctId":956,"briefTitle":957,"status":105,"phases":5454,"primaryCompletion":107,"completion":206,"start":959,"enrollment":960,"conditions":5455,"interventions":5456},[90],[15,23],[112,95,210,211,114,115,328,289,212,117],{"nctId":5458,"briefTitle":5459,"status":105,"phases":5460,"primaryCompletion":5461,"completion":5462,"start":5463,"enrollment":2643,"conditions":5464,"interventions":5467},"NCT01149096","Collection of Bone Marrow From Donors Treated With or Without Filgrastim",[90],"2011-12-14","2016-09-30","2010-06-14",[5465,5466],"Healthy Stem Cell Donor","No Evidence of Disease",[228],{"nctId":980,"briefTitle":981,"status":105,"phases":5469,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":5470,"interventions":5471},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":992,"briefTitle":993,"status":105,"phases":5473,"primaryCompletion":679,"completion":983,"start":995,"enrollment":996,"conditions":5474,"interventions":5475},[90],[170],[327,112,113,95,114,115,117],{"nctId":5477,"briefTitle":5478,"status":105,"phases":5479,"primaryCompletion":5480,"completion":206,"start":394,"enrollment":5481,"conditions":5482,"interventions":5485},"NCT00003739","Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy",[90],"2002-12",67,[5483,5484,26],"Fever, Sweats, and Hot Flashes","Neutropenia",[112],{"nctId":1597,"briefTitle":1598,"status":105,"phases":5487,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":5488,"interventions":5489},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1026,"briefTitle":1027,"status":105,"phases":5491,"primaryCompletion":206,"completion":1029,"start":1030,"enrollment":1031,"conditions":5492,"interventions":5493},[90],[21],[327,112,578,95,117],{"nctId":2185,"briefTitle":2186,"status":105,"phases":5495,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":5496,"interventions":5497},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"nctId":1035,"briefTitle":1036,"status":105,"phases":5499,"primaryCompletion":1038,"completion":1038,"start":193,"enrollment":1039,"conditions":5500,"interventions":5501},[90],[18],[112,578,113,95,114,115],{"nctId":1082,"briefTitle":1083,"status":105,"phases":5503,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":5504,"interventions":5505},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1678,"briefTitle":1679,"status":105,"phases":5507,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":5508,"interventions":5509},[90],[751,23],[537,112,496,114,115,117],{"nctId":1140,"briefTitle":1141,"status":105,"phases":5511,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":5512,"interventions":5513},[90],[196,197],[112,199,95,1147,116,117],{"nctId":1178,"briefTitle":1179,"status":105,"phases":5515,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":5516,"interventions":5517},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":5519,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":5520,"interventions":5521},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":1199,"briefTitle":1200,"status":105,"phases":5523,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":5524,"interventions":5525},[90],[274,275],[112,113,199,95,115],{"nctId":1208,"briefTitle":1209,"status":105,"phases":5527,"primaryCompletion":206,"completion":1029,"start":1211,"enrollment":1212,"conditions":5528,"interventions":5529},[90],[18],[112,578,113,95,114,115],{"nctId":1216,"briefTitle":1217,"status":105,"phases":5531,"primaryCompletion":1219,"completion":59,"start":1220,"enrollment":12,"conditions":5532,"interventions":5533},[90],[21],[327,95,114,115,328,589,117,112],{"trials":5535,"activeCount":99},[],{"trials":5537,"activeCount":99},[5538,5542,5546],{"nctId":1241,"briefTitle":1242,"status":105,"phases":5539,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":5540,"interventions":5541},[92],[1248,1249],[537,112,199,95,115,329],{"nctId":1252,"briefTitle":1253,"status":105,"phases":5543,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":5544,"interventions":5545},[92],[1258,1259],[115,328,114,95,117,240,112],{"nctId":1262,"briefTitle":1263,"status":105,"phases":5547,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":5548,"interventions":5549},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"intervention":409,"totalTrials":33,"cells":5551},{"EARLY_PHASE1":5552,"PHASE1":5554,"PHASE2":5560,"PHASE3":5578,"PHASE4":5616,"NA":5618},{"trials":5553,"activeCount":99},[],{"trials":5555,"activeCount":99},[5556],{"nctId":2292,"briefTitle":2293,"status":647,"phases":5557,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":99,"conditions":5558,"interventions":5559},[88],[29,1230,2298,2299,2300,790],[75,157,1357,797],{"trials":5561,"activeCount":99},[5562,5566,5570,5574],{"nctId":1824,"briefTitle":1825,"status":105,"phases":5563,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":5564,"interventions":5565},[89],[15],[112,1830,210,115,212,389,409],{"nctId":400,"briefTitle":401,"status":105,"phases":5567,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":5568,"interventions":5569},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":485,"briefTitle":486,"status":105,"phases":5571,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":5572,"interventions":5573},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"nctId":591,"briefTitle":592,"status":105,"phases":5575,"primaryCompletion":594,"completion":248,"start":595,"conditions":5576,"interventions":5577},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":5579,"activeCount":1449,"soonestReadout":785},[5580,5584,5588,5592,5596,5600,5604,5608,5612],{"nctId":602,"briefTitle":603,"status":105,"phases":5581,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":5582,"interventions":5583},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":700,"briefTitle":701,"status":105,"phases":5585,"primaryCompletion":532,"completion":464,"start":703,"enrollment":704,"conditions":5586,"interventions":5587},[90],[15,23],[112,95,210,114,115,212,707,305,409,117],{"nctId":782,"briefTitle":783,"status":257,"phases":5589,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5590,"interventions":5591},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":5593,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":5594,"interventions":5595},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":1528,"briefTitle":1529,"status":105,"phases":5597,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":5598,"interventions":5599},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":1009,"briefTitle":1010,"status":756,"phases":5601,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":5602,"interventions":5603},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":2222,"briefTitle":2223,"status":333,"phases":5605,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":5606,"interventions":5607},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"nctId":1178,"briefTitle":1179,"status":105,"phases":5609,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":5610,"interventions":5611},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":2609,"briefTitle":2610,"status":105,"phases":5613,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":5614,"interventions":5615},[90],[15,2309,2615],[287,210,288,212,409,291],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[5620],{"nctId":1262,"briefTitle":1263,"status":105,"phases":5621,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":5622,"interventions":5623},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"intervention":139,"totalTrials":2643,"cells":5625},{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5653,"PHASE3":5671,"PHASE4":5689,"NA":5691},{"trials":5627,"activeCount":99},[],{"trials":5629,"activeCount":99},[5630,5634,5641,5645,5649],{"nctId":119,"briefTitle":120,"status":105,"phases":5631,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":5632,"interventions":5633},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":5635,"briefTitle":5636,"status":105,"phases":5637,"primaryCompletion":968,"completion":2315,"start":5638,"enrollment":36,"conditions":5639,"interventions":5640},"NCT02097134","Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma",[88],"2014-10-31",[1951],[139],{"nctId":2333,"briefTitle":2334,"status":105,"phases":5642,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":5643,"interventions":5644},[88],[15],[112,287,210,288,239,291],{"nctId":214,"briefTitle":215,"status":105,"phases":5646,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":5647,"interventions":5648},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":5650,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":5651,"interventions":5652},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":5654,"activeCount":2060,"soonestReadout":259},[5655,5659,5663,5667],{"nctId":268,"briefTitle":269,"status":105,"phases":5656,"primaryCompletion":271,"completion":248,"start":272,"enrollment":235,"conditions":5657,"interventions":5658},[89],[274,275],[277,95,239],{"nctId":517,"briefTitle":518,"status":105,"phases":5660,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":5661,"interventions":5662},[89],[523],[134,47,525,139,526,527],{"nctId":1942,"briefTitle":1943,"status":333,"phases":5664,"primaryCompletion":259,"completion":259,"start":1945,"enrollment":444,"conditions":5665,"interventions":5666},[89],[1947,1948,1949,1950,1951],[60,227,139,266],{"nctId":570,"briefTitle":571,"status":105,"phases":5668,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":5669,"interventions":5670},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":5672,"activeCount":2060,"soonestReadout":630},[5673,5677,5681,5685],{"nctId":668,"briefTitle":669,"status":105,"phases":5674,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":5675,"interventions":5676},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":2185,"briefTitle":2186,"status":105,"phases":5678,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":5679,"interventions":5680},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"nctId":1190,"briefTitle":1191,"status":105,"phases":5682,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":5683,"interventions":5684},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"nctId":1224,"briefTitle":1225,"status":257,"phases":5686,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":5687,"interventions":5688},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":5690,"activeCount":99},[],{"trials":5692,"activeCount":99},[],{"intervention":304,"totalTrials":2268,"cells":5694},{"EARLY_PHASE1":5695,"PHASE1":5697,"PHASE2":5699,"PHASE3":5739,"PHASE4":5753,"NA":5755},{"trials":5696,"activeCount":99},[],{"trials":5698,"activeCount":99},[],{"trials":5700,"activeCount":99},[5701,5705,5709,5727,5731,5735],{"nctId":293,"briefTitle":294,"status":105,"phases":5702,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":5703,"interventions":5704},[89],[301],[303,95,304,305],{"nctId":307,"briefTitle":308,"status":105,"phases":5706,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":5707,"interventions":5708},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":5710,"briefTitle":5711,"status":105,"phases":5712,"primaryCompletion":2107,"completion":2107,"start":311,"enrollment":5713,"conditions":5714,"interventions":5725},"NCT00309907","Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant",[89],39,[5715,5716,972,5380,5381,2158,5382,2159,5717,523,4816,5383,5718,492,2345,5719,5720,4821,5721,32,5722,5723,5724,2160,2161],"Accelerated Phase Chronic Myelogenous Leukemia","Blastic Phase Chronic Myelogenous Leukemia","Disseminated Neuroblastoma","Pulmonary Complications","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Wilms Tumor and Other Childhood Kidney Tumors","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Relapsing Chronic Myelogenous Leukemia",[5726,304],"etanercept",{"nctId":461,"briefTitle":462,"status":105,"phases":5728,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":5729,"interventions":5730},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"nctId":505,"briefTitle":506,"status":105,"phases":5732,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":5733,"interventions":5734},[89],[15],[514,387,95,315,212,304,515],{"nctId":591,"briefTitle":592,"status":105,"phases":5736,"primaryCompletion":594,"completion":248,"start":595,"conditions":5737,"interventions":5738},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":5740,"activeCount":2365,"soonestReadout":785},[5741,5745,5749],{"nctId":782,"briefTitle":783,"status":257,"phases":5742,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5743,"interventions":5744},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1009,"briefTitle":1010,"status":756,"phases":5746,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":5747,"interventions":5748},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":5750,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":5751,"interventions":5752},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"trials":5754,"activeCount":99},[],{"trials":5756,"activeCount":99},[],{"intervention":698,"totalTrials":324,"cells":5758},{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5781,"PHASE4":5799,"NA":5801},{"trials":5760,"activeCount":99},[],{"trials":5762,"activeCount":99},[],{"trials":5764,"activeCount":99},[5765,5773,5777],{"nctId":5766,"briefTitle":5767,"status":105,"phases":5768,"primaryCompletion":1038,"completion":248,"start":5769,"enrollment":5770,"conditions":5771,"interventions":5772},"NCT00003234","Vinorelbine in Treating Children With Recurrent or Refractory Cancers",[89],"1998-05",50,[35,18,21],[698],{"nctId":3993,"briefTitle":3994,"status":105,"phases":5774,"primaryCompletion":1045,"completion":404,"start":613,"enrollment":1759,"conditions":5775,"interventions":5776},[89],[23],[112,328,698],{"nctId":5295,"briefTitle":5296,"status":105,"phases":5778,"primaryCompletion":403,"start":1245,"enrollment":4785,"conditions":5779,"interventions":5780},[89],[23],[112,5300,698],{"trials":5782,"activeCount":2365,"soonestReadout":630},[5783,5787,5791,5795],{"nctId":627,"briefTitle":628,"status":257,"phases":5784,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":5785,"interventions":5786},[90],[634,635,636,637,638,639,640,641],[47,42,141,643],{"nctId":685,"briefTitle":686,"status":105,"phases":5788,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":5789,"interventions":5790},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":754,"briefTitle":755,"status":756,"phases":5792,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":5793,"interventions":5794},[90],[762],[47,42,370,141,643],{"nctId":980,"briefTitle":981,"status":105,"phases":5796,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":5797,"interventions":5798},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"trials":5800,"activeCount":99},[],{"trials":5802,"activeCount":99},[],{"intervention":265,"totalTrials":324,"cells":5804},{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5817,"PHASE3":5836,"PHASE4":5854,"NA":5856},{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[5809],{"nctId":5810,"briefTitle":5811,"status":105,"phases":5812,"primaryCompletion":310,"completion":206,"start":5813,"enrollment":5814,"conditions":5815,"interventions":5816},"NCT00006024","Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma",[88],"2000-11",32,[274,275],[1147,1308],{"trials":5818,"activeCount":2060,"soonestReadout":259},[5819,5823],{"nctId":255,"briefTitle":256,"status":257,"phases":5820,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":5821,"interventions":5822},[89],[263],[135,47,265,266,141],{"nctId":5824,"briefTitle":5825,"status":105,"phases":5826,"primaryCompletion":5827,"completion":968,"start":5828,"enrollment":632,"conditions":5829,"interventions":5835},"NCT00100802","Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas",[89],"2012-09-01","2005-03-21",[5830,5831,5832,5833,5834],"Anaplastic Astrocytoma","Central Nervous System Neoplasm","Glioblastoma","Gliosarcoma","Spinal Cord Neoplasm",[265,3790],{"trials":5837,"activeCount":2060,"soonestReadout":1115},[5838,5842,5846,5850],{"nctId":917,"briefTitle":918,"status":105,"phases":5839,"primaryCompletion":546,"completion":920,"start":921,"enrollment":922,"conditions":5840,"interventions":5841},[90],[263],[135,47,265,141],{"nctId":1617,"briefTitle":1618,"status":105,"phases":5843,"primaryCompletion":983,"completion":1620,"start":1621,"enrollment":1622,"conditions":5844,"interventions":5845},[90],[196,197],[113,1147,540,291,117],{"nctId":1112,"briefTitle":1113,"status":333,"phases":5847,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":5848,"interventions":5849},[90],[1119],[135,47,265,1121,266],{"nctId":1140,"briefTitle":1141,"status":105,"phases":5851,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":5852,"interventions":5853},[90],[196,197],[112,199,95,1147,116,117],{"trials":5855,"activeCount":99},[],{"trials":5857,"activeCount":99},[],{"intervention":134,"totalTrials":324,"cells":5859},{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5872,"PHASE3":5886,"PHASE4":5896,"NA":5898},{"trials":5861,"activeCount":99},[],{"trials":5863,"activeCount":99},[5864,5868],{"nctId":119,"briefTitle":120,"status":105,"phases":5865,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":5866,"interventions":5867},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":214,"briefTitle":215,"status":105,"phases":5869,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":5870,"interventions":5871},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"trials":5873,"activeCount":99},[5874,5878,5882],{"nctId":380,"briefTitle":381,"status":105,"phases":5875,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":5876,"interventions":5877},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":505,"briefTitle":506,"status":105,"phases":5879,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":5880,"interventions":5881},[89],[15],[514,387,95,315,212,304,515],{"nctId":517,"briefTitle":518,"status":105,"phases":5883,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":5884,"interventions":5885},[89],[523],[134,47,525,139,526,527],{"trials":5887,"activeCount":2365,"soonestReadout":630},[5888,5892],{"nctId":1057,"briefTitle":1058,"status":333,"phases":5889,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":5890,"interventions":5891},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1224,"briefTitle":1225,"status":257,"phases":5893,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":5894,"interventions":5895},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":5897,"activeCount":99},[],{"trials":5899,"activeCount":99},[],{"intervention":568,"totalTrials":2365,"cells":5901},{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5912,"PHASE4":5918,"NA":5920},{"trials":5903,"activeCount":99},[],{"trials":5905,"activeCount":99},[],{"trials":5907,"activeCount":2060,"soonestReadout":555},[5908],{"nctId":552,"briefTitle":553,"status":333,"phases":5909,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":5910,"interventions":5911},[89],[559,560,561,562,563],[60,47,565,227,566,567,568,266],{"trials":5913,"activeCount":2060,"soonestReadout":712},[5914],{"nctId":709,"briefTitle":710,"status":333,"phases":5915,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":5916,"interventions":5917},[90],[716],[47,42,718,565,566,568,266],{"trials":5919,"activeCount":99},[],{"trials":5921,"activeCount":99},[],{"intervention":346,"totalTrials":2365,"cells":5923},{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5928,"PHASE3":5934,"PHASE4":5940,"NA":5942},{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":2060,"soonestReadout":335},[5930],{"nctId":331,"briefTitle":332,"status":333,"phases":5931,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":5932,"interventions":5933},[89],[339,340,341,342],[344,345,47,75,346,347,157,158,266],{"trials":5935,"activeCount":2060,"soonestReadout":1102},[5936],{"nctId":1099,"briefTitle":1100,"status":333,"phases":5937,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":5938,"interventions":5939},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"intervention":1233,"totalTrials":2365,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5954,"PHASE3":5956,"PHASE4":5962,"NA":5964},{"trials":5947,"activeCount":99},[],{"trials":5949,"activeCount":2060,"soonestReadout":259},[5950],{"nctId":2340,"briefTitle":2341,"status":333,"phases":5951,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":5952,"interventions":5953},[88],[2345,2346,2347,2348,2349,2350],[75,1233,1356,2352,347,157],{"trials":5955,"activeCount":99},[],{"trials":5957,"activeCount":2060,"soonestReadout":630},[5958],{"nctId":1224,"briefTitle":1225,"status":257,"phases":5959,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":5960,"interventions":5961},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[],{"intervention":290,"totalTrials":4472,"cells":5967},{"EARLY_PHASE1":5968,"PHASE1":5970,"PHASE2":5976,"PHASE3":5998,"PHASE4":6084,"NA":6086},{"trials":5969,"activeCount":99},[],{"trials":5971,"activeCount":99},[5972],{"nctId":143,"briefTitle":144,"status":105,"phases":5973,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":5974,"interventions":5975},[88],[29,151,152],[47,75,154,155,136,156,157,158,159,160,141],{"trials":5977,"activeCount":99},[5978,5982,5986,5990,5994],{"nctId":279,"briefTitle":280,"status":105,"phases":5979,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":5980,"interventions":5981},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":5983,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":5984,"interventions":5985},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":391,"briefTitle":392,"status":105,"phases":5987,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":5988,"interventions":5989},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":5991,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":5992,"interventions":5993},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":591,"briefTitle":592,"status":105,"phases":5995,"primaryCompletion":594,"completion":248,"start":595,"conditions":5996,"interventions":5997},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":5999,"activeCount":2365,"soonestReadout":785},[6000,6004,6012,6016,6020,6024,6028,6032,6036,6040,6044,6048,6052,6056,6060,6064,6068,6072,6076,6080],{"nctId":602,"briefTitle":603,"status":105,"phases":6001,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":6002,"interventions":6003},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":6005,"briefTitle":6006,"status":105,"phases":6007,"primaryCompletion":59,"completion":803,"start":6008,"enrollment":6009,"conditions":6010,"interventions":6011},"NCT01503632","Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission",[90],"2012-02-21",570,[29],[156],{"nctId":2484,"briefTitle":2485,"status":105,"phases":6013,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":6014,"interventions":6015},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"nctId":720,"briefTitle":721,"status":105,"phases":6017,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":6018,"interventions":6019},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":765,"briefTitle":766,"status":105,"phases":6021,"primaryCompletion":768,"completion":533,"start":725,"enrollment":769,"conditions":6022,"interventions":6023},[90],[15],[95,210,288,211,114,290,212,316,291,117],{"nctId":782,"briefTitle":783,"status":257,"phases":6025,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6026,"interventions":6027},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"nctId":1509,"briefTitle":1510,"status":105,"phases":6029,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":6030,"interventions":6031},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":833,"briefTitle":834,"status":105,"phases":6033,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":6034,"interventions":6035},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"nctId":947,"briefTitle":948,"status":105,"phases":6037,"primaryCompletion":950,"completion":147,"start":951,"enrollment":952,"conditions":6038,"interventions":6039},[90],[29,152],[47,75,155,136,347,156,157,158,160,141],{"nctId":1597,"briefTitle":1598,"status":105,"phases":6041,"primaryCompletion":959,"completion":206,"start":1600,"enrollment":1601,"conditions":6042,"interventions":6043},[90],[23],[112,210,114,289,290,212,305,117],{"nctId":1000,"briefTitle":1001,"status":105,"phases":6045,"primaryCompletion":1003,"start":1004,"enrollment":1005,"conditions":6046,"interventions":6047},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1043,"briefTitle":603,"status":105,"phases":6049,"primaryCompletion":1045,"completion":1003,"start":1004,"enrollment":1046,"conditions":6050,"interventions":6051},[90],[15],[95,210,288,211,289,290,212,316,291,117],{"nctId":1050,"briefTitle":1001,"status":105,"phases":6053,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":6054,"interventions":6055},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":6057,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":6058,"interventions":6059},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":6061,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":6062,"interventions":6063},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":1099,"briefTitle":1100,"status":333,"phases":6065,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":6066,"interventions":6067},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"nctId":1123,"briefTitle":1124,"status":105,"phases":6069,"primaryCompletion":1126,"completion":803,"start":1127,"enrollment":1128,"conditions":6070,"interventions":6071},[90],[29,1130,1131,1132,152,1133,1134,1135,1136,1137],[47,75,155,136,347,156,157,158,160,141],{"nctId":1169,"briefTitle":1170,"status":105,"phases":6073,"primaryCompletion":1172,"completion":147,"start":1173,"enrollment":1174,"conditions":6074,"interventions":6075},[90],[29,151,152],[47,75,154,155,136,347,156,157,158,159,160,141],{"nctId":1178,"briefTitle":1179,"status":105,"phases":6077,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":6078,"interventions":6079},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":1717,"briefTitle":1718,"status":105,"phases":6081,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":6082,"interventions":6083},[90],[23],[114,290,212,305,459,117],{"trials":6085,"activeCount":99},[],{"trials":6087,"activeCount":99},[6088,6098,6102],{"nctId":6089,"briefTitle":6090,"status":6091,"phases":6092,"primaryCompletion":6093,"completion":6093,"start":6094,"enrollment":6095,"conditions":6096,"interventions":6097},"NCT06639958","A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home","SUSPENDED",[92],"2027-03-03","2024-12-04",64,[29,2298],[156],{"nctId":1262,"briefTitle":1263,"status":105,"phases":6099,"primaryCompletion":1265,"start":323,"enrollment":501,"conditions":6100,"interventions":6101},[92],[15],[112,95,210,288,211,115,289,290,212,316,409,117],{"nctId":3511,"briefTitle":3512,"status":105,"phases":6103,"primaryCompletion":3514,"completion":3515,"start":3516,"enrollment":3517,"conditions":6104,"interventions":6105},[],[972],[156,157],{"intervention":398,"totalTrials":324,"cells":6107},{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6112,"PHASE3":6126,"PHASE4":6144,"NA":6146},{"trials":6109,"activeCount":99},[],{"trials":6111,"activeCount":99},[],{"trials":6113,"activeCount":99},[6114,6118,6122],{"nctId":2389,"briefTitle":2390,"status":105,"phases":6115,"primaryCompletion":1255,"completion":1255,"start":2392,"enrollment":36,"conditions":6116,"interventions":6117},[88,89],[15],[210,398,2395],{"nctId":5288,"briefTitle":5289,"status":105,"phases":6119,"primaryCompletion":5291,"completion":248,"start":193,"enrollment":1531,"conditions":6120,"interventions":6121},[89],[15],[112,1830,398],{"nctId":391,"briefTitle":392,"status":105,"phases":6123,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":6124,"interventions":6125},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"trials":6127,"activeCount":2060,"soonestReadout":64},[6128,6132,6136,6140],{"nctId":62,"briefTitle":63,"status":257,"phases":6129,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":6130,"interventions":6131},[90],[2469],[65,75,155,2471,2014,2472],{"nctId":2484,"briefTitle":2485,"status":105,"phases":6133,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":6134,"interventions":6135},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"nctId":1528,"briefTitle":1529,"status":105,"phases":6137,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":6138,"interventions":6139},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":1091,"briefTitle":1092,"status":105,"phases":6141,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":6142,"interventions":6143},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"trials":6145,"activeCount":99},[],{"trials":6147,"activeCount":99},[],{"intervention":579,"totalTrials":3501,"cells":6149},{"EARLY_PHASE1":6150,"PHASE1":6152,"PHASE2":6158,"PHASE3":6164,"PHASE4":6178,"NA":6180},{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":99},[6154],{"nctId":119,"briefTitle":120,"status":105,"phases":6155,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":6156,"interventions":6157},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"trials":6159,"activeCount":99},[6160],{"nctId":570,"briefTitle":571,"status":105,"phases":6161,"primaryCompletion":108,"completion":573,"start":574,"enrollment":575,"conditions":6162,"interventions":6163},[89],[18],[112,578,113,199,95,114,115,579,328,238,239,200,117],{"trials":6165,"activeCount":2060,"soonestReadout":1060},[6166,6170,6174],{"nctId":685,"briefTitle":686,"status":105,"phases":6167,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":6168,"interventions":6169},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":980,"briefTitle":981,"status":105,"phases":6171,"primaryCompletion":404,"completion":59,"start":983,"enrollment":984,"conditions":6172,"interventions":6173},[90],[986,987,988,989,864,865],[114,117,305,95,328,698,211,579,199,210,112],{"nctId":1057,"briefTitle":1058,"status":333,"phases":6175,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":6176,"interventions":6177},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"trials":6179,"activeCount":99},[],{"trials":6181,"activeCount":99},[],{"intervention":515,"totalTrials":3501,"cells":6183},{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6188,"PHASE3":6198,"PHASE4":6212,"NA":6214},{"trials":6185,"activeCount":99},[],{"trials":6187,"activeCount":99},[],{"trials":6189,"activeCount":99},[6190,6194],{"nctId":505,"briefTitle":506,"status":105,"phases":6191,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":6192,"interventions":6193},[89],[15],[514,387,95,315,212,304,515],{"nctId":517,"briefTitle":518,"status":105,"phases":6195,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":6196,"interventions":6197},[89],[523],[134,47,525,139,526,527],{"trials":6199,"activeCount":2060,"soonestReadout":630},[6200,6204,6208],{"nctId":964,"briefTitle":965,"status":105,"phases":6201,"primaryCompletion":967,"completion":968,"start":248,"enrollment":969,"conditions":6202,"interventions":6203},[90],[971,972,973,974,975,976],[200,95,515,212,978],{"nctId":4423,"briefTitle":4424,"status":105,"phases":6205,"primaryCompletion":4426,"completion":1029,"start":4427,"enrollment":880,"conditions":6206,"interventions":6207},[90],[973],[315,4430,305,515],{"nctId":1224,"briefTitle":1225,"status":257,"phases":6209,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":6210,"interventions":6211},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":6213,"activeCount":99},[],{"trials":6215,"activeCount":99},[],{"intervention":388,"totalTrials":598,"cells":6217},{"EARLY_PHASE1":6218,"PHASE1":6220,"PHASE2":6226,"PHASE3":6232,"PHASE4":6242,"NA":6244},{"trials":6219,"activeCount":99},[],{"trials":6221,"activeCount":99},[6222],{"nctId":2303,"briefTitle":2304,"status":105,"phases":6223,"primaryCompletion":206,"completion":404,"start":2306,"enrollment":2307,"conditions":6224,"interventions":6225},[88],[15,2309],[287,210,388,389],{"trials":6227,"activeCount":99},[6228],{"nctId":380,"briefTitle":381,"status":105,"phases":6229,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":6230,"interventions":6231},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"trials":6233,"activeCount":2060,"soonestReadout":2225},[6234,6238],{"nctId":2210,"briefTitle":2211,"status":105,"phases":6235,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":6236,"interventions":6237},[90],[15],[287,210,288,115,388,389],{"nctId":2222,"briefTitle":2223,"status":333,"phases":6239,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":6240,"interventions":6241},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"trials":6243,"activeCount":99},[],{"trials":6245,"activeCount":99},[],{"intervention":303,"totalTrials":598,"cells":6247},{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6252,"PHASE3":6277,"PHASE4":6283,"NA":6285},{"trials":6249,"activeCount":99},[],{"trials":6251,"activeCount":99},[],{"trials":6253,"activeCount":99},[6254,6258,6273],{"nctId":293,"briefTitle":294,"status":105,"phases":6255,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":6256,"interventions":6257},[89],[301],[303,95,304,305],{"nctId":6259,"briefTitle":6260,"status":105,"phases":6261,"primaryCompletion":147,"completion":123,"start":6262,"enrollment":30,"conditions":6263,"interventions":6271},"NCT02900976","Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder",[89],"2017-03-22",[6264,6265,6266,6267,6268,6269,6270],"EBV-Related Post-Transplant Lymphoproliferative Disorder","Monomorphic Post-Transplant Lymphoproliferative Disorder","Polymorphic Post-Transplant Lymphoproliferative Disorder","Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder","Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder","Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder","Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder",[6272,1235],"Allogeneic LMP1\u002FLMP2-Specific Cytotoxic T-Lymphocytes",{"nctId":461,"briefTitle":462,"status":105,"phases":6274,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":6275,"interventions":6276},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"trials":6278,"activeCount":2060,"soonestReadout":630},[6279],{"nctId":1224,"briefTitle":1225,"status":257,"phases":6280,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":6281,"interventions":6282},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":6284,"activeCount":99},[],{"trials":6286,"activeCount":99},[],{"intervention":1665,"totalTrials":1449,"cells":6288},{"EARLY_PHASE1":6289,"PHASE1":6291,"PHASE2":6293,"PHASE3":6295,"PHASE4":6309,"NA":6311},{"trials":6290,"activeCount":99},[],{"trials":6292,"activeCount":99},[],{"trials":6294,"activeCount":99},[],{"trials":6296,"activeCount":2060,"soonestReadout":335},[6297,6301,6305],{"nctId":3629,"briefTitle":3630,"status":105,"phases":6298,"primaryCompletion":41,"completion":74,"start":3632,"enrollment":9,"conditions":6299,"interventions":6300},[90],[3634,3635,3636,3637,3638,3639,3640,3641],[3643,135,1665],{"nctId":1516,"briefTitle":1517,"status":105,"phases":6302,"primaryCompletion":424,"start":394,"enrollment":1519,"conditions":6303,"interventions":6304},[90],[1521,1522,1523],[199,117,1525,1526,113],{"nctId":1653,"briefTitle":1654,"status":257,"phases":6306,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":6307,"interventions":6308},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":6310,"activeCount":99},[],{"trials":6312,"activeCount":99},[],{"intervention":2232,"totalTrials":1449,"cells":6314},{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6329,"PHASE4":6335,"NA":6337},{"trials":6316,"activeCount":99},[],{"trials":6318,"activeCount":99},[],{"trials":6320,"activeCount":99},[6321,6325],{"nctId":2397,"briefTitle":2398,"status":105,"phases":6322,"primaryCompletion":178,"completion":79,"start":2400,"enrollment":455,"conditions":6323,"interventions":6324},[88,89],[2402,2345,2160],[75,228,525,2232],{"nctId":2417,"briefTitle":2418,"status":647,"phases":6326,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":6327,"interventions":6328},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"trials":6330,"activeCount":2060,"soonestReadout":2225},[6331],{"nctId":2222,"briefTitle":2223,"status":333,"phases":6332,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":6333,"interventions":6334},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"trials":6336,"activeCount":99},[],{"trials":6338,"activeCount":99},[],{"intervention":821,"totalTrials":1449,"cells":6340},{"EARLY_PHASE1":6341,"PHASE1":6343,"PHASE2":6345,"PHASE3":6347,"PHASE4":6361,"NA":6363},{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":99},[],{"trials":6346,"activeCount":99},[],{"trials":6348,"activeCount":2060,"soonestReadout":51},[6349,6353,6357],{"nctId":49,"briefTitle":50,"status":257,"phases":6350,"primaryCompletion":51,"completion":816,"start":817,"enrollment":818,"conditions":6351,"interventions":6352},[90],[562,563],[47,42,136,227,821],{"nctId":855,"briefTitle":856,"status":105,"phases":6354,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":6355,"interventions":6356},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":1190,"briefTitle":1191,"status":105,"phases":6358,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":6359,"interventions":6360},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"intervention":65,"totalTrials":2365,"cells":6366},{"EARLY_PHASE1":6367,"PHASE1":6369,"PHASE2":6371,"PHASE3":6373,"PHASE4":6383,"NA":6385},{"trials":6368,"activeCount":99},[],{"trials":6370,"activeCount":99},[],{"trials":6372,"activeCount":99},[],{"trials":6374,"activeCount":2060,"soonestReadout":64},[6375,6379],{"nctId":62,"briefTitle":63,"status":257,"phases":6376,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":6377,"interventions":6378},[90],[2469],[65,75,155,2471,2014,2472],{"nctId":2484,"briefTitle":2485,"status":105,"phases":6380,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":6381,"interventions":6382},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"trials":6384,"activeCount":99},[],{"trials":6386,"activeCount":99},[],{"intervention":2472,"totalTrials":2365,"cells":6388},{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6393,"PHASE3":6395,"PHASE4":6405,"NA":6407},{"trials":6390,"activeCount":99},[],{"trials":6392,"activeCount":99},[],{"trials":6394,"activeCount":99},[],{"trials":6396,"activeCount":2060,"soonestReadout":64},[6397,6401],{"nctId":62,"briefTitle":63,"status":257,"phases":6398,"primaryCompletion":64,"completion":2225,"start":2467,"enrollment":511,"conditions":6399,"interventions":6400},[90],[2469],[65,75,155,2471,2014,2472],{"nctId":2484,"briefTitle":2485,"status":105,"phases":6402,"primaryCompletion":2487,"completion":74,"start":2488,"enrollment":2489,"conditions":6403,"interventions":6404},[90],[2491,2492],[65,75,2471,156,157,2014,2472],{"trials":6406,"activeCount":99},[],{"trials":6408,"activeCount":99},[],{"intervention":6410,"totalTrials":2365,"cells":6411},"sodium thiosulfate",{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6416,"PHASE3":6418,"PHASE4":6435,"NA":6437},{"trials":6413,"activeCount":99},[],{"trials":6415,"activeCount":99},[],{"trials":6417,"activeCount":99},[],{"trials":6419,"activeCount":2060,"soonestReadout":1115},[6420,6431],{"nctId":6421,"briefTitle":6422,"status":105,"phases":6423,"primaryCompletion":6424,"completion":776,"start":6425,"enrollment":6426,"conditions":6427,"interventions":6430},"NCT00716976","Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy",[90],"2015-04-09","2008-06-23",131,[274,275,1248,1249,6428,18,6429,1916,21],"Liver Cancer","Ototoxicity",[6410],{"nctId":1112,"briefTitle":1113,"status":333,"phases":6432,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":6433,"interventions":6434},[90],[1119],[135,47,265,1121,266],{"trials":6436,"activeCount":99},[],{"trials":6438,"activeCount":99},[],{"intervention":718,"totalTrials":2365,"cells":6440},{"EARLY_PHASE1":6441,"PHASE1":6443,"PHASE2":6445,"PHASE3":6447,"PHASE4":6457,"NA":6459},{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[],{"trials":6446,"activeCount":99},[],{"trials":6448,"activeCount":2060,"soonestReadout":712},[6449,6453],{"nctId":709,"briefTitle":710,"status":333,"phases":6450,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":6451,"interventions":6452},[90],[716],[47,42,718,565,566,568,266],{"nctId":1158,"briefTitle":1159,"status":105,"phases":6454,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":6455,"interventions":6456},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"trials":6458,"activeCount":99},[],{"trials":6460,"activeCount":99},[],{"intervention":793,"totalTrials":2365,"cells":6462},{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6475,"PHASE3":6477,"PHASE4":6483,"NA":6485},{"trials":6464,"activeCount":99},[],{"trials":6466,"activeCount":99},[6467],{"nctId":6468,"briefTitle":6469,"status":105,"phases":6470,"primaryCompletion":108,"completion":108,"start":6471,"enrollment":235,"conditions":6472,"interventions":6473},"NCT00004932","STI571 in Treating Patients With Recurrent Leukemia",[88],"2002-01",[15],[6474],"imatinib mesylate",{"trials":6476,"activeCount":99},[],{"trials":6478,"activeCount":2060,"soonestReadout":785},[6479],{"nctId":782,"briefTitle":783,"status":257,"phases":6480,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6481,"interventions":6482},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"trials":6484,"activeCount":99},[],{"trials":6486,"activeCount":99},[],{"intervention":526,"totalTrials":2365,"cells":6488},{"EARLY_PHASE1":6489,"PHASE1":6491,"PHASE2":6493,"PHASE3":6499,"PHASE4":6505,"NA":6507},{"trials":6490,"activeCount":99},[],{"trials":6492,"activeCount":99},[],{"trials":6494,"activeCount":99},[6495],{"nctId":517,"briefTitle":518,"status":105,"phases":6496,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":6497,"interventions":6498},[89],[523],[134,47,525,139,526,527],{"trials":6500,"activeCount":2060,"soonestReadout":630},[6501],{"nctId":1224,"briefTitle":1225,"status":257,"phases":6502,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":6503,"interventions":6504},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":6506,"activeCount":99},[],{"trials":6508,"activeCount":99},[],{"intervention":794,"totalTrials":2060,"cells":6510},{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6517,"PHASE4":6523,"NA":6525},{"trials":6512,"activeCount":99},[],{"trials":6514,"activeCount":99},[],{"trials":6516,"activeCount":99},[],{"trials":6518,"activeCount":2060,"soonestReadout":785},[6519],{"nctId":782,"briefTitle":783,"status":257,"phases":6520,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6521,"interventions":6522},[90],[29,789,790,791],[345,47,75,154,155,186,565,227,228,566,793,347,794,156,156,157,795,158,796,797,160,141],{"trials":6524,"activeCount":99},[],{"trials":6526,"activeCount":99},[],{"intervention":70,"totalTrials":2060,"cells":6528},{"EARLY_PHASE1":6529,"PHASE1":6531,"PHASE2":6533,"PHASE3":6535,"PHASE4":6546,"NA":6548},{"trials":6530,"activeCount":99},[],{"trials":6532,"activeCount":99},[],{"trials":6534,"activeCount":99},[],{"trials":6536,"activeCount":2060,"soonestReadout":69},[6537],{"nctId":67,"briefTitle":68,"status":257,"phases":6538,"primaryCompletion":69,"completion":630,"start":6539,"enrollment":6540,"conditions":6541,"interventions":6544},[90],"2018-04-30",173,[6542,6543,15,23],"Acute Graft Versus Host Disease","Hematopoietic and Lymphatic System Neoplasm",[70,6545],"Lactobacillus plantarum strain 299v",{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"intervention":6545,"totalTrials":2060,"cells":6551},{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6556,"PHASE3":6558,"PHASE4":6564,"NA":6566},{"trials":6553,"activeCount":99},[],{"trials":6555,"activeCount":99},[],{"trials":6557,"activeCount":99},[],{"trials":6559,"activeCount":2060,"soonestReadout":69},[6560],{"nctId":67,"briefTitle":68,"status":257,"phases":6561,"primaryCompletion":69,"completion":630,"start":6539,"enrollment":6540,"conditions":6562,"interventions":6563},[90],[6542,6543,15,23],[70,6545],{"trials":6565,"activeCount":99},[],{"trials":6567,"activeCount":99},[],{"intervention":6569,"totalTrials":2060,"cells":6570},"Memantine Hydrochloride",{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6575,"PHASE3":6577,"PHASE4":6588,"NA":6590},{"trials":6572,"activeCount":99},[],{"trials":6574,"activeCount":99},[],{"trials":6576,"activeCount":99},[],{"trials":6578,"activeCount":2060,"soonestReadout":630},[6579],{"nctId":6580,"briefTitle":6581,"status":257,"phases":6582,"primaryCompletion":630,"completion":785,"start":6583,"enrollment":6584,"conditions":6585,"interventions":6587},"NCT04939597","A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor",[90],"2022-05-10",192,[6586],"Central Nervous System Carcinoma",[6569],{"trials":6589,"activeCount":99},[],{"trials":6591,"activeCount":99},[],{"intervention":915,"totalTrials":2060,"cells":6593},{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6600,"PHASE4":6606,"NA":6608},{"trials":6595,"activeCount":99},[],{"trials":6597,"activeCount":99},[],{"trials":6599,"activeCount":99},[],{"trials":6601,"activeCount":2060,"soonestReadout":903},[6602],{"nctId":900,"briefTitle":901,"status":257,"phases":6603,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":6604,"interventions":6605},[89,90],[907,908,909,910,911,912,913],[47,136,227,566,370,915,141],{"trials":6607,"activeCount":99},[],{"trials":6609,"activeCount":99},[],{"intervention":1021,"totalTrials":2060,"cells":6611},{"EARLY_PHASE1":6612,"PHASE1":6614,"PHASE2":6616,"PHASE3":6618,"PHASE4":6624,"NA":6626},{"trials":6613,"activeCount":99},[],{"trials":6615,"activeCount":99},[],{"trials":6617,"activeCount":99},[],{"trials":6619,"activeCount":2060,"soonestReadout":1012},[6620],{"nctId":1009,"briefTitle":1010,"status":756,"phases":6621,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":6622,"interventions":6623},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"trials":6625,"activeCount":99},[],{"trials":6627,"activeCount":99},[],{"intervention":1022,"totalTrials":2060,"cells":6629},{"EARLY_PHASE1":6630,"PHASE1":6632,"PHASE2":6634,"PHASE3":6636,"PHASE4":6642,"NA":6644},{"trials":6631,"activeCount":99},[],{"trials":6633,"activeCount":99},[],{"trials":6635,"activeCount":99},[],{"trials":6637,"activeCount":2060,"soonestReadout":1012},[6638],{"nctId":1009,"briefTitle":1010,"status":756,"phases":6639,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":6640,"interventions":6641},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"trials":6643,"activeCount":99},[],{"trials":6645,"activeCount":99},[],{"intervention":1023,"totalTrials":2060,"cells":6647},{"EARLY_PHASE1":6648,"PHASE1":6650,"PHASE2":6652,"PHASE3":6654,"PHASE4":6660,"NA":6662},{"trials":6649,"activeCount":99},[],{"trials":6651,"activeCount":99},[],{"trials":6653,"activeCount":99},[],{"trials":6655,"activeCount":2060,"soonestReadout":1012},[6656],{"nctId":1009,"briefTitle":1010,"status":756,"phases":6657,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":6658,"interventions":6659},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"trials":6661,"activeCount":99},[],{"trials":6663,"activeCount":99},[],{"intervention":1024,"totalTrials":2060,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6672,"PHASE4":6678,"NA":6680},{"trials":6667,"activeCount":99},[],{"trials":6669,"activeCount":99},[],{"trials":6671,"activeCount":99},[],{"trials":6673,"activeCount":2060,"soonestReadout":1012},[6674],{"nctId":1009,"briefTitle":1010,"status":756,"phases":6675,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":6676,"interventions":6677},[89,90],[1016,1017,1018,791,1019],[1021,345,47,75,1022,154,155,136,1023,157,795,1024,158,796,159,797,160,141],{"trials":6679,"activeCount":99},[],{"trials":6681,"activeCount":99},[],{"intervention":6683,"totalTrials":2060,"cells":6684},"Triptorelin Pamoate",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6691,"PHASE4":6701,"NA":6703},{"trials":6686,"activeCount":99},[],{"trials":6688,"activeCount":99},[],{"trials":6690,"activeCount":99},[],{"trials":6692,"activeCount":2060,"soonestReadout":6697},[6693],{"nctId":6694,"briefTitle":6695,"status":333,"phases":6696,"primaryCompletion":6697,"completion":6697,"start":6698,"enrollment":942,"conditions":6699,"interventions":6700},"NCT06513962","Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer",[90],"2029-10-30","2025-02-27",[6543,3182],[6683],{"trials":6702,"activeCount":99},[],{"trials":6704,"activeCount":99},[],{"intervention":1066,"totalTrials":2060,"cells":6706},{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6711,"PHASE3":6713,"PHASE4":6719,"NA":6721},{"trials":6708,"activeCount":99},[],{"trials":6710,"activeCount":99},[],{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":2060,"soonestReadout":1060},[6715],{"nctId":1057,"briefTitle":1058,"status":333,"phases":6716,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":6717,"interventions":6718},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"trials":6720,"activeCount":99},[],{"trials":6722,"activeCount":99},[],{"intervention":1067,"totalTrials":2060,"cells":6724},{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6731,"PHASE4":6737,"NA":6739},{"trials":6726,"activeCount":99},[],{"trials":6728,"activeCount":99},[],{"trials":6730,"activeCount":99},[],{"trials":6732,"activeCount":2060,"soonestReadout":1060},[6733],{"nctId":1057,"briefTitle":1058,"status":333,"phases":6734,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":6735,"interventions":6736},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"trials":6738,"activeCount":99},[],{"trials":6740,"activeCount":99},[],{"intervention":1666,"totalTrials":2060,"cells":6742},{"EARLY_PHASE1":6743,"PHASE1":6745,"PHASE2":6747,"PHASE3":6749,"PHASE4":6755,"NA":6757},{"trials":6744,"activeCount":99},[],{"trials":6746,"activeCount":99},[],{"trials":6748,"activeCount":99},[],{"trials":6750,"activeCount":2060,"soonestReadout":335},[6751],{"nctId":1653,"briefTitle":1654,"status":257,"phases":6752,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":6753,"interventions":6754},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":6756,"activeCount":99},[],{"trials":6758,"activeCount":99},[],{"intervention":1667,"totalTrials":2060,"cells":6760},{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6767,"PHASE4":6773,"NA":6775},{"trials":6762,"activeCount":99},[],{"trials":6764,"activeCount":99},[],{"trials":6766,"activeCount":99},[],{"trials":6768,"activeCount":2060,"soonestReadout":335},[6769],{"nctId":1653,"briefTitle":1654,"status":257,"phases":6770,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":6771,"interventions":6772},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"intervention":1668,"totalTrials":2060,"cells":6778},{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6783,"PHASE3":6785,"PHASE4":6791,"NA":6793},{"trials":6780,"activeCount":99},[],{"trials":6782,"activeCount":99},[],{"trials":6784,"activeCount":99},[],{"trials":6786,"activeCount":2060,"soonestReadout":335},[6787],{"nctId":1653,"briefTitle":1654,"status":257,"phases":6788,"primaryCompletion":335,"completion":335,"start":1656,"enrollment":1657,"conditions":6789,"interventions":6790},[90],[1659,1660,1661,1662,1663],[60,135,565,227,1665,1666,567,1667,1668,141],{"trials":6792,"activeCount":99},[],{"trials":6794,"activeCount":99},[],{"intervention":1110,"totalTrials":2060,"cells":6796},{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6803,"PHASE4":6809,"NA":6811},{"trials":6798,"activeCount":99},[],{"trials":6800,"activeCount":99},[],{"trials":6802,"activeCount":99},[],{"trials":6804,"activeCount":2060,"soonestReadout":1102},[6805],{"nctId":1099,"briefTitle":1100,"status":333,"phases":6806,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":6807,"interventions":6808},[90],[789,1106,1107,790,1108],[1110,345,47,75,154,155,136,346,347,156,157,158,796,159,160,141],{"trials":6810,"activeCount":99},[],{"trials":6812,"activeCount":99},[],{"intervention":2231,"totalTrials":2060,"cells":6814},{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6821,"PHASE4":6827,"NA":6829},{"trials":6816,"activeCount":99},[],{"trials":6818,"activeCount":99},[],{"trials":6820,"activeCount":99},[],{"trials":6822,"activeCount":2060,"soonestReadout":2225},[6823],{"nctId":2222,"briefTitle":2223,"status":333,"phases":6824,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":2227,"conditions":6825,"interventions":6826},[90],[1230],[344,75,154,186,227,2230,2231,2232,157,2014,797],{"trials":6828,"activeCount":99},[],{"trials":6830,"activeCount":99},[],{"intervention":6832,"totalTrials":2060,"cells":6833},"Letermovir",{"EARLY_PHASE1":6834,"PHASE1":6836,"PHASE2":6838,"PHASE3":6840,"PHASE4":6850,"NA":6852},{"trials":6835,"activeCount":99},[],{"trials":6837,"activeCount":99},[],{"trials":6839,"activeCount":99},[],{"trials":6841,"activeCount":2060,"soonestReadout":2225},[6842],{"nctId":6843,"briefTitle":6844,"status":333,"phases":6845,"primaryCompletion":2225,"completion":2225,"start":6846,"enrollment":6847,"conditions":6848,"interventions":6849},"NCT05711667","A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients",[90],"2024-07-11",105,[3181,3182],[6832],{"trials":6851,"activeCount":99},[],{"trials":6853,"activeCount":99},[],{"intervention":1234,"totalTrials":2060,"cells":6855},{"EARLY_PHASE1":6856,"PHASE1":6858,"PHASE2":6860,"PHASE3":6862,"PHASE4":6868,"NA":6870},{"trials":6857,"activeCount":99},[],{"trials":6859,"activeCount":99},[],{"trials":6861,"activeCount":99},[],{"trials":6863,"activeCount":2060,"soonestReadout":630},[6864],{"nctId":1224,"briefTitle":1225,"status":257,"phases":6865,"primaryCompletion":630,"completion":630,"start":1227,"enrollment":1228,"conditions":6866,"interventions":6867},[90],[29,1230,790,1231],[134,47,1233,1234,139,157,526,1235,527,853],{"trials":6869,"activeCount":99},[],{"trials":6871,"activeCount":99},[],{"intervention":287,"totalTrials":207,"cells":6873},{"EARLY_PHASE1":6874,"PHASE1":6876,"PHASE2":6886,"PHASE3":6912,"PHASE4":6958,"NA":6960},{"trials":6875,"activeCount":99},[],{"trials":6877,"activeCount":99},[6878,6882],{"nctId":2303,"briefTitle":2304,"status":105,"phases":6879,"primaryCompletion":206,"completion":404,"start":2306,"enrollment":2307,"conditions":6880,"interventions":6881},[88],[15,2309],[287,210,388,389],{"nctId":2333,"briefTitle":2334,"status":105,"phases":6883,"primaryCompletion":2336,"completion":248,"start":534,"enrollment":1256,"conditions":6884,"interventions":6885},[88],[15],[112,287,210,288,239,291],{"trials":6887,"activeCount":99},[6888,6892,6896,6900,6904,6908],{"nctId":279,"briefTitle":280,"status":105,"phases":6889,"primaryCompletion":247,"completion":282,"start":283,"enrollment":284,"conditions":6890,"interventions":6891},[89],[15],[287,95,210,288,211,289,290,212,291,117],{"nctId":307,"briefTitle":308,"status":105,"phases":6893,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":6894,"interventions":6895},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":380,"briefTitle":381,"status":105,"phases":6897,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":6898,"interventions":6899},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":391,"briefTitle":392,"status":105,"phases":6901,"primaryCompletion":247,"completion":248,"start":394,"enrollment":395,"conditions":6902,"interventions":6903},[89],[15],[112,287,95,210,288,211,115,398,289,290,212,305,117],{"nctId":400,"briefTitle":401,"status":105,"phases":6905,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":6906,"interventions":6907},[89],[15],[112,287,95,210,288,115,289,290,212,305,409,117],{"nctId":591,"briefTitle":592,"status":105,"phases":6909,"primaryCompletion":594,"completion":248,"start":595,"conditions":6910,"interventions":6911},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":6913,"activeCount":2060,"soonestReadout":84},[6914,6918,6922,6926,6930,6934,6938,6942,6946,6950,6954],{"nctId":602,"briefTitle":603,"status":105,"phases":6915,"primaryCompletion":248,"completion":248,"start":109,"enrollment":605,"conditions":6916,"interventions":6917},[90],[15],[287,95,210,288,211,114,290,212,316,305,409,291,117],{"nctId":82,"briefTitle":83,"status":257,"phases":6919,"primaryCompletion":84,"completion":630,"start":2008,"enrollment":2009,"conditions":6920,"interventions":6921},[90],[1230,1135,1231,2011,2012],[85,344,75,154,227,2014,160],{"nctId":720,"briefTitle":721,"status":105,"phases":6923,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":6924,"interventions":6925},[90],[23],[287,95,210,288,211,114,289,290,212,305,291,117],{"nctId":1509,"briefTitle":1510,"status":105,"phases":6927,"primaryCompletion":1512,"completion":205,"start":405,"enrollment":1212,"conditions":6928,"interventions":6929},[90],[751,15,23],[287,210,496,114,289,290,212,305,409,117],{"nctId":2143,"briefTitle":2144,"status":105,"phases":6931,"primaryCompletion":2146,"completion":802,"start":248,"enrollment":828,"conditions":6932,"interventions":6933},[90],[2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162],[287,288,210,291,115],{"nctId":1050,"briefTitle":1001,"status":105,"phases":6935,"primaryCompletion":108,"start":1052,"enrollment":1053,"conditions":6936,"interventions":6937},[90],[15],[287,95,210,288,211,114,290,212,305,291,117],{"nctId":1082,"briefTitle":1083,"status":105,"phases":6939,"primaryCompletion":1085,"start":248,"enrollment":1086,"conditions":6940,"interventions":6941},[90],[971,974,975,1088],[117,305,114,316,210,212,211,115,95,289,112,287,290],{"nctId":1091,"briefTitle":1092,"status":105,"phases":6943,"primaryCompletion":1038,"start":1094,"enrollment":1095,"conditions":6944,"interventions":6945},[90],[15],[287,95,210,288,211,114,398,290,212,316,305,291,117],{"nctId":2210,"briefTitle":2211,"status":105,"phases":6947,"primaryCompletion":2213,"completion":2108,"start":612,"enrollment":2214,"conditions":6948,"interventions":6949},[90],[15],[287,210,288,115,388,389],{"nctId":1178,"briefTitle":1179,"status":105,"phases":6951,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":6952,"interventions":6953},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"nctId":2609,"briefTitle":2610,"status":105,"phases":6955,"primaryCompletion":248,"completion":1620,"start":2612,"enrollment":2613,"conditions":6956,"interventions":6957},[90],[15,2309,2615],[287,210,288,212,409,291],{"trials":6959,"activeCount":99},[],{"trials":6961,"activeCount":99},[6962],{"nctId":6963,"briefTitle":6964,"status":105,"phases":6965,"primaryCompletion":836,"start":6966,"enrollment":284,"conditions":6967,"interventions":6969},"NCT00537030","Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia",[92],"2008-02-11",[6968,2298],"Adult Acute Lymphoblastic Leukemia",[85],{"intervention":240,"totalTrials":36,"cells":6971},{"EARLY_PHASE1":6972,"PHASE1":6974,"PHASE2":6992,"PHASE3":7004,"PHASE4":7034,"NA":7036},{"trials":6973,"activeCount":99},[],{"trials":6975,"activeCount":99},[6976,6980,6984,6988],{"nctId":119,"briefTitle":120,"status":105,"phases":6977,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":6978,"interventions":6979},[88],[127,128,129,130,131,132],[134,135,47,136,137,138,139,140,141],{"nctId":175,"briefTitle":176,"status":105,"phases":6981,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":6982,"interventions":6983},[88],[182,183,32],[185,47,186,136,140,141],{"nctId":214,"briefTitle":215,"status":105,"phases":6985,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":6986,"interventions":6987},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"nctId":231,"briefTitle":232,"status":105,"phases":6989,"primaryCompletion":206,"completion":234,"start":107,"enrollment":235,"conditions":6990,"interventions":6991},[88],[18],[112,199,95,114,115,238,239,240,117],{"trials":6993,"activeCount":99},[6994,7000],{"nctId":6995,"briefTitle":6996,"status":105,"phases":6997,"primaryCompletion":247,"completion":206,"start":283,"enrollment":1725,"conditions":6998,"interventions":6999},"NCT00003735","Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia",[89],[15],[240],{"nctId":5362,"briefTitle":5363,"status":320,"phases":7001,"primaryCompletion":424,"start":1305,"enrollment":324,"conditions":7002,"interventions":7003},[88,89],[196,197],[112,240],{"trials":7005,"activeCount":2060,"soonestReadout":1060},[7006,7010,7014,7018,7022,7026,7030],{"nctId":645,"briefTitle":646,"status":647,"phases":7007,"primaryCompletion":649,"start":650,"enrollment":99,"conditions":7008,"interventions":7009},[90],[21],[95,496,114,115,328,240,117],{"nctId":668,"briefTitle":669,"status":105,"phases":7011,"primaryCompletion":424,"start":671,"enrollment":672,"conditions":7012,"interventions":7013},[90],[18],[112,113,199,95,114,115,238,239,240,117],{"nctId":730,"briefTitle":731,"status":105,"phases":7015,"primaryCompletion":424,"start":733,"enrollment":734,"conditions":7016,"interventions":7017},[90],[736,662,737,738,663,664,739,665,740,741,742],[327,117,95,240,112,578],{"nctId":773,"briefTitle":774,"status":105,"phases":7019,"primaryCompletion":146,"completion":776,"start":777,"enrollment":778,"conditions":7020,"interventions":7021},[90],[18],[113,95,114,115,240,138,228],{"nctId":1057,"briefTitle":1058,"status":333,"phases":7023,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":7024,"interventions":7025},[90],[127,1064,18],[134,60,135,47,186,80,136,137,138,1066,1067,277,853,140,141],{"nctId":1158,"briefTitle":1159,"status":105,"phases":7027,"primaryCompletion":509,"completion":123,"start":1161,"enrollment":1162,"conditions":7028,"interventions":7029},[90],[1164,1165,1166],[47,718,136,227,566,140,141],{"nctId":1190,"briefTitle":1191,"status":105,"phases":7031,"primaryCompletion":1193,"completion":689,"start":1194,"enrollment":1195,"conditions":7032,"interventions":7033},[90],[128,129,32,130,131,132],[60,135,47,136,227,228,138,139,853,140,821],{"trials":7035,"activeCount":99},[],{"trials":7037,"activeCount":99},[7038],{"nctId":1252,"briefTitle":1253,"status":105,"phases":7039,"primaryCompletion":1255,"start":322,"enrollment":1256,"conditions":7040,"interventions":7041},[92],[1258,1259],[115,328,114,95,117,240,112],{"intervention":537,"totalTrials":2268,"cells":7043},{"EARLY_PHASE1":7044,"PHASE1":7046,"PHASE2":7048,"PHASE3":7058,"PHASE4":7084,"NA":7086},{"trials":7045,"activeCount":99},[],{"trials":7047,"activeCount":99},[],{"trials":7049,"activeCount":99},[7050,7054],{"nctId":529,"briefTitle":530,"status":105,"phases":7051,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":7052,"interventions":7053},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"nctId":1910,"briefTitle":1911,"status":105,"phases":7055,"primaryCompletion":205,"completion":403,"start":1004,"enrollment":1913,"conditions":7056,"interventions":7057},[89],[1248,1915,1249,1916],[537,1526,199,115],{"trials":7059,"activeCount":2060,"soonestReadout":1967},[7060,7064,7068,7072,7076,7080],{"nctId":1964,"briefTitle":1965,"status":333,"phases":7061,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":7062,"interventions":7063},[90],[1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000],[867,60,135,227],{"nctId":685,"briefTitle":686,"status":105,"phases":7065,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":7066,"interventions":7067},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":745,"briefTitle":746,"status":105,"phases":7069,"primaryCompletion":205,"completion":533,"start":748,"enrollment":749,"conditions":7070,"interventions":7071},[90],[751,23],[537,112,95,496,114,115,305,117],{"nctId":855,"briefTitle":856,"status":105,"phases":7073,"primaryCompletion":858,"start":733,"enrollment":859,"conditions":7074,"interventions":7075},[90],[861,862,693,863,864,865,694,695],[867,135,47,75,155,136,227,228,159,821],{"nctId":2113,"briefTitle":2114,"status":105,"phases":7077,"primaryCompletion":2116,"completion":776,"start":2117,"enrollment":2118,"conditions":7078,"interventions":7079},[90],[2120,1971,2121,2122,2123,2124,2125,2126,2127,2128,2129,2130,2131,2132,2133,2134,2135,2136],[199,115,537],{"nctId":1678,"briefTitle":1679,"status":105,"phases":7081,"primaryCompletion":205,"completion":533,"start":1681,"enrollment":1682,"conditions":7082,"interventions":7083},[90],[751,23],[537,112,496,114,115,117],{"trials":7085,"activeCount":99},[],{"trials":7087,"activeCount":99},[7088],{"nctId":1241,"briefTitle":1242,"status":105,"phases":7089,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":7090,"interventions":7091},[92],[1248,1249],[537,112,199,95,115,329],{"intervention":1356,"totalTrials":598,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7102,"PHASE3":7116,"PHASE4":7118,"NA":7120},{"trials":7095,"activeCount":99},[],{"trials":7097,"activeCount":2060,"soonestReadout":259},[7098],{"nctId":2340,"briefTitle":2341,"status":333,"phases":7099,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":7100,"interventions":7101},[88],[2345,2346,2347,2348,2349,2350],[75,1233,1356,2352,347,157],{"trials":7103,"activeCount":2060,"soonestReadout":903},[7104,7108,7112],{"nctId":1338,"briefTitle":1339,"status":257,"phases":7105,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":7106,"interventions":7107},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":2417,"briefTitle":2418,"status":647,"phases":7109,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":7110,"interventions":7111},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"nctId":461,"briefTitle":462,"status":105,"phases":7113,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":7114,"interventions":7115},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"trials":7117,"activeCount":99},[],{"trials":7119,"activeCount":99},[],{"trials":7121,"activeCount":99},[],{"intervention":1308,"totalTrials":1725,"cells":7123},{"EARLY_PHASE1":7124,"PHASE1":7126,"PHASE2":7151,"PHASE3":7176,"PHASE4":7178,"NA":7180},{"trials":7125,"activeCount":99},[],{"trials":7127,"activeCount":99},[7128,7132,7136,7140,7144],{"nctId":3777,"briefTitle":3778,"status":105,"phases":7129,"primaryCompletion":658,"completion":1863,"start":3780,"enrollment":24,"conditions":7130,"interventions":7131},[88],[3782,3783,3784,3785,3786,3787],[567,3789,3790],{"nctId":4781,"briefTitle":4782,"status":105,"phases":7133,"primaryCompletion":689,"completion":920,"start":4784,"enrollment":4785,"conditions":7134,"interventions":7135},[88],[182,3783,3784,3786,3787],[370,4788,3790],{"nctId":1301,"briefTitle":1302,"status":105,"phases":7137,"primaryCompletion":1304,"completion":1029,"start":1305,"enrollment":575,"conditions":7138,"interventions":7139},[88],[35,26],[589,1308,117],{"nctId":5810,"briefTitle":5811,"status":105,"phases":7141,"primaryCompletion":310,"completion":206,"start":5813,"enrollment":5814,"conditions":7142,"interventions":7143},[88],[274,275],[1147,1308],{"nctId":7145,"briefTitle":7146,"status":105,"phases":7147,"primaryCompletion":7148,"completion":533,"start":107,"enrollment":1788,"conditions":7149,"interventions":7150},"NCT00083070","Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia",[88],"2004-09",[15],[1308],{"trials":7152,"activeCount":2365,"soonestReadout":79},[7153,7157,7161,7165,7169],{"nctId":77,"briefTitle":78,"status":257,"phases":7154,"primaryCompletion":79,"completion":785,"start":3795,"enrollment":3796,"conditions":7155,"interventions":7156},[89],[1064,18],[80,567,138,277,3790],{"nctId":4828,"briefTitle":4829,"status":257,"phases":7158,"primaryCompletion":4831,"completion":712,"start":4832,"enrollment":194,"conditions":7159,"interventions":7160},[89],[4834,32,4835],[80,4837,370,277,3790],{"nctId":5824,"briefTitle":5825,"status":105,"phases":7162,"primaryCompletion":5827,"completion":968,"start":5828,"enrollment":632,"conditions":7163,"interventions":7164},[89],[5830,5831,5832,5833,5834],[265,3790],{"nctId":4843,"briefTitle":4844,"status":105,"phases":7166,"primaryCompletion":4846,"completion":234,"start":311,"enrollment":284,"conditions":7167,"interventions":7168},[89],[18],[589,1308],{"nctId":7170,"briefTitle":7171,"status":105,"phases":7172,"primaryCompletion":403,"completion":404,"start":5480,"enrollment":7173,"conditions":7174,"interventions":7175},"NCT00028795","Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma",[89],170,[35],[1308],{"trials":7177,"activeCount":99},[],{"trials":7179,"activeCount":99},[],{"trials":7181,"activeCount":99},[7182],{"nctId":1756,"briefTitle":1757,"status":105,"phases":7183,"primaryCompletion":1255,"completion":234,"start":1245,"enrollment":1759,"conditions":7184,"interventions":7185},[92],[274,275],[113,1308,117],{"intervention":1908,"totalTrials":1449,"cells":7187},{"EARLY_PHASE1":7188,"PHASE1":7190,"PHASE2":7192,"PHASE3":7202,"PHASE4":7208,"NA":7210},{"trials":7189,"activeCount":99},[],{"trials":7191,"activeCount":99},[],{"trials":7193,"activeCount":2060,"soonestReadout":1894},[7194,7198],{"nctId":1891,"briefTitle":1892,"status":333,"phases":7195,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":7196,"interventions":7197},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":581,"briefTitle":582,"status":105,"phases":7199,"primaryCompletion":310,"completion":464,"start":584,"enrollment":585,"conditions":7200,"interventions":7201},[89],[21],[327,112,588,578,95,589,117],{"trials":7203,"activeCount":99},[7204],{"nctId":2028,"briefTitle":2029,"status":105,"phases":7205,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":7206,"interventions":7207},[90],[2034,2035,2036,2037],[135,136,227,228,2039,1908],{"trials":7209,"activeCount":99},[],{"trials":7211,"activeCount":99},[],{"intervention":525,"totalTrials":598,"cells":7213},{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7215,"activeCount":99},[],{"trials":7217,"activeCount":99},[],{"trials":7219,"activeCount":2060,"soonestReadout":903},[7220,7224,7228,7232],{"nctId":1338,"briefTitle":1339,"status":257,"phases":7221,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":7222,"interventions":7223},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"nctId":2397,"briefTitle":2398,"status":105,"phases":7225,"primaryCompletion":178,"completion":79,"start":2400,"enrollment":455,"conditions":7226,"interventions":7227},[88,89],[2402,2345,2160],[75,228,525,2232],{"nctId":2417,"briefTitle":2418,"status":647,"phases":7229,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":7230,"interventions":7231},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"nctId":517,"briefTitle":518,"status":105,"phases":7233,"primaryCompletion":520,"completion":520,"start":521,"enrollment":24,"conditions":7234,"interventions":7235},[89],[523],[134,47,525,139,526,527],{"trials":7237,"activeCount":99},[],{"trials":7239,"activeCount":99},[],{"trials":7241,"activeCount":99},[],{"intervention":1357,"totalTrials":2365,"cells":7243},{"EARLY_PHASE1":7244,"PHASE1":7246,"PHASE2":7252,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7245,"activeCount":99},[],{"trials":7247,"activeCount":99},[7248],{"nctId":2292,"briefTitle":2293,"status":647,"phases":7249,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":99,"conditions":7250,"interventions":7251},[88],[29,1230,2298,2299,2300,790],[75,157,1357,797],{"trials":7253,"activeCount":2060,"soonestReadout":903},[7254],{"nctId":1338,"briefTitle":1339,"status":257,"phases":7255,"primaryCompletion":903,"completion":903,"start":1341,"enrollment":8,"conditions":7256,"interventions":7257},[89],[1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354],[345,75,525,1356,157,796,159,1357,141],{"trials":7259,"activeCount":99},[],{"trials":7261,"activeCount":99},[],{"trials":7263,"activeCount":99},[],{"intervention":4837,"totalTrials":2060,"cells":7265},{"EARLY_PHASE1":7266,"PHASE1":7268,"PHASE2":7270,"PHASE3":7276,"PHASE4":7278,"NA":7280},{"trials":7267,"activeCount":99},[],{"trials":7269,"activeCount":99},[],{"trials":7271,"activeCount":2060,"soonestReadout":4831},[7272],{"nctId":4828,"briefTitle":4829,"status":257,"phases":7273,"primaryCompletion":4831,"completion":712,"start":4832,"enrollment":194,"conditions":7274,"interventions":7275},[89],[4834,32,4835],[80,4837,370,277,3790],{"trials":7277,"activeCount":99},[],{"trials":7279,"activeCount":99},[],{"trials":7281,"activeCount":99},[],{"intervention":7283,"totalTrials":2060,"cells":7284},"Tegavivint",{"EARLY_PHASE1":7285,"PHASE1":7287,"PHASE2":7289,"PHASE3":7317,"PHASE4":7319,"NA":7321},{"trials":7286,"activeCount":99},[],{"trials":7288,"activeCount":99},[],{"trials":7290,"activeCount":2060,"soonestReadout":870},[7291],{"nctId":7292,"briefTitle":7293,"status":333,"phases":7294,"primaryCompletion":870,"completion":870,"start":7295,"enrollment":7296,"conditions":7297,"interventions":7316},"NCT04851119","Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",[88,89],"2021-11-08",147,[7298,7299,7300,18,7301,7302,7303,7304,7305,7306,3783,7307,4825,7308,7309,7310,7311,3786,7312,7313,7314,7315],"Colorectal Carcinoma","Endometrial Carcinoma","Melanoma","Ovarian Carcinoma","Pancreatic Ductal Adenocarcinoma","Recurrent Desmoid Fibromatosis","Recurrent Ewing Sarcoma","Recurrent Hepatoblastoma","Recurrent Hepatocellular Carcinoma","Recurrent Non-Hodgkin Lymphoma","Refractory Desmoid Fibromatosis","Refractory Ewing Sarcoma","Refractory Hepatoblastoma","Refractory Hepatocellular Carcinoma","Refractory Non-Hodgkin Lymphoma","Refractory Osteosarcoma","Solid Pseudopapillary Neoplasm of the Pancreas","Wilms Tumor",[7283],{"trials":7318,"activeCount":99},[],{"trials":7320,"activeCount":99},[],{"trials":7322,"activeCount":99},[],{"intervention":7324,"totalTrials":2060,"cells":7325},"Nirogacestat",{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7330,"PHASE3":7342,"PHASE4":7344,"NA":7346},{"trials":7327,"activeCount":99},[],{"trials":7329,"activeCount":99},[],{"trials":7331,"activeCount":2060,"soonestReadout":803},[7332],{"nctId":7333,"briefTitle":7334,"status":257,"phases":7335,"primaryCompletion":803,"completion":7336,"start":7337,"enrollment":235,"conditions":7338,"interventions":7341},"NCT04195399","A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery",[89],"2027-04-10","2020-10-07",[7339,7303,7340],"Desmoid Fibromatosis","Unresectable Desmoid Fibromatosis",[7324],{"trials":7343,"activeCount":99},[],{"trials":7345,"activeCount":99},[],{"trials":7347,"activeCount":99},[],{"intervention":7349,"totalTrials":2060,"cells":7350},"Larotrectinib Sulfate",{"EARLY_PHASE1":7351,"PHASE1":7353,"PHASE2":7355,"PHASE3":7369,"PHASE4":7371,"NA":7373},{"trials":7352,"activeCount":99},[],{"trials":7354,"activeCount":99},[],{"trials":7356,"activeCount":2060,"soonestReadout":1863},[7357],{"nctId":7358,"briefTitle":7359,"status":257,"phases":7360,"primaryCompletion":1863,"completion":7361,"start":7362,"enrollment":4785,"conditions":7363,"interventions":7368},"NCT03834961","Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia",[89],"2027-07-25","2019-10-25",[5831,7364,7365,7366,7367],"Infantile Fibrosarcoma","Recurrent Acute Leukemia","Refractory Acute Leukemia","Solid Neoplasm",[7349],{"trials":7370,"activeCount":99},[],{"trials":7372,"activeCount":99},[],{"trials":7374,"activeCount":99},[],{"intervention":3815,"totalTrials":2060,"cells":7376},{"EARLY_PHASE1":7377,"PHASE1":7379,"PHASE2":7381,"PHASE3":7387,"PHASE4":7389,"NA":7391},{"trials":7378,"activeCount":99},[],{"trials":7380,"activeCount":99},[],{"trials":7382,"activeCount":2060,"soonestReadout":3803},[7383],{"nctId":3800,"briefTitle":3801,"status":333,"phases":7384,"primaryCompletion":3803,"completion":3803,"start":3804,"enrollment":3805,"conditions":7385,"interventions":7386},[88,89],[3807,3808,3809,3810,3783,3811,3812,3813,3786],[3815,567],{"trials":7388,"activeCount":99},[],{"trials":7390,"activeCount":99},[],{"trials":7392,"activeCount":99},[],{"intervention":7394,"totalTrials":2060,"cells":7395},"Enasidenib",{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7410,"PHASE4":7412,"NA":7414},{"trials":7397,"activeCount":99},[],{"trials":7399,"activeCount":99},[],{"trials":7401,"activeCount":2060,"soonestReadout":845},[7402],{"nctId":7403,"briefTitle":7404,"status":257,"phases":7405,"primaryCompletion":845,"completion":7406,"start":3547,"enrollment":2060,"conditions":7407,"interventions":7408},"NCT04203316","Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation",[89],"2026-10-03",[2357,2358],[7394,7409],"Enasidenib Mesylate",{"trials":7411,"activeCount":99},[],{"trials":7413,"activeCount":99},[],{"trials":7415,"activeCount":99},[],{"intervention":7409,"totalTrials":2060,"cells":7417},{"EARLY_PHASE1":7418,"PHASE1":7420,"PHASE2":7422,"PHASE3":7428,"PHASE4":7430,"NA":7432},{"trials":7419,"activeCount":99},[],{"trials":7421,"activeCount":99},[],{"trials":7423,"activeCount":2060,"soonestReadout":845},[7424],{"nctId":7403,"briefTitle":7404,"status":257,"phases":7425,"primaryCompletion":845,"completion":7406,"start":3547,"enrollment":2060,"conditions":7426,"interventions":7427},[89],[2357,2358],[7394,7409],{"trials":7429,"activeCount":99},[],{"trials":7431,"activeCount":99},[],{"trials":7433,"activeCount":99},[],{"intervention":7435,"totalTrials":2060,"cells":7436},"FACT Complex-targeting Curaxin CBL0137",{"EARLY_PHASE1":7437,"PHASE1":7439,"PHASE2":7441,"PHASE3":7457,"PHASE4":7459,"NA":7461},{"trials":7438,"activeCount":99},[],{"trials":7440,"activeCount":99},[],{"trials":7442,"activeCount":2060,"soonestReadout":335},[7443],{"nctId":7444,"briefTitle":7445,"status":333,"phases":7446,"primaryCompletion":335,"completion":335,"start":7447,"enrollment":7448,"conditions":7449,"interventions":7456},"NCT04870944","CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",[88,89],"2022-01-28",63,[7450,7451,7452,7453,3782,3783,7454,3785,3786,7455],"Diffuse Midline Glioma, H3 K27-Altered","Metastatic Malignant Neoplasm in the Central Nervous System","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Diffuse Midline Glioma, H3 K27-Altered","Recurrent Primary Malignant Central Nervous System Neoplasm","Refractory Primary Malignant Central Nervous System Neoplasm",[7435],{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[],{"trials":7462,"activeCount":99},[],{"intervention":7464,"totalTrials":2060,"cells":7465},"Bosutinib",{"EARLY_PHASE1":7466,"PHASE1":7468,"PHASE2":7470,"PHASE3":7481,"PHASE4":7483,"NA":7485},{"trials":7467,"activeCount":99},[],{"trials":7469,"activeCount":99},[],{"trials":7471,"activeCount":2060,"soonestReadout":7476},[7472],{"nctId":7473,"briefTitle":7474,"status":257,"phases":7475,"primaryCompletion":7476,"completion":7476,"start":7477,"enrollment":942,"conditions":7478,"interventions":7480},"NCT04258943","Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant\u002FIntolerant Ph + Chronic Myeloid Leukemia",[88,89],"2028-07","2020-07-06",[7479,5715,5716,5382],"Philadelphia Chromosome Positive CML",[7464],{"trials":7482,"activeCount":99},[],{"trials":7484,"activeCount":99},[],{"trials":7486,"activeCount":99},[],{"intervention":7488,"totalTrials":2060,"cells":7489},"Tyrosine Kinase Inhibitor",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7494,"PHASE3":7504,"PHASE4":7506,"NA":7508},{"trials":7491,"activeCount":99},[],{"trials":7493,"activeCount":99},[],{"trials":7495,"activeCount":2060,"soonestReadout":1152},[7496],{"nctId":7497,"briefTitle":7498,"status":257,"phases":7499,"primaryCompletion":1152,"completion":1152,"start":7500,"enrollment":714,"conditions":7501,"interventions":7503},"NCT03817398","Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia",[89],"2019-11-08",[7502],"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive",[7488],{"trials":7505,"activeCount":99},[],{"trials":7507,"activeCount":99},[],{"trials":7509,"activeCount":99},[],{"intervention":116,"totalTrials":36,"cells":7511},{"EARLY_PHASE1":7512,"PHASE1":7514,"PHASE2":7528,"PHASE3":7558,"PHASE4":7572,"NA":7574},{"trials":7513,"activeCount":99},[],{"trials":7515,"activeCount":99},[7516,7520,7524],{"nctId":103,"briefTitle":104,"status":105,"phases":7517,"primaryCompletion":107,"completion":108,"start":109,"enrollment":24,"conditions":7518,"interventions":7519},[88],[18],[112,113,95,114,115,116,117],{"nctId":1774,"briefTitle":1775,"status":105,"phases":7521,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":7522,"interventions":7523},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"nctId":214,"briefTitle":215,"status":105,"phases":7525,"primaryCompletion":217,"completion":84,"start":218,"enrollment":219,"conditions":7526,"interventions":7527},[88],[127,221,222,223,224,225,131,132],[134,135,47,136,227,228,139,229,140,141],{"trials":7529,"activeCount":2060,"soonestReadout":1894},[7530,7534,7538,7542,7546,7550,7554],{"nctId":244,"briefTitle":245,"status":105,"phases":7531,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":7532,"interventions":7533},[89],[23],[253,95,115,116],{"nctId":318,"briefTitle":319,"status":320,"phases":7535,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":7536,"interventions":7537},[89],[21],[327,95,115,328,117,329,228],{"nctId":451,"briefTitle":452,"status":105,"phases":7539,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":7540,"interventions":7541},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":1891,"briefTitle":1892,"status":333,"phases":7543,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":7544,"interventions":7545},[89],[1867,1898,1899,1900,1901,1902,1903,1904,1905,1906],[60,227,228,566,229,1908,853],{"nctId":1427,"briefTitle":1428,"status":105,"phases":7547,"primaryCompletion":725,"completion":311,"start":1094,"enrollment":1430,"conditions":7548,"interventions":7549},[89],[21],[112,114,328,116,117],{"nctId":542,"briefTitle":543,"status":105,"phases":7551,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":7552,"interventions":7553},[89],[274,275],[112,113,95,115,117,229],{"nctId":591,"briefTitle":592,"status":105,"phases":7555,"primaryCompletion":594,"completion":248,"start":595,"conditions":7556,"interventions":7557},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":7559,"activeCount":99},[7560,7564,7568],{"nctId":799,"briefTitle":800,"status":105,"phases":7561,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":7562,"interventions":7563},[90],[807,808,809,810,811,812],[60,135,47,227,228,229,266],{"nctId":1528,"briefTitle":1529,"status":105,"phases":7565,"primaryCompletion":247,"completion":311,"start":1143,"enrollment":1531,"conditions":7566,"interventions":7567},[90],[15],[210,211,115,398,328,289,116,316,409,291,117,157],{"nctId":1140,"briefTitle":1141,"status":105,"phases":7569,"primaryCompletion":983,"completion":1029,"start":1143,"enrollment":1144,"conditions":7570,"interventions":7571},[90],[196,197],[112,199,95,1147,116,117],{"trials":7573,"activeCount":99},[],{"trials":7575,"activeCount":99},[7576],{"nctId":1241,"briefTitle":1242,"status":105,"phases":7577,"primaryCompletion":1244,"start":1245,"enrollment":1246,"conditions":7578,"interventions":7579},[92],[1248,1249],[537,112,199,95,115,329],{"intervention":7581,"totalTrials":2060,"cells":7582},"SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years",{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7600,"PHASE3":7602,"PHASE4":7604,"NA":7606},{"trials":7584,"activeCount":99},[],{"trials":7586,"activeCount":2060,"soonestReadout":903},[7587],{"nctId":7588,"briefTitle":7589,"status":257,"phases":7590,"primaryCompletion":903,"completion":903,"start":7591,"enrollment":1256,"conditions":7592,"interventions":7597},"NCT04978727","A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma",[88],"2022-07-01",[263,7593,5830,7594,7595,807,811,7596],"Glioblastoma Multiforme","High-grade Astrocytoma NOS","Anaplastic Oligodendroglioma","Diffuse Intrinsic Pontine Glioma",[7581,7598,7599],"SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and \u003C10 years","SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years",{"trials":7601,"activeCount":99},[],{"trials":7603,"activeCount":99},[],{"trials":7605,"activeCount":99},[],{"trials":7607,"activeCount":99},[],{"intervention":7598,"totalTrials":2060,"cells":7609},{"EARLY_PHASE1":7610,"PHASE1":7612,"PHASE2":7618,"PHASE3":7620,"PHASE4":7622,"NA":7624},{"trials":7611,"activeCount":99},[],{"trials":7613,"activeCount":2060,"soonestReadout":903},[7614],{"nctId":7588,"briefTitle":7589,"status":257,"phases":7615,"primaryCompletion":903,"completion":903,"start":7591,"enrollment":1256,"conditions":7616,"interventions":7617},[88],[263,7593,5830,7594,7595,807,811,7596],[7581,7598,7599],{"trials":7619,"activeCount":99},[],{"trials":7621,"activeCount":99},[],{"trials":7623,"activeCount":99},[],{"trials":7625,"activeCount":99},[],{"intervention":7599,"totalTrials":2060,"cells":7627},{"EARLY_PHASE1":7628,"PHASE1":7630,"PHASE2":7636,"PHASE3":7638,"PHASE4":7640,"NA":7642},{"trials":7629,"activeCount":99},[],{"trials":7631,"activeCount":2060,"soonestReadout":903},[7632],{"nctId":7588,"briefTitle":7589,"status":257,"phases":7633,"primaryCompletion":903,"completion":903,"start":7591,"enrollment":1256,"conditions":7634,"interventions":7635},[88],[263,7593,5830,7594,7595,807,811,7596],[7581,7598,7599],{"trials":7637,"activeCount":99},[],{"trials":7639,"activeCount":99},[],{"trials":7641,"activeCount":99},[],{"trials":7643,"activeCount":99},[],{"intervention":7645,"totalTrials":2060,"cells":7646},"ATM Kinase Inhibitor AZD1390",{"EARLY_PHASE1":7647,"PHASE1":7649,"PHASE2":7664,"PHASE3":7666,"PHASE4":7668,"NA":7670},{"trials":7648,"activeCount":99},[],{"trials":7650,"activeCount":2060,"soonestReadout":259},[7651],{"nctId":7652,"briefTitle":7653,"status":333,"phases":7654,"primaryCompletion":259,"completion":259,"start":7655,"enrollment":7656,"conditions":7657,"interventions":7663},"NCT06894979","Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma",[88],"2025-06-18",54,[7658,7659,7660,7661,7662],"Childhood Astrocytoma","Childhood Diffuse Intrinsic Pontine Glioma","Childhood Diffuse Midline Glioma","Childhood Glioblastoma","Childhood Malignant Glioma",[7645],{"trials":7665,"activeCount":99},[],{"trials":7667,"activeCount":99},[],{"trials":7669,"activeCount":99},[],{"trials":7671,"activeCount":99},[],{"intervention":7673,"totalTrials":2060,"cells":7674},"HER2 Specific CAR T Cell",{"EARLY_PHASE1":7675,"PHASE1":7677,"PHASE2":7687,"PHASE3":7689,"PHASE4":7691,"NA":7693},{"trials":7676,"activeCount":99},[],{"trials":7678,"activeCount":2060,"soonestReadout":7683},[7679],{"nctId":7680,"briefTitle":7681,"status":257,"phases":7682,"primaryCompletion":7683,"completion":7683,"start":7684,"enrollment":5770,"conditions":7685,"interventions":7686},"NCT04903080","HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma",[88],"2033-03-31","2022-07-27",[811],[7673],{"trials":7688,"activeCount":99},[],{"trials":7690,"activeCount":99},[],{"trials":7692,"activeCount":99},[],{"trials":7694,"activeCount":99},[],{"intervention":2352,"totalTrials":2060,"cells":7696},{"EARLY_PHASE1":7697,"PHASE1":7699,"PHASE2":7705,"PHASE3":7707,"PHASE4":7709,"NA":7711},{"trials":7698,"activeCount":99},[],{"trials":7700,"activeCount":2060,"soonestReadout":259},[7701],{"nctId":2340,"briefTitle":2341,"status":333,"phases":7702,"primaryCompletion":259,"completion":259,"start":2343,"enrollment":395,"conditions":7703,"interventions":7704},[88],[2345,2346,2347,2348,2349,2350],[75,1233,1356,2352,347,157],{"trials":7706,"activeCount":99},[],{"trials":7708,"activeCount":99},[],{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"intervention":2360,"totalTrials":2060,"cells":7714},{"EARLY_PHASE1":7715,"PHASE1":7717,"PHASE2":7723,"PHASE3":7725,"PHASE4":7727,"NA":7729},{"trials":7716,"activeCount":99},[],{"trials":7718,"activeCount":2060,"soonestReadout":74},[7719],{"nctId":72,"briefTitle":73,"status":257,"phases":7720,"primaryCompletion":74,"completion":803,"start":2355,"enrollment":1788,"conditions":7721,"interventions":7722},[88],[2357,2358],[75,2360],{"trials":7724,"activeCount":99},[],{"trials":7726,"activeCount":99},[],{"trials":7728,"activeCount":99},[],{"trials":7730,"activeCount":99},[],{"intervention":7732,"totalTrials":2060,"cells":7733},"Concurrent Optune and RT followed by Optune System alone",{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7738,"PHASE3":7740,"PHASE4":7742,"NA":7744},{"trials":7735,"activeCount":99},[],{"trials":7737,"activeCount":99},[],{"trials":7739,"activeCount":99},[],{"trials":7741,"activeCount":99},[],{"trials":7743,"activeCount":99},[],{"trials":7745,"activeCount":2060,"soonestReadout":7750},[7746],{"nctId":7747,"briefTitle":7748,"status":257,"phases":7749,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":337,"conditions":7752,"interventions":7754},"NCT03033992","Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG",[92],"2032-07-22","2017-04-04",[7753,811,7596],"Malignant Glioma",[7732],{"intervention":315,"totalTrials":324,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7765,"PHASE3":7783,"PHASE4":7793,"NA":7795},{"trials":7758,"activeCount":99},[],{"trials":7760,"activeCount":99},[7761],{"nctId":1326,"briefTitle":1327,"status":105,"phases":7762,"primaryCompletion":671,"completion":311,"start":283,"enrollment":324,"conditions":7763,"interventions":7764},[88],[196,197],[315,115,117],{"trials":7766,"activeCount":99},[7767,7771,7775,7779],{"nctId":307,"briefTitle":308,"status":105,"phases":7768,"primaryCompletion":310,"completion":311,"start":247,"enrollment":312,"conditions":7769,"interventions":7770},[89],[15],[287,95,315,210,288,211,114,290,212,304,316,291,117],{"nctId":380,"briefTitle":381,"status":105,"phases":7772,"primaryCompletion":206,"completion":234,"start":383,"enrollment":384,"conditions":7773,"interventions":7774},[89],[15],[287,387,95,315,210,288,115,388,212,389],{"nctId":505,"briefTitle":506,"status":105,"phases":7776,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":7777,"interventions":7778},[89],[15],[514,387,95,315,212,304,515],{"nctId":591,"briefTitle":592,"status":105,"phases":7780,"primaryCompletion":594,"completion":248,"start":595,"conditions":7781,"interventions":7782},[89],[15],[112,287,95,315,210,288,211,115,289,290,116,212,304,316,305,409,117],{"trials":7784,"activeCount":99},[7785,7789],{"nctId":2185,"briefTitle":2186,"status":105,"phases":7786,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":7787,"interventions":7788},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"nctId":4423,"briefTitle":4424,"status":105,"phases":7790,"primaryCompletion":4426,"completion":1029,"start":4427,"enrollment":880,"conditions":7791,"interventions":7792},[90],[973],[315,4430,305,515],{"trials":7794,"activeCount":99},[],{"trials":7796,"activeCount":99},[],{"intervention":459,"totalTrials":3501,"cells":7798},{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7807,"PHASE3":7821,"PHASE4":7827,"NA":7829},{"trials":7800,"activeCount":99},[],{"trials":7802,"activeCount":99},[7803],{"nctId":2652,"briefTitle":2653,"status":105,"phases":7804,"primaryCompletion":2107,"completion":404,"start":353,"enrollment":444,"conditions":7805,"interventions":7806},[88],[35,2656],[113,459],{"trials":7808,"activeCount":99},[7809,7813,7817],{"nctId":3304,"briefTitle":3305,"status":105,"phases":7810,"primaryCompletion":3307,"completion":206,"start":1030,"enrollment":1560,"conditions":7811,"interventions":7812},[89],[3309],[212,459],{"nctId":451,"briefTitle":452,"status":105,"phases":7814,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":7815,"interventions":7816},[89],[21],[458,95,114,115,328,459,117,329,228],{"nctId":529,"briefTitle":530,"status":105,"phases":7818,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":7819,"interventions":7820},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"trials":7822,"activeCount":99},[7823],{"nctId":1717,"briefTitle":1718,"status":105,"phases":7824,"primaryCompletion":1720,"completion":465,"start":1721,"enrollment":1722,"conditions":7825,"interventions":7826},[90],[23],[114,290,212,305,459,117],{"trials":7828,"activeCount":99},[],{"trials":7830,"activeCount":99},[],{"intervention":697,"totalTrials":1449,"cells":7832},{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7839,"PHASE4":7853,"NA":7855},{"trials":7834,"activeCount":99},[],{"trials":7836,"activeCount":99},[],{"trials":7838,"activeCount":99},[],{"trials":7840,"activeCount":99},[7841,7845,7849],{"nctId":685,"briefTitle":686,"status":105,"phases":7842,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":7843,"interventions":7844},[90],[693,694,695],[537,114,697,698,95,579,305,112,328],{"nctId":2104,"briefTitle":2105,"status":105,"phases":7846,"primaryCompletion":2107,"completion":2108,"start":650,"enrollment":2109,"conditions":7847,"interventions":7848},[90],[1562],[697,113,115],{"nctId":2165,"briefTitle":2166,"status":105,"phases":7850,"primaryCompletion":2168,"completion":776,"start":2169,"enrollment":24,"conditions":7851,"interventions":7852},[90],[1562],[697,113,115,112],{"trials":7854,"activeCount":99},[],{"trials":7856,"activeCount":99},[],{"intervention":1526,"totalTrials":1449,"cells":7858},{"EARLY_PHASE1":7859,"PHASE1":7861,"PHASE2":7863,"PHASE3":7875,"PHASE4":7881,"NA":7883},{"trials":7860,"activeCount":99},[],{"trials":7862,"activeCount":99},[],{"trials":7864,"activeCount":99},[7865,7871],{"nctId":7866,"briefTitle":7867,"status":105,"phases":7868,"primaryCompletion":424,"completion":464,"start":310,"enrollment":2452,"conditions":7869,"interventions":7870},"NCT00098683","Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes",[89],[2309,2615],[1526],{"nctId":1910,"briefTitle":1911,"status":105,"phases":7872,"primaryCompletion":205,"completion":403,"start":1004,"enrollment":1913,"conditions":7873,"interventions":7874},[89],[1248,1915,1249,1916],[537,1526,199,115],{"trials":7876,"activeCount":99},[7877],{"nctId":1516,"briefTitle":1517,"status":105,"phases":7878,"primaryCompletion":424,"start":394,"enrollment":1519,"conditions":7879,"interventions":7880},[90],[1521,1522,1523],[199,117,1525,1526,113],{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"intervention":253,"totalTrials":2365,"cells":7886},{"EARLY_PHASE1":7887,"PHASE1":7889,"PHASE2":7891,"PHASE3":7897,"PHASE4":7903,"NA":7905},{"trials":7888,"activeCount":99},[],{"trials":7890,"activeCount":99},[],{"trials":7892,"activeCount":99},[7893],{"nctId":244,"briefTitle":245,"status":105,"phases":7894,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":7895,"interventions":7896},[89],[23],[253,95,115,116],{"trials":7898,"activeCount":99},[7899],{"nctId":2185,"briefTitle":2186,"status":105,"phases":7900,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":7901,"interventions":7902},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"trials":7904,"activeCount":99},[],{"trials":7906,"activeCount":99},[],{"intervention":7908,"totalTrials":2365,"cells":7909},"Caspofungin Acetate",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7916,"PHASE4":7959,"NA":7961},{"trials":7911,"activeCount":99},[],{"trials":7913,"activeCount":99},[],{"trials":7915,"activeCount":99},[],{"trials":7917,"activeCount":99},[7918,7930],{"nctId":7919,"briefTitle":7920,"status":105,"phases":7921,"primaryCompletion":7922,"completion":658,"start":7923,"enrollment":7924,"conditions":7925,"interventions":7927},"NCT01503515","Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant",[90],"2019-12-31","2013-03-21",292,[7926,3181],"Fungal Infection",[7908,7928,7929],"Fluconazole","Voriconazole",{"nctId":7931,"briefTitle":7932,"status":105,"phases":7933,"primaryCompletion":940,"completion":3515,"start":7934,"enrollment":7935,"conditions":7936,"interventions":7958},"NCT01307579","Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia",[90],"2011-04-04",517,[1230,7937,7938,7939,7940,7941,7942,7943,7944,7945,7946,7947,7948,7949,7950,5380,7951,7952,7953,7954,7926,2492,5484,7955,2345,2160,7956,7957],"Adult Acute Monoblastic Leukemia","Adult Acute Monocytic Leukemia","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With Maturation","Adult Acute Myeloid Leukemia With Minimal Differentiation","Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Adult Acute Myeloid Leukemia Without Maturation","Adult Acute Myelomonocytic Leukemia","Alkylating Agent-Related Acute Myeloid Leukemia","Childhood Acute Monoblastic Leukemia","Childhood Acute Monocytic Leukemia","Childhood Acute Myeloid Leukemia With Maturation","Childhood Acute Myeloid Leukemia With Minimal Differentiation","Childhood Acute Myeloid Leukemia Without Maturation","Childhood Acute Myelomonocytic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia","Untreated Childhood Myeloid Neoplasm",[7908,7928],{"trials":7960,"activeCount":99},[],{"trials":7962,"activeCount":99},[],{"intervention":7928,"totalTrials":2365,"cells":7964},{"EARLY_PHASE1":7965,"PHASE1":7967,"PHASE2":7969,"PHASE3":7971,"PHASE4":7981,"NA":7983},{"trials":7966,"activeCount":99},[],{"trials":7968,"activeCount":99},[],{"trials":7970,"activeCount":99},[],{"trials":7972,"activeCount":99},[7973,7977],{"nctId":7919,"briefTitle":7920,"status":105,"phases":7974,"primaryCompletion":7922,"completion":658,"start":7923,"enrollment":7924,"conditions":7975,"interventions":7976},[90],[7926,3181],[7908,7928,7929],{"nctId":7931,"briefTitle":7932,"status":105,"phases":7978,"primaryCompletion":940,"completion":3515,"start":7934,"enrollment":7935,"conditions":7979,"interventions":7980},[90],[1230,7937,7938,7939,7940,7941,7942,7943,7944,7945,7946,7947,7948,7949,7950,5380,7951,7952,7953,7954,7926,2492,5484,7955,2345,2160,7956,7957],[7908,7928],{"trials":7982,"activeCount":99},[],{"trials":7984,"activeCount":99},[],{"intervention":2395,"totalTrials":2365,"cells":7986},{"EARLY_PHASE1":7987,"PHASE1":7989,"PHASE2":7991,"PHASE3":7997,"PHASE4":8003,"NA":8005},{"trials":7988,"activeCount":99},[],{"trials":7990,"activeCount":99},[],{"trials":7992,"activeCount":99},[7993],{"nctId":2389,"briefTitle":2390,"status":105,"phases":7994,"primaryCompletion":1255,"completion":1255,"start":2392,"enrollment":36,"conditions":7995,"interventions":7996},[88,89],[15],[210,398,2395],{"trials":7998,"activeCount":99},[7999],{"nctId":1178,"briefTitle":1179,"status":105,"phases":8000,"primaryCompletion":1181,"completion":84,"start":1182,"enrollment":1183,"conditions":8001,"interventions":8002},[90],[29,1185,1186],[85,47,75,154,155,227,228,1188,347,156,157,795,158,159,797,141],{"trials":8004,"activeCount":99},[],{"trials":8006,"activeCount":99},[],{"intervention":2191,"totalTrials":2365,"cells":8008},{"EARLY_PHASE1":8009,"PHASE1":8011,"PHASE2":8019,"PHASE3":8021,"PHASE4":8027,"NA":8029},{"trials":8010,"activeCount":99},[],{"trials":8012,"activeCount":99},[8013],{"nctId":8014,"briefTitle":8015,"status":105,"phases":8016,"primaryCompletion":703,"completion":108,"start":193,"enrollment":2060,"conditions":8017,"interventions":8018},"NCT00009698","Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia",[88],[15],[2191],{"trials":8020,"activeCount":99},[],{"trials":8022,"activeCount":99},[8023],{"nctId":2185,"briefTitle":2186,"status":105,"phases":8024,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":8025,"interventions":8026},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"trials":8028,"activeCount":99},[],{"trials":8030,"activeCount":99},[],{"intervention":540,"totalTrials":2365,"cells":8032},{"EARLY_PHASE1":8033,"PHASE1":8035,"PHASE2":8037,"PHASE3":8043,"PHASE4":8049,"NA":8051},{"trials":8034,"activeCount":99},[],{"trials":8036,"activeCount":99},[],{"trials":8038,"activeCount":99},[8039],{"nctId":529,"briefTitle":530,"status":105,"phases":8040,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":8041,"interventions":8042},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"trials":8044,"activeCount":99},[8045],{"nctId":1617,"briefTitle":1618,"status":105,"phases":8046,"primaryCompletion":983,"completion":1620,"start":1621,"enrollment":1622,"conditions":8047,"interventions":8048},[90],[196,197],[113,1147,540,291,117],{"trials":8050,"activeCount":99},[],{"trials":8052,"activeCount":99},[],{"intervention":625,"totalTrials":2060,"cells":8054},{"EARLY_PHASE1":8055,"PHASE1":8057,"PHASE2":8059,"PHASE3":8061,"PHASE4":8067,"NA":8069},{"trials":8056,"activeCount":99},[],{"trials":8058,"activeCount":99},[],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[8063],{"nctId":618,"briefTitle":619,"status":105,"phases":8064,"primaryCompletion":621,"completion":442,"start":622,"enrollment":426,"conditions":8065,"interventions":8066},[90],[128,129,130,131,132],[47,159,625],{"trials":8068,"activeCount":99},[],{"trials":8070,"activeCount":99},[],{"intervention":8072,"totalTrials":2060,"cells":8073},"supersaturated calcium phosphate rinse",{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8078,"PHASE3":8080,"PHASE4":8096,"NA":8098},{"trials":8075,"activeCount":99},[],{"trials":8077,"activeCount":99},[],{"trials":8079,"activeCount":99},[],{"trials":8081,"activeCount":99},[8082],{"nctId":8083,"briefTitle":8084,"status":105,"phases":8085,"primaryCompletion":8086,"completion":2487,"start":8087,"enrollment":8088,"conditions":8089,"interventions":8095},"NCT01305200","Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant",[90],"2015-06","2011-03",226,[972,5380,5381,2158,8090,8091,8092,2159,5717,523,8093,8094,4816,5383,492,2345,5719,5720,4821,5721,2672,5722,5723,5724,2160,2161,26],"Chronic Eosinophilic Leukemia","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","Mucositis","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable",[8072],{"trials":8097,"activeCount":99},[],{"trials":8099,"activeCount":99},[],{"intervention":8101,"totalTrials":2060,"cells":8102},"enalapril maleate",{"EARLY_PHASE1":8103,"PHASE1":8105,"PHASE2":8107,"PHASE3":8109,"PHASE4":8117,"NA":8119},{"trials":8104,"activeCount":99},[],{"trials":8106,"activeCount":99},[],{"trials":8108,"activeCount":99},[],{"trials":8110,"activeCount":99},[8111],{"nctId":8112,"briefTitle":8113,"status":105,"phases":8114,"primaryCompletion":3307,"completion":248,"start":959,"enrollment":2643,"conditions":8115,"interventions":8116},"NCT00003070","Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer",[90],[751,26],[8101],{"trials":8118,"activeCount":99},[],{"trials":8120,"activeCount":99},[],{"intervention":3643,"totalTrials":2060,"cells":8122},{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8127,"PHASE3":8129,"PHASE4":8135,"NA":8137},{"trials":8124,"activeCount":99},[],{"trials":8126,"activeCount":99},[],{"trials":8128,"activeCount":99},[],{"trials":8130,"activeCount":99},[8131],{"nctId":3629,"briefTitle":3630,"status":105,"phases":8132,"primaryCompletion":41,"completion":74,"start":3632,"enrollment":9,"conditions":8133,"interventions":8134},[90],[3634,3635,3636,3637,3638,3639,3640,3641],[3643,135,1665],{"trials":8136,"activeCount":99},[],{"trials":8138,"activeCount":99},[],{"intervention":2039,"totalTrials":2060,"cells":8140},{"EARLY_PHASE1":8141,"PHASE1":8143,"PHASE2":8145,"PHASE3":8147,"PHASE4":8153,"NA":8155},{"trials":8142,"activeCount":99},[],{"trials":8144,"activeCount":99},[],{"trials":8146,"activeCount":99},[],{"trials":8148,"activeCount":99},[8149],{"nctId":2028,"briefTitle":2029,"status":105,"phases":8150,"primaryCompletion":2031,"completion":79,"start":2032,"enrollment":8,"conditions":8151,"interventions":8152},[90],[2034,2035,2036,2037],[135,136,227,228,2039,1908],{"trials":8154,"activeCount":99},[],{"trials":8156,"activeCount":99},[],{"intervention":2055,"totalTrials":2060,"cells":8158},{"EARLY_PHASE1":8159,"PHASE1":8161,"PHASE2":8163,"PHASE3":8165,"PHASE4":8171,"NA":8173},{"trials":8160,"activeCount":99},[],{"trials":8162,"activeCount":99},[],{"trials":8164,"activeCount":99},[],{"trials":8166,"activeCount":99},[8167],{"nctId":2045,"briefTitle":2046,"status":105,"phases":8168,"primaryCompletion":2048,"completion":74,"start":2049,"enrollment":2050,"conditions":8169,"interventions":8170},[90],[2052,2053],[135,136,227,566,157,2055],{"trials":8172,"activeCount":99},[],{"trials":8174,"activeCount":99},[],{"intervention":7929,"totalTrials":2060,"cells":8176},{"EARLY_PHASE1":8177,"PHASE1":8179,"PHASE2":8181,"PHASE3":8183,"PHASE4":8189,"NA":8191},{"trials":8178,"activeCount":99},[],{"trials":8180,"activeCount":99},[],{"trials":8182,"activeCount":99},[],{"trials":8184,"activeCount":99},[8185],{"nctId":7919,"briefTitle":7920,"status":105,"phases":8186,"primaryCompletion":7922,"completion":658,"start":7923,"enrollment":7924,"conditions":8187,"interventions":8188},[90],[7926,3181],[7908,7928,7929],{"trials":8190,"activeCount":99},[],{"trials":8192,"activeCount":99},[],{"intervention":840,"totalTrials":2060,"cells":8194},{"EARLY_PHASE1":8195,"PHASE1":8197,"PHASE2":8199,"PHASE3":8201,"PHASE4":8207,"NA":8209},{"trials":8196,"activeCount":99},[],{"trials":8198,"activeCount":99},[],{"trials":8200,"activeCount":99},[],{"trials":8202,"activeCount":99},[8203],{"nctId":833,"briefTitle":834,"status":105,"phases":8204,"primaryCompletion":836,"completion":147,"start":837,"enrollment":691,"conditions":8205,"interventions":8206},[90],[29,151,152],[840,47,75,154,155,136,156,157,158,159,160,141],{"trials":8208,"activeCount":99},[],{"trials":8210,"activeCount":99},[],{"intervention":978,"totalTrials":2060,"cells":8212},{"EARLY_PHASE1":8213,"PHASE1":8215,"PHASE2":8217,"PHASE3":8219,"PHASE4":8225,"NA":8227},{"trials":8214,"activeCount":99},[],{"trials":8216,"activeCount":99},[],{"trials":8218,"activeCount":99},[],{"trials":8220,"activeCount":99},[8221],{"nctId":964,"briefTitle":965,"status":105,"phases":8222,"primaryCompletion":967,"completion":968,"start":248,"enrollment":969,"conditions":8223,"interventions":8224},[90],[971,972,973,974,975,976],[200,95,515,212,978],{"trials":8226,"activeCount":99},[],{"trials":8228,"activeCount":99},[],{"intervention":2192,"totalTrials":2060,"cells":8230},{"EARLY_PHASE1":8231,"PHASE1":8233,"PHASE2":8235,"PHASE3":8237,"PHASE4":8243,"NA":8245},{"trials":8232,"activeCount":99},[],{"trials":8234,"activeCount":99},[],{"trials":8236,"activeCount":99},[],{"trials":8238,"activeCount":99},[8239],{"nctId":2185,"briefTitle":2186,"status":105,"phases":8240,"primaryCompletion":2188,"start":1721,"enrollment":1204,"conditions":8241,"interventions":8242},[89,90],[23],[2191,112,2192,253,315,210,115,239],{"trials":8244,"activeCount":99},[],{"trials":8246,"activeCount":99},[],{"intervention":4430,"totalTrials":2060,"cells":8248},{"EARLY_PHASE1":8249,"PHASE1":8251,"PHASE2":8253,"PHASE3":8255,"PHASE4":8261,"NA":8263},{"trials":8250,"activeCount":99},[],{"trials":8252,"activeCount":99},[],{"trials":8254,"activeCount":99},[],{"trials":8256,"activeCount":99},[8257],{"nctId":4423,"briefTitle":4424,"status":105,"phases":8258,"primaryCompletion":4426,"completion":1029,"start":4427,"enrollment":880,"conditions":8259,"interventions":8260},[90],[973],[315,4430,305,515],{"trials":8262,"activeCount":99},[],{"trials":8264,"activeCount":99},[],{"intervention":8266,"totalTrials":2060,"cells":8267},"levofloxacin",{"EARLY_PHASE1":8268,"PHASE1":8270,"PHASE2":8272,"PHASE3":8274,"PHASE4":8288,"NA":8290},{"trials":8269,"activeCount":99},[],{"trials":8271,"activeCount":99},[],{"trials":8273,"activeCount":99},[],{"trials":8275,"activeCount":99},[8276],{"nctId":8277,"briefTitle":8278,"status":105,"phases":8279,"primaryCompletion":8280,"completion":8280,"start":2107,"enrollment":8281,"conditions":8282,"interventions":8287},"NCT01371656","Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation",[90],"2017-06",624,[8283,8284,8285,7926,8286,5484,492,2345,2160,2162],"Acute Leukemias of Ambiguous Lineage","Bacterial Infection","Diarrhea","Musculoskeletal Complications",[8266],{"trials":8289,"activeCount":99},[],{"trials":8291,"activeCount":99},[],{"intervention":185,"totalTrials":2365,"cells":8293},{"EARLY_PHASE1":8294,"PHASE1":8296,"PHASE2":8302,"PHASE3":8313,"PHASE4":8315,"NA":8317},{"trials":8295,"activeCount":99},[],{"trials":8297,"activeCount":99},[8298],{"nctId":175,"briefTitle":176,"status":105,"phases":8299,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":8300,"interventions":8301},[88],[182,183,32],[185,47,186,136,140,141],{"trials":8303,"activeCount":99},[8304],{"nctId":8305,"briefTitle":8306,"status":105,"phases":8307,"primaryCompletion":178,"completion":178,"start":8308,"enrollment":8309,"conditions":8310,"interventions":8312},"NCT00939770","Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",[88,89],"2009-09-21",122,[183,3783,32,8311,3786,4835],"Refractory Anaplastic Large Cell Lymphoma",[185],{"trials":8314,"activeCount":99},[],{"trials":8316,"activeCount":99},[],{"trials":8318,"activeCount":99},[],{"intervention":1830,"totalTrials":2365,"cells":8320},{"EARLY_PHASE1":8321,"PHASE1":8323,"PHASE2":8325,"PHASE3":8335,"PHASE4":8337,"NA":8339},{"trials":8322,"activeCount":99},[],{"trials":8324,"activeCount":99},[],{"trials":8326,"activeCount":99},[8327,8331],{"nctId":1824,"briefTitle":1825,"status":105,"phases":8328,"primaryCompletion":613,"completion":533,"start":1030,"enrollment":1827,"conditions":8329,"interventions":8330},[89],[15],[112,1830,210,115,212,389,409],{"nctId":5288,"briefTitle":5289,"status":105,"phases":8332,"primaryCompletion":5291,"completion":248,"start":193,"enrollment":1531,"conditions":8333,"interventions":8334},[89],[15],[112,1830,398],{"trials":8336,"activeCount":99},[],{"trials":8338,"activeCount":99},[],{"trials":8340,"activeCount":99},[],{"intervention":5300,"totalTrials":2365,"cells":8342},{"EARLY_PHASE1":8343,"PHASE1":8345,"PHASE2":8347,"PHASE3":8359,"PHASE4":8361,"NA":8363},{"trials":8344,"activeCount":99},[],{"trials":8346,"activeCount":99},[],{"trials":8348,"activeCount":99},[8349,8355],{"nctId":8350,"briefTitle":8351,"status":105,"phases":8352,"primaryCompletion":547,"completion":206,"start":574,"enrollment":5814,"conditions":8353,"interventions":8354},"NCT00006462","Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",[89],[15],[5300],{"nctId":5295,"briefTitle":5296,"status":105,"phases":8356,"primaryCompletion":403,"start":1245,"enrollment":4785,"conditions":8357,"interventions":8358},[89],[23],[112,5300,698],{"trials":8360,"activeCount":99},[],{"trials":8362,"activeCount":99},[],{"trials":8364,"activeCount":99},[],{"intervention":8366,"totalTrials":2365,"cells":8367},"Imetelstat Sodium",{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8381,"PHASE3":8390,"PHASE4":8392,"NA":8394},{"trials":8369,"activeCount":99},[],{"trials":8371,"activeCount":99},[8372],{"nctId":8373,"briefTitle":8374,"status":105,"phases":8375,"primaryCompletion":1265,"completion":8376,"start":967,"enrollment":3570,"conditions":8377,"interventions":8379},"NCT01273090","Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma",[88],"2013-10",[35,23,301,8378,26],"Small Intestine Cancer",[8380],"imetelstat sodium",{"trials":8382,"activeCount":99},[8383],{"nctId":8384,"briefTitle":8385,"status":647,"phases":8386,"primaryCompletion":8387,"start":146,"enrollment":99,"conditions":8388,"interventions":8389},"NCT02011126","Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors",[89],"2016-03-25",[1662,4816,1522,4821,4824,32,4825,762],[8366],{"trials":8391,"activeCount":99},[],{"trials":8393,"activeCount":99},[],{"trials":8395,"activeCount":99},[],{"intervention":4969,"totalTrials":2365,"cells":8397},{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8410,"PHASE3":8416,"PHASE4":8418,"NA":8420},{"trials":8399,"activeCount":99},[],{"trials":8401,"activeCount":99},[8402],{"nctId":8403,"briefTitle":8404,"status":105,"phases":8405,"primaryCompletion":310,"completion":108,"start":8406,"enrollment":1560,"conditions":8407,"interventions":8409},"NCT00003750","Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors",[88],"2001-10",[8408,18,21,26],"Melanoma (Skin)",[4969],{"trials":8411,"activeCount":99},[8412],{"nctId":4962,"briefTitle":4963,"status":105,"phases":8413,"primaryCompletion":297,"completion":4965,"start":2107,"enrollment":4966,"conditions":8414,"interventions":8415},[89],[32],[4969,238,578],{"trials":8417,"activeCount":99},[],{"trials":8419,"activeCount":99},[],{"trials":8421,"activeCount":99},[],{"intervention":2678,"totalTrials":2060,"cells":8423},{"EARLY_PHASE1":8424,"PHASE1":8426,"PHASE2":8428,"PHASE3":8434,"PHASE4":8436,"NA":8438},{"trials":8425,"activeCount":99},[],{"trials":8427,"activeCount":99},[],{"trials":8429,"activeCount":99},[8430],{"nctId":2665,"briefTitle":2666,"status":105,"phases":8431,"primaryCompletion":688,"completion":940,"start":1194,"enrollment":207,"conditions":8432,"interventions":8433},[89],[1971,2669,2122,2123,2670,2125,2126,2671,2672,2673,2674,2136,1998,2000,2675,2676],[60,228,566,2678],{"trials":8435,"activeCount":99},[],{"trials":8437,"activeCount":99},[],{"trials":8439,"activeCount":99},[],{"intervention":8441,"totalTrials":2060,"cells":8442},"recombinant interferon alfa",{"EARLY_PHASE1":8443,"PHASE1":8445,"PHASE2":8447,"PHASE3":8455,"PHASE4":8457,"NA":8459},{"trials":8444,"activeCount":99},[],{"trials":8446,"activeCount":99},[],{"trials":8448,"activeCount":99},[8449],{"nctId":8450,"briefTitle":8451,"status":105,"phases":8452,"primaryCompletion":2306,"completion":108,"start":1600,"enrollment":3112,"conditions":8453,"interventions":8454},"NCT00002621","Interferon Alfa in Treating Children With HIV-Related Cancer",[89],[15,23,26],[8441],{"trials":8456,"activeCount":99},[],{"trials":8458,"activeCount":99},[],{"trials":8460,"activeCount":99},[],{"intervention":8462,"totalTrials":2060,"cells":8463},"Carvedilol",{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8478,"PHASE4":8480,"NA":8482},{"trials":8465,"activeCount":99},[],{"trials":8467,"activeCount":99},[],{"trials":8469,"activeCount":99},[8470],{"nctId":8471,"briefTitle":8472,"status":105,"phases":8473,"primaryCompletion":69,"completion":4831,"start":8474,"enrollment":8475,"conditions":8476,"interventions":8477},"NCT02717507","Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors",[89],"2016-04-04",196,[3181,3182],[8462],{"trials":8479,"activeCount":99},[],{"trials":8481,"activeCount":99},[],{"trials":8483,"activeCount":99},[],{"intervention":5726,"totalTrials":2060,"cells":8485},{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8490,"PHASE3":8496,"PHASE4":8498,"NA":8500},{"trials":8487,"activeCount":99},[],{"trials":8489,"activeCount":99},[],{"trials":8491,"activeCount":99},[8492],{"nctId":5710,"briefTitle":5711,"status":105,"phases":8493,"primaryCompletion":2107,"completion":2107,"start":311,"enrollment":5713,"conditions":8494,"interventions":8495},[89],[5715,5716,972,5380,5381,2158,5382,2159,5717,523,4816,5383,5718,492,2345,5719,5720,4821,5721,32,5722,5723,5724,2160,2161],[5726,304],{"trials":8497,"activeCount":99},[],{"trials":8499,"activeCount":99},[],{"trials":8501,"activeCount":99},[],{"intervention":6272,"totalTrials":2060,"cells":8503},{"EARLY_PHASE1":8504,"PHASE1":8506,"PHASE2":8508,"PHASE3":8514,"PHASE4":8516,"NA":8518},{"trials":8505,"activeCount":99},[],{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[8510],{"nctId":6259,"briefTitle":6260,"status":105,"phases":8511,"primaryCompletion":147,"completion":123,"start":6262,"enrollment":30,"conditions":8512,"interventions":8513},[89],[6264,6265,6266,6267,6268,6269,6270],[6272,1235],{"trials":8515,"activeCount":99},[],{"trials":8517,"activeCount":99},[],{"trials":8519,"activeCount":99},[],{"intervention":8521,"totalTrials":2060,"cells":8522},"Palifermin",{"EARLY_PHASE1":8523,"PHASE1":8525,"PHASE2":8527,"PHASE3":8539,"PHASE4":8541,"NA":8543},{"trials":8524,"activeCount":99},[],{"trials":8526,"activeCount":99},[],{"trials":8528,"activeCount":99},[8529],{"nctId":8530,"briefTitle":8531,"status":647,"phases":8532,"primaryCompletion":8533,"start":8534,"enrollment":99,"conditions":8535,"interventions":8538},"NCT00728585","Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and\u002For Radiation Therapy in Young Patients Undergoing Stem Cell Transplant",[89],"2009-05-08","2008-03-13",[8536,8537],"Gastrointestinal Mucositis","Malignant Neoplasm",[8521],{"trials":8540,"activeCount":99},[],{"trials":8542,"activeCount":99},[],{"trials":8544,"activeCount":99},[],{"intervention":8546,"totalTrials":2060,"cells":8547},"trabectedin",{"EARLY_PHASE1":8548,"PHASE1":8550,"PHASE2":8552,"PHASE3":8563,"PHASE4":8565,"NA":8567},{"trials":8549,"activeCount":99},[],{"trials":8551,"activeCount":99},[],{"trials":8553,"activeCount":99},[8554],{"nctId":8555,"briefTitle":8556,"status":105,"phases":8557,"primaryCompletion":8558,"completion":234,"start":510,"enrollment":5770,"conditions":8559,"interventions":8562},"NCT00070109","Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors",[89],"2010-10",[4816,4821,8560,7304,8561],"Recurrent Childhood Soft Tissue Sarcoma","Peripheral Primitive Neuroectodermal Tumor",[8546],{"trials":8564,"activeCount":99},[],{"trials":8566,"activeCount":99},[],{"trials":8568,"activeCount":99},[],{"intervention":2426,"totalTrials":2060,"cells":8570},{"EARLY_PHASE1":8571,"PHASE1":8573,"PHASE2":8575,"PHASE3":8581,"PHASE4":8583,"NA":8585},{"trials":8572,"activeCount":99},[],{"trials":8574,"activeCount":99},[],{"trials":8576,"activeCount":99},[8577],{"nctId":2417,"briefTitle":2418,"status":647,"phases":8578,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":8579,"interventions":8580},[88,89],[2357,339,1348,2423,2358,341,1354,2424],[2426,75,525,1356,2232,157,796],{"trials":8582,"activeCount":99},[],{"trials":8584,"activeCount":99},[],{"trials":8586,"activeCount":99},[],{"intervention":8588,"totalTrials":2060,"cells":8589},"Denosumab",{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8594,"PHASE3":8608,"PHASE4":8610,"NA":8612},{"trials":8591,"activeCount":99},[],{"trials":8593,"activeCount":99},[],{"trials":8595,"activeCount":99},[8596],{"nctId":8597,"briefTitle":8598,"status":105,"phases":8599,"primaryCompletion":7922,"completion":8600,"start":8601,"enrollment":8602,"conditions":8603,"interventions":8607},"NCT02470091","Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma",[89],"2023-12-31","2015-11-21",56,[2053,4825,7313,8604,8605,8606],"Stage IV Osteosarcoma AJCC v7","Stage IVA Osteosarcoma AJCC v7","Stage IVB Osteosarcoma AJCC v7",[8588],{"trials":8609,"activeCount":99},[],{"trials":8611,"activeCount":99},[],{"trials":8613,"activeCount":99},[],{"intervention":8615,"totalTrials":2060,"cells":8616},"hu14.18-Interleukin-2 fusion protein",{"EARLY_PHASE1":8617,"PHASE1":8619,"PHASE2":8621,"PHASE3":8632,"PHASE4":8634,"NA":8636},{"trials":8618,"activeCount":99},[],{"trials":8620,"activeCount":99},[],{"trials":8622,"activeCount":99},[8623],{"nctId":8624,"briefTitle":8625,"status":105,"phases":8626,"primaryCompletion":8627,"completion":8628,"start":8629,"enrollment":5713,"conditions":8630,"interventions":8631},"NCT00082758","hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma",[89],"2008-02","2012-05","2005-08",[18],[8615],{"trials":8633,"activeCount":99},[],{"trials":8635,"activeCount":99},[],{"trials":8637,"activeCount":99},[],{"intervention":458,"totalTrials":2060,"cells":8639},{"EARLY_PHASE1":8640,"PHASE1":8642,"PHASE2":8644,"PHASE3":8650,"PHASE4":8652,"NA":8654},{"trials":8641,"activeCount":99},[],{"trials":8643,"activeCount":99},[],{"trials":8645,"activeCount":99},[8646],{"nctId":451,"briefTitle":452,"status":105,"phases":8647,"primaryCompletion":454,"completion":234,"start":298,"enrollment":455,"conditions":8648,"interventions":8649},[89],[21],[458,95,114,115,328,459,117,329,228],{"trials":8651,"activeCount":99},[],{"trials":8653,"activeCount":99},[],{"trials":8655,"activeCount":99},[],{"intervention":8657,"totalTrials":2060,"cells":8658},"Lorvotuzumab Mertansine",{"EARLY_PHASE1":8659,"PHASE1":8661,"PHASE2":8663,"PHASE3":8675,"PHASE4":8677,"NA":8679},{"trials":8660,"activeCount":99},[],{"trials":8662,"activeCount":99},[],{"trials":8664,"activeCount":99},[8665],{"nctId":8666,"briefTitle":8667,"status":105,"phases":8668,"primaryCompletion":968,"completion":658,"start":8669,"enrollment":2830,"conditions":8670,"interventions":8674},"NCT02452554","Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma",[89],"2015-10-12",[716,8671,32,8672,8673,7315],"Recurrent Malignant Peripheral Nerve Sheath Tumor","Recurrent Rhabdomyosarcoma","Recurrent Synovial Sarcoma",[8657],{"trials":8676,"activeCount":99},[],{"trials":8678,"activeCount":99},[],{"trials":8680,"activeCount":99},[],{"intervention":2438,"totalTrials":2060,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8693,"PHASE4":8695,"NA":8697},{"trials":8684,"activeCount":99},[],{"trials":8686,"activeCount":99},[],{"trials":8688,"activeCount":99},[8689],{"nctId":2432,"briefTitle":2433,"status":105,"phases":8690,"primaryCompletion":858,"completion":858,"start":248,"enrollment":2435,"conditions":8691,"interventions":8692},[88,89],[15],[2438,210,212],{"trials":8694,"activeCount":99},[],{"trials":8696,"activeCount":99},[],{"trials":8698,"activeCount":99},[],{"intervention":482,"totalTrials":2060,"cells":8700},{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8705,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8702,"activeCount":99},[],{"trials":8704,"activeCount":99},[],{"trials":8706,"activeCount":99},[8707],{"nctId":461,"briefTitle":462,"status":105,"phases":8708,"primaryCompletion":464,"completion":465,"start":466,"enrollment":467,"conditions":8709,"interventions":8710},[89],[469,470,471,472,473,474,475,476,477,478,479,480],[114,95,212,482,289,305,304,112,303,210,115,117,483],{"trials":8712,"activeCount":99},[],{"trials":8714,"activeCount":99},[],{"trials":8716,"activeCount":99},[],{"intervention":494,"totalTrials":2060,"cells":8718},{"EARLY_PHASE1":8719,"PHASE1":8721,"PHASE2":8723,"PHASE3":8729,"PHASE4":8731,"NA":8733},{"trials":8720,"activeCount":99},[],{"trials":8722,"activeCount":99},[],{"trials":8724,"activeCount":99},[8725],{"nctId":485,"briefTitle":486,"status":105,"phases":8726,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":8727,"interventions":8728},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"trials":8730,"activeCount":99},[],{"trials":8732,"activeCount":99},[],{"trials":8734,"activeCount":99},[],{"intervention":495,"totalTrials":2060,"cells":8736},{"EARLY_PHASE1":8737,"PHASE1":8739,"PHASE2":8741,"PHASE3":8747,"PHASE4":8749,"NA":8751},{"trials":8738,"activeCount":99},[],{"trials":8740,"activeCount":99},[],{"trials":8742,"activeCount":99},[8743],{"nctId":485,"briefTitle":486,"status":105,"phases":8744,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":8745,"interventions":8746},[88,89],[492],[494,114,409,117,495,210,305,316,496,212,115,95,289,112],{"trials":8748,"activeCount":99},[],{"trials":8750,"activeCount":99},[],{"trials":8752,"activeCount":99},[],{"intervention":514,"totalTrials":2060,"cells":8754},{"EARLY_PHASE1":8755,"PHASE1":8757,"PHASE2":8759,"PHASE3":8765,"PHASE4":8767,"NA":8769},{"trials":8756,"activeCount":99},[],{"trials":8758,"activeCount":99},[],{"trials":8760,"activeCount":99},[8761],{"nctId":505,"briefTitle":506,"status":105,"phases":8762,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":8763,"interventions":8764},[89],[15],[514,387,95,315,212,304,515],{"trials":8766,"activeCount":99},[],{"trials":8768,"activeCount":99},[],{"trials":8770,"activeCount":99},[],{"intervention":8772,"totalTrials":2060,"cells":8773},"Alisertib",{"EARLY_PHASE1":8774,"PHASE1":8776,"PHASE2":8778,"PHASE3":8788,"PHASE4":8790,"NA":8792},{"trials":8775,"activeCount":99},[],{"trials":8777,"activeCount":99},[],{"trials":8779,"activeCount":99},[8780],{"nctId":8781,"briefTitle":8782,"status":105,"phases":8783,"primaryCompletion":2031,"completion":59,"start":8784,"enrollment":632,"conditions":8785,"interventions":8787},"NCT01154816","Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia",[89],"2011-02",[1662,4816,492,2345,8786,2671,4821,8560,4824,32,4825],"Recurrent Childhood Kidney Neoplasm",[8772],{"trials":8789,"activeCount":99},[],{"trials":8791,"activeCount":99},[],{"trials":8793,"activeCount":99},[],{"intervention":538,"totalTrials":2060,"cells":8795},{"EARLY_PHASE1":8796,"PHASE1":8798,"PHASE2":8800,"PHASE3":8806,"PHASE4":8808,"NA":8810},{"trials":8797,"activeCount":99},[],{"trials":8799,"activeCount":99},[],{"trials":8801,"activeCount":99},[8802],{"nctId":529,"briefTitle":530,"status":105,"phases":8803,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":8804,"interventions":8805},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"trials":8807,"activeCount":99},[],{"trials":8809,"activeCount":99},[],{"trials":8811,"activeCount":99},[],{"intervention":539,"totalTrials":2060,"cells":8813},{"EARLY_PHASE1":8814,"PHASE1":8816,"PHASE2":8818,"PHASE3":8824,"PHASE4":8826,"NA":8828},{"trials":8815,"activeCount":99},[],{"trials":8817,"activeCount":99},[],{"trials":8819,"activeCount":99},[8820],{"nctId":529,"briefTitle":530,"status":105,"phases":8821,"primaryCompletion":532,"completion":533,"start":534,"enrollment":125,"conditions":8822,"interventions":8823},[89],[23],[537,112,538,95,539,114,115,305,540,459,117],{"trials":8825,"activeCount":99},[],{"trials":8827,"activeCount":99},[],{"trials":8829,"activeCount":99},[],{"intervention":8831,"totalTrials":2060,"cells":8832},"tamoxifen citrate",{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8837,"PHASE3":8848,"PHASE4":8850,"NA":8852},{"trials":8834,"activeCount":99},[],{"trials":8836,"activeCount":99},[],{"trials":8838,"activeCount":99},[8839],{"nctId":8840,"briefTitle":8841,"status":105,"phases":8842,"primaryCompletion":8843,"completion":8843,"start":8844,"enrollment":932,"conditions":8845,"interventions":8846},"NCT00068419","Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor",[89],"2010-04-26","2004-02",[3309],[8831,8847],"sulindac",{"trials":8849,"activeCount":99},[],{"trials":8851,"activeCount":99},[],{"trials":8853,"activeCount":99},[],{"intervention":8847,"totalTrials":2060,"cells":8855},{"EARLY_PHASE1":8856,"PHASE1":8858,"PHASE2":8860,"PHASE3":8866,"PHASE4":8868,"NA":8870},{"trials":8857,"activeCount":99},[],{"trials":8859,"activeCount":99},[],{"trials":8861,"activeCount":99},[8862],{"nctId":8840,"briefTitle":8841,"status":105,"phases":8863,"primaryCompletion":8843,"completion":8843,"start":8844,"enrollment":932,"conditions":8864,"interventions":8865},[89],[3309],[8831,8847],{"trials":8867,"activeCount":99},[],{"trials":8869,"activeCount":99},[],{"trials":8871,"activeCount":99},[],{"intervention":8873,"totalTrials":2060,"cells":8874},"docetaxel",{"EARLY_PHASE1":8875,"PHASE1":8877,"PHASE2":8879,"PHASE3":8888,"PHASE4":8890,"NA":8892},{"trials":8876,"activeCount":99},[],{"trials":8878,"activeCount":99},[],{"trials":8880,"activeCount":99},[8881],{"nctId":8882,"briefTitle":8883,"status":105,"phases":8884,"primaryCompletion":1038,"completion":206,"start":8885,"enrollment":2317,"conditions":8886,"interventions":8887},"NCT00021242","Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia",[89],"2002-08",[15],[8873],{"trials":8889,"activeCount":99},[],{"trials":8891,"activeCount":99},[],{"trials":8893,"activeCount":99},[],{"intervention":8895,"totalTrials":2060,"cells":8896},"ABT-751",{"EARLY_PHASE1":8897,"PHASE1":8899,"PHASE2":8901,"PHASE3":8912,"PHASE4":8914,"NA":8916},{"trials":8898,"activeCount":99},[],{"trials":8900,"activeCount":99},[],{"trials":8902,"activeCount":99},[8903],{"nctId":8904,"briefTitle":8905,"status":105,"phases":8906,"primaryCompletion":8907,"completion":8908,"start":1203,"enrollment":8909,"conditions":8910,"interventions":8911},"NCT00436852","ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment",[89],"2010-09-01","2015-03-30",92,[5717,32],[8895],{"trials":8913,"activeCount":99},[],{"trials":8915,"activeCount":99},[],{"trials":8917,"activeCount":99},[],{"intervention":8919,"totalTrials":2060,"cells":8920},"Pepinemab",{"EARLY_PHASE1":8921,"PHASE1":8923,"PHASE2":8925,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8922,"activeCount":99},[],{"trials":8924,"activeCount":99},[],{"trials":8926,"activeCount":99},[8927],{"nctId":8928,"briefTitle":8929,"status":105,"phases":8930,"primaryCompletion":3795,"completion":84,"start":8931,"enrollment":444,"conditions":8932,"interventions":8933},"NCT03320330","Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors",[88,89],"2018-01-31",[3783,4825,3786,7313],[8919],{"trials":8935,"activeCount":99},[],{"trials":8937,"activeCount":99},[],{"trials":8939,"activeCount":99},[],{"intervention":8941,"totalTrials":2060,"cells":8942},"ECTEINASCIDIN 743",{"EARLY_PHASE1":8943,"PHASE1":8945,"PHASE2":8953,"PHASE3":8955,"PHASE4":8957,"NA":8959},{"trials":8944,"activeCount":99},[],{"trials":8946,"activeCount":99},[8947],{"nctId":8948,"briefTitle":8949,"status":105,"phases":8950,"primaryCompletion":310,"completion":108,"start":879,"enrollment":2643,"conditions":8951,"interventions":8952},"NCT00006463","Ecteinascidin 743 in Treating Children With Refractory Solid Tumors",[88],[26],[8941],{"trials":8954,"activeCount":99},[],{"trials":8956,"activeCount":99},[],{"trials":8958,"activeCount":99},[],{"trials":8960,"activeCount":99},[],{"intervention":8962,"totalTrials":2060,"cells":8963},"MLN8237",{"EARLY_PHASE1":8964,"PHASE1":8966,"PHASE2":8977,"PHASE3":8979,"PHASE4":8981,"NA":8983},{"trials":8965,"activeCount":99},[],{"trials":8967,"activeCount":99},[8968],{"nctId":8969,"briefTitle":8970,"status":105,"phases":8971,"primaryCompletion":8972,"completion":8972,"start":8973,"enrollment":7656,"conditions":8974,"interventions":8976},"NCT02444884","MLN8237 to Treat Children With Relapsed\u002FRefractory Solid Tumors",[88],"2011-12","2008-09",[8975,18],"Unspecified Childhood Solid Tumor, Excluding CNS",[8962],{"trials":8978,"activeCount":99},[],{"trials":8980,"activeCount":99},[],{"trials":8982,"activeCount":99},[],{"trials":8984,"activeCount":99},[],{"intervention":8986,"totalTrials":2060,"cells":8987},"Axitinib",{"EARLY_PHASE1":8988,"PHASE1":8990,"PHASE2":9002,"PHASE3":9004,"PHASE4":9006,"NA":9008},{"trials":8989,"activeCount":99},[],{"trials":8991,"activeCount":99},[8992],{"nctId":8993,"briefTitle":8994,"status":105,"phases":8995,"primaryCompletion":8996,"completion":8996,"start":8997,"enrollment":8998,"conditions":8999,"interventions":9001},"NCT02164838","VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors",[88],"2017-10-19","2014-09",51,[9000],"Refractory or Recurrent Solid Tumors, Excluding CNS Tumors",[8986],{"trials":9003,"activeCount":99},[],{"trials":9005,"activeCount":99},[],{"trials":9007,"activeCount":99},[],{"trials":9009,"activeCount":99},[],{"intervention":2326,"totalTrials":2060,"cells":9011},{"EARLY_PHASE1":9012,"PHASE1":9014,"PHASE2":9020,"PHASE3":9022,"PHASE4":9024,"NA":9026},{"trials":9013,"activeCount":99},[],{"trials":9015,"activeCount":99},[9016],{"nctId":2312,"briefTitle":2313,"status":105,"phases":9017,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":9018,"interventions":9019},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"trials":9021,"activeCount":99},[],{"trials":9023,"activeCount":99},[],{"trials":9025,"activeCount":99},[],{"trials":9027,"activeCount":99},[],{"intervention":2327,"totalTrials":2060,"cells":9029},{"EARLY_PHASE1":9030,"PHASE1":9032,"PHASE2":9038,"PHASE3":9040,"PHASE4":9042,"NA":9044},{"trials":9031,"activeCount":99},[],{"trials":9033,"activeCount":99},[9034],{"nctId":2312,"briefTitle":2313,"status":105,"phases":9035,"primaryCompletion":776,"completion":2315,"start":2316,"enrollment":2317,"conditions":9036,"interventions":9037},[88],[2319,2320,2321,2322,2323,2324],[2326,75,157,2327,565,796,266,158,2327,159],{"trials":9039,"activeCount":99},[],{"trials":9041,"activeCount":99},[],{"trials":9043,"activeCount":99},[],{"trials":9045,"activeCount":99},[],{"intervention":9047,"totalTrials":2060,"cells":9048},"valproic acid",{"EARLY_PHASE1":9049,"PHASE1":9051,"PHASE2":9059,"PHASE3":9061,"PHASE4":9063,"NA":9065},{"trials":9050,"activeCount":99},[],{"trials":9052,"activeCount":99},[9053],{"nctId":9054,"briefTitle":9055,"status":105,"phases":9056,"primaryCompletion":424,"completion":404,"start":4426,"enrollment":444,"conditions":9057,"interventions":9058},"NCT00107458","Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors",[88],[35,26],[9047],{"trials":9060,"activeCount":99},[],{"trials":9062,"activeCount":99},[],{"trials":9064,"activeCount":99},[],{"trials":9066,"activeCount":99},[],{"intervention":1779,"totalTrials":2060,"cells":9068},{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9077,"PHASE3":9079,"PHASE4":9081,"NA":9083},{"trials":9070,"activeCount":99},[],{"trials":9072,"activeCount":99},[9073],{"nctId":1774,"briefTitle":1775,"status":105,"phases":9074,"primaryCompletion":1620,"start":723,"enrollment":1204,"conditions":9075,"interventions":9076},[88],[21],[199,496,114,115,328,289,212,1779,112,229],{"trials":9078,"activeCount":99},[],{"trials":9080,"activeCount":99},[],{"trials":9082,"activeCount":99},[],{"trials":9084,"activeCount":99},[],{"intervention":2646,"totalTrials":2060,"cells":9086},{"EARLY_PHASE1":9087,"PHASE1":9089,"PHASE2":9095,"PHASE3":9097,"PHASE4":9099,"NA":9101},{"trials":9088,"activeCount":99},[],{"trials":9090,"activeCount":99},[9091],{"nctId":2640,"briefTitle":2641,"status":105,"phases":9092,"primaryCompletion":310,"completion":108,"start":671,"enrollment":2643,"conditions":9093,"interventions":9094},[88],[35],[113,2646],{"trials":9096,"activeCount":99},[],{"trials":9098,"activeCount":99},[],{"trials":9100,"activeCount":99},[],{"trials":9102,"activeCount":99},[],{"intervention":3789,"totalTrials":2060,"cells":9104},{"EARLY_PHASE1":9105,"PHASE1":9107,"PHASE2":9113,"PHASE3":9115,"PHASE4":9117,"NA":9119},{"trials":9106,"activeCount":99},[],{"trials":9108,"activeCount":99},[9109],{"nctId":3777,"briefTitle":3778,"status":105,"phases":9110,"primaryCompletion":658,"completion":1863,"start":3780,"enrollment":24,"conditions":9111,"interventions":9112},[88],[3782,3783,3784,3785,3786,3787],[567,3789,3790],{"trials":9114,"activeCount":99},[],{"trials":9116,"activeCount":99},[],{"trials":9118,"activeCount":99},[],{"trials":9120,"activeCount":99},[],{"intervention":9122,"totalTrials":2060,"cells":9123},"Selinexor",{"EARLY_PHASE1":9124,"PHASE1":9126,"PHASE2":9139,"PHASE3":9141,"PHASE4":9143,"NA":9145},{"trials":9125,"activeCount":99},[],{"trials":9127,"activeCount":99},[9128],{"nctId":9129,"briefTitle":9130,"status":105,"phases":9131,"primaryCompletion":74,"completion":920,"start":9132,"enrollment":284,"conditions":9133,"interventions":9138},"NCT02323880","Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas",[88],"2015-10-30",[7753,9134,9135,9136,3782,3783,3785,3786,3787,9137],"Recurrent Brain Neoplasm","Recurrent Childhood Central Nervous System Neoplasm","Recurrent Childhood Glioblastoma","WHO Grade 3 Glioma",[9122],{"trials":9140,"activeCount":99},[],{"trials":9142,"activeCount":99},[],{"trials":9144,"activeCount":99},[],{"trials":9146,"activeCount":99},[],{"intervention":9148,"totalTrials":2060,"cells":9149},"Prexasertib",{"EARLY_PHASE1":9150,"PHASE1":9152,"PHASE2":9161,"PHASE3":9163,"PHASE4":9165,"NA":9167},{"trials":9151,"activeCount":99},[],{"trials":9153,"activeCount":99},[9154],{"nctId":9155,"briefTitle":9156,"status":105,"phases":9157,"primaryCompletion":7922,"completion":147,"start":9158,"enrollment":24,"conditions":9159,"interventions":9160},"NCT02808650","Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",[88],"2017-02-27",[182,3783,3784,3786,3787],[9148],{"trials":9162,"activeCount":99},[],{"trials":9164,"activeCount":99},[],{"trials":9166,"activeCount":99},[],{"trials":9168,"activeCount":99},[],{"intervention":9170,"totalTrials":2060,"cells":9171},"ruxolitinib phosphate",{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9185,"PHASE3":9187,"PHASE4":9189,"NA":9191},{"trials":9173,"activeCount":99},[],{"trials":9175,"activeCount":99},[9176],{"nctId":9177,"briefTitle":9178,"status":105,"phases":9179,"primaryCompletion":9180,"start":9181,"enrollment":4975,"conditions":9182,"interventions":9184},"NCT01164163","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",[88],"2014-10","2010-09",[9183,15,2309,2615,26],"Chronic Myeloproliferative Disorders",[9170],{"trials":9186,"activeCount":99},[],{"trials":9188,"activeCount":99},[],{"trials":9190,"activeCount":99},[],{"trials":9192,"activeCount":99},[],{"intervention":4788,"totalTrials":2060,"cells":9194},{"EARLY_PHASE1":9195,"PHASE1":9197,"PHASE2":9203,"PHASE3":9205,"PHASE4":9207,"NA":9209},{"trials":9196,"activeCount":99},[],{"trials":9198,"activeCount":99},[9199],{"nctId":4781,"briefTitle":4782,"status":105,"phases":9200,"primaryCompletion":689,"completion":920,"start":4784,"enrollment":4785,"conditions":9201,"interventions":9202},[88],[182,3783,3784,3786,3787],[370,4788,3790],{"trials":9204,"activeCount":99},[],{"trials":9206,"activeCount":99},[],{"trials":9208,"activeCount":99},[],{"trials":9210,"activeCount":99},[],{"intervention":1792,"totalTrials":2060,"cells":9212},{"EARLY_PHASE1":9213,"PHASE1":9215,"PHASE2":9221,"PHASE3":9223,"PHASE4":9225,"NA":9227},{"trials":9214,"activeCount":99},[],{"trials":9216,"activeCount":99},[9217],{"nctId":1785,"briefTitle":1786,"status":105,"phases":9218,"primaryCompletion":205,"completion":108,"start":425,"enrollment":1788,"conditions":9219,"interventions":9220},[88],[1790],[1792,113,115,328,1793],{"trials":9222,"activeCount":99},[],{"trials":9224,"activeCount":99},[],{"trials":9226,"activeCount":99},[],{"trials":9228,"activeCount":99},[],{"intervention":1793,"totalTrials":2060,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9239,"PHASE3":9241,"PHASE4":9243,"NA":9245},{"trials":9232,"activeCount":99},[],{"trials":9234,"activeCount":99},[9235],{"nctId":1785,"briefTitle":1786,"status":105,"phases":9236,"primaryCompletion":205,"completion":108,"start":425,"enrollment":1788,"conditions":9237,"interventions":9238},[88],[1790],[1792,113,115,328,1793],{"trials":9240,"activeCount":99},[],{"trials":9242,"activeCount":99},[],{"trials":9244,"activeCount":99},[],{"trials":9246,"activeCount":99},[],{"intervention":9248,"totalTrials":2060,"cells":9249},"pemetrexed disodium",{"EARLY_PHASE1":9250,"PHASE1":9252,"PHASE2":9260,"PHASE3":9262,"PHASE4":9264,"NA":9266},{"trials":9251,"activeCount":99},[],{"trials":9253,"activeCount":99},[9254],{"nctId":9255,"briefTitle":9256,"status":105,"phases":9257,"primaryCompletion":1038,"completion":533,"start":532,"enrollment":4785,"conditions":9258,"interventions":9259},"NCT00070473","Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors",[88],[26],[9248],{"trials":9261,"activeCount":99},[],{"trials":9263,"activeCount":99},[],{"trials":9265,"activeCount":99},[],{"trials":9267,"activeCount":99},[],{"intervention":173,"totalTrials":2060,"cells":9269},{"EARLY_PHASE1":9270,"PHASE1":9272,"PHASE2":9278,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9271,"activeCount":99},[],{"trials":9273,"activeCount":99},[9274],{"nctId":162,"briefTitle":163,"status":105,"phases":9275,"primaryCompletion":165,"start":166,"enrollment":27,"conditions":9276,"interventions":9277},[88],[168,169,170,18,171,21],[173,95],{"trials":9279,"activeCount":99},[],{"trials":9281,"activeCount":99},[],{"trials":9283,"activeCount":99},[],{"trials":9285,"activeCount":99},[],{"intervention":9287,"totalTrials":2060,"cells":9288},"talotrexin",{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9301,"PHASE3":9303,"PHASE4":9305,"NA":9307},{"trials":9290,"activeCount":99},[],{"trials":9292,"activeCount":99},[9293],{"nctId":9294,"briefTitle":9295,"status":647,"phases":9296,"primaryCompletion":9297,"start":9298,"enrollment":99,"conditions":9299,"interventions":9300},"NCT00458744","Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment",[88],"2008-07","2007-02",[35,15,23,26],[9287],{"trials":9302,"activeCount":99},[],{"trials":9304,"activeCount":99},[],{"trials":9306,"activeCount":99},[],{"trials":9308,"activeCount":99},[],{"intervention":9310,"totalTrials":19,"cells":9311},"gene expression analysis",{"EARLY_PHASE1":9312,"PHASE1":9314,"PHASE2":9316,"PHASE3":9318,"PHASE4":9320,"NA":9322},{"trials":9313,"activeCount":99},[],{"trials":9315,"activeCount":99},[],{"trials":9317,"activeCount":99},[],{"trials":9319,"activeCount":99},[],{"trials":9321,"activeCount":99},[],{"trials":9323,"activeCount":99},[9324,9334,9344,9352,9367,9375,9382,9389,9397,9404,9412,9422,9429,9436,9444,9451,9457,9465,9471,9478,9486,9493,9499,9506,9512,9520,9528,9534,9541,9548,9555,9563,9569,9575,9581,9587,9594],{"nctId":9325,"briefTitle":9326,"status":105,"phases":9327,"primaryCompletion":2107,"completion":2107,"start":1219,"enrollment":125,"conditions":9328,"interventions":9329},"NCT01062438","Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma",[],[21],[9330,9331,9310,9332,9333],"DNA analysis","RNA analysis","gene rearrangement analysis","mutation analysis",{"nctId":9335,"briefTitle":9336,"status":105,"phases":9337,"primaryCompletion":9338,"start":464,"enrollment":9339,"conditions":9340,"interventions":9341},"NCT01035307","Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421",[],"2016-05",90,[15],[9310,9342,9343],"microarray analysis","proteomic profiling",{"nctId":9345,"briefTitle":9346,"status":105,"phases":9347,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":9348,"interventions":9349},"NCT01430637","Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1",[],[21],[9330,9331,9310,9333,9350,9351],"nucleic acid sequencing","polymerase chain reaction",{"nctId":9353,"briefTitle":9354,"status":105,"phases":9355,"primaryCompletion":9338,"start":9356,"enrollment":9357,"conditions":9358,"interventions":9364},"NCT01118078","Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor",[],"2010-05",185,[358,5722,360,9359,9360,9361,9362,9363],"Stage I Wilms Tumor","Stage II Wilms Tumor","Stage III Wilms Tumor","Stage IV Wilms Tumor","Stage V Wilms Tumor",[9365,9310,9342,9366],"DNA methylation analysis","reverse transcriptase-polymerase chain reaction",{"nctId":9368,"briefTitle":9369,"status":105,"phases":9370,"primaryCompletion":9371,"start":404,"enrollment":376,"conditions":9372,"interventions":9373},"NCT01553175","Studying Gene Expression in Samples From Patients With Rhabdoid Tumors",[],"2016-07",[35,170],[9330,9310,9333,9374],"protein expression analysis",{"nctId":9376,"briefTitle":9377,"status":105,"phases":9378,"primaryCompletion":9371,"start":1620,"enrollment":5770,"conditions":9379,"interventions":9381},"NCT01572467","Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors",[],[1248,9380,1916],"Leydig Cell Tumor",[9331,9310,9333,9366],{"nctId":9383,"briefTitle":9384,"status":105,"phases":9385,"primaryCompletion":9338,"start":9386,"enrollment":942,"conditions":9387,"interventions":9388},"NCT01365962","Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma",[],"2011-06",[21],[9310],{"nctId":9390,"briefTitle":9391,"status":105,"phases":9392,"primaryCompletion":9393,"completion":9393,"start":9394,"enrollment":207,"conditions":9395,"interventions":9396},"NCT01057303","Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia",[],"2010-06","2010-02",[15],[9331,9310,9366],{"nctId":9398,"briefTitle":9399,"status":105,"phases":9400,"primaryCompletion":9338,"start":464,"enrollment":33,"conditions":9401,"interventions":9402},"NCT01139931","Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia",[],[15],[9365,9310,9342,9403],"polymorphism analysis",{"nctId":9405,"briefTitle":9406,"status":105,"phases":9407,"primaryCompletion":9408,"completion":9408,"start":488,"enrollment":9409,"conditions":9410,"interventions":9411},"NCT01295476","Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia",[],"2013-05",135,[15],[9310,9342],{"nctId":9413,"briefTitle":9414,"status":105,"phases":9415,"primaryCompletion":9416,"start":488,"enrollment":125,"conditions":9417,"interventions":9421},"NCT01336881","Biomarkers in Tissue Samples From Young Patients With Liver Cancer",[],"2011-07",[1521,1523,9418,9419,9420],"Stage II Childhood Liver Cancer","Stage III Childhood Liver Cancer","Stage IV Childhood Liver Cancer",[9331,9310,9342,9350],{"nctId":9423,"briefTitle":9424,"status":105,"phases":9425,"primaryCompletion":9338,"start":166,"enrollment":4966,"conditions":9426,"interventions":9427},"NCT01139333","Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia",[],[15],[9310,9428],"western blotting",{"nctId":9430,"briefTitle":9431,"status":105,"phases":9432,"primaryCompletion":9338,"start":1620,"enrollment":2452,"conditions":9433,"interventions":9434},"NCT01585389","Studying Gene Expression and Location in Samples From Patients With Brain Tumors",[],[35],[9310,9435,9342],"genetic linkage analysis",{"nctId":9437,"briefTitle":9438,"status":105,"phases":9439,"primaryCompletion":9371,"start":8972,"enrollment":3501,"conditions":9440,"interventions":9441},"NCT01493830","Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma",[],[18],[9442,9310,9342,9333,9443],"fluorescence in situ hybridization","protein analysis",{"nctId":9445,"briefTitle":9446,"status":105,"phases":9447,"primaryCompletion":9338,"completion":9338,"start":2107,"enrollment":9448,"conditions":9449,"interventions":9450},"NCT01433237","Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma",[],40,[21],[9331,9310],{"nctId":9452,"briefTitle":9453,"status":105,"phases":9454,"primaryCompletion":9338,"start":9393,"enrollment":5770,"conditions":9455,"interventions":9456},"NCT01150656","Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia",[],[15],[9310,9342,9374,9366,9428],{"nctId":9458,"briefTitle":9459,"status":105,"phases":9460,"primaryCompletion":9338,"start":404,"enrollment":9461,"conditions":9462,"interventions":9464},"NCT01553448","Studying Gene Expression in Samples From Younger Patients With Neuroblastoma",[],75,[9463,18],"Neoplastic Syndrome",[9310,9374],{"nctId":9466,"briefTitle":9467,"status":105,"phases":9468,"primaryCompletion":9371,"start":573,"enrollment":207,"conditions":9469,"interventions":9470},"NCT01520246","Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia",[],[15,23],[9310],{"nctId":9472,"briefTitle":9473,"status":105,"phases":9474,"primaryCompletion":9338,"start":9475,"enrollment":5814,"conditions":9476,"interventions":9477},"NCT01229956","Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia",[],"2010-11",[15],[9365,9310,9342,9366],{"nctId":9479,"briefTitle":9480,"status":105,"phases":9481,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":9482,"interventions":9484},"NCT01353300","Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer",[],[35,9483,170,6428,18,716,21],"Hereditary Wilms Tumor",[9330,9485,9310,9332,9333,9351,9403],"cytogenetic analysis",{"nctId":9487,"briefTitle":9488,"status":105,"phases":9489,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":9491,"interventions":9492},"NCT01528956","Studying Genes in Samples From Younger Patients With Adrenocortical Tumor",[],"2012-02",[168],[9365,9331,9310,9350,9403],{"nctId":9494,"briefTitle":9495,"status":105,"phases":9496,"primaryCompletion":9338,"start":9490,"enrollment":207,"conditions":9497,"interventions":9498},"NCT01542333","Studying Biomarkers in Samples From Younger Patients With Wilms Tumor",[],[170],[9310,9343,9366,9428],{"nctId":9500,"briefTitle":9501,"status":105,"phases":9502,"primaryCompletion":9338,"start":9416,"enrollment":9503,"conditions":9504,"interventions":9505},"NCT01407757","Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531",[],1000,[15],[9330,9310],{"nctId":9507,"briefTitle":9508,"status":105,"phases":9509,"primaryCompletion":9338,"start":1620,"enrollment":33,"conditions":9510,"interventions":9511},"NCT01581528","Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia",[],[15],[9310],{"nctId":9513,"briefTitle":9514,"status":105,"phases":9515,"primaryCompletion":9338,"completion":9338,"start":9516,"enrollment":9517,"conditions":9518,"interventions":9519},"NCT01138306","Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia",[],"2013-02",149,[15],[9310,9333],{"nctId":9521,"briefTitle":9522,"status":105,"phases":9523,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":9524,"interventions":9525},"NCT01480518","Biomarkers in Tissue Samples From Patients With Ewing Sarcoma",[],[21],[9330,9526,9310,9333,9351,9527],"comparative genomic hybridization","polymorphic microsatellite marker analysis",{"nctId":9529,"briefTitle":9530,"status":105,"phases":9531,"primaryCompletion":9338,"start":1620,"enrollment":207,"conditions":9532,"interventions":9533},"NCT01553162","Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia",[],[15],[9330,9331,9310],{"nctId":9535,"briefTitle":9536,"status":105,"phases":9537,"primaryCompletion":9338,"start":9538,"enrollment":9461,"conditions":9539,"interventions":9540},"NCT01057290","Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia",[],"2012-09",[15],[9310,9374],{"nctId":9542,"briefTitle":9543,"status":105,"phases":9544,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":9545,"interventions":9546},"NCT01544569","Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors",[],[170],[9330,9442,9310,9547,9342,9351,9374],"gene mapping",{"nctId":9549,"briefTitle":9550,"status":105,"phases":9551,"primaryCompletion":858,"completion":9338,"start":9552,"enrollment":125,"conditions":9553,"interventions":9554},"NCT01629745","Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial",[],"2012-06",[15],[9310],{"nctId":9556,"briefTitle":9557,"status":105,"phases":9558,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":9560,"interventions":9561},"NCT01004783","Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors",[],165,[170],[9365,9310,9562,9342,9333,9351,9366],"loss of heterozygosity analysis",{"nctId":9564,"briefTitle":9565,"status":105,"phases":9566,"primaryCompletion":9338,"completion":9338,"start":573,"enrollment":11,"conditions":9567,"interventions":9568},"NCT01520233","Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma",[],[18],[9331,9310],{"nctId":9570,"briefTitle":9571,"status":105,"phases":9572,"primaryCompletion":9393,"completion":9393,"start":1219,"enrollment":312,"conditions":9573,"interventions":9574},"NCT01057199","Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia",[],[15],[9331,9310,9333,9374],{"nctId":9576,"briefTitle":9577,"status":105,"phases":9578,"primaryCompletion":9338,"start":8972,"enrollment":207,"conditions":9579,"interventions":9580},"NCT01500499","Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia",[],[15],[9310,9332,9351,9443,9428],{"nctId":9582,"briefTitle":9583,"status":105,"phases":9584,"primaryCompletion":9338,"start":192,"enrollment":207,"conditions":9585,"interventions":9586},"NCT01466283","Biomarkers in Patients With Rhabdomyosarcoma",[],[21],[9365,9442,9310,9366],{"nctId":9588,"briefTitle":9589,"status":105,"phases":9590,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":9591,"interventions":9592},"NCT01576211","Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor",[],[170],[9365,9331,9593,9310,9350,9403],"allele-specific oligonucleotide real-time quantitative polymerase chain reaction",{"nctId":9595,"briefTitle":9596,"status":105,"phases":9597,"primaryCompletion":9598,"completion":9598,"start":1219,"enrollment":207,"conditions":9599,"interventions":9600},"NCT01057095","Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia",[],"2010-04",[15],[9331,9310,9366],{"intervention":9331,"totalTrials":27,"cells":9602},{"EARLY_PHASE1":9603,"PHASE1":9605,"PHASE2":9607,"PHASE3":9609,"PHASE4":9611,"NA":9613},{"trials":9604,"activeCount":99},[],{"trials":9606,"activeCount":99},[],{"trials":9608,"activeCount":99},[],{"trials":9610,"activeCount":99},[],{"trials":9612,"activeCount":99},[],{"trials":9614,"activeCount":99},[9615,9622,9626,9632,9636,9640,9644,9650,9656,9660,9668,9674,9680,9687,9691,9698,9702,9706,9710,9714,9718,9722],{"nctId":9616,"briefTitle":9617,"status":105,"phases":9618,"primaryCompletion":9338,"start":9386,"enrollment":9619,"conditions":9620,"interventions":9621},"NCT01387724","Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma",[],300,[18],[9331,9351,9374,9343,9428],{"nctId":9325,"briefTitle":9326,"status":105,"phases":9623,"primaryCompletion":2107,"completion":2107,"start":1219,"enrollment":125,"conditions":9624,"interventions":9625},[],[21],[9330,9331,9310,9332,9333],{"nctId":9627,"briefTitle":9628,"status":105,"phases":9629,"primaryCompletion":9338,"start":967,"enrollment":207,"conditions":9630,"interventions":9631},"NCT01342783","Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma",[],[21],[9330,9331,9333,9350],{"nctId":9345,"briefTitle":9346,"status":105,"phases":9633,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":9634,"interventions":9635},[],[21],[9330,9331,9310,9333,9350,9351],{"nctId":9376,"briefTitle":9377,"status":105,"phases":9637,"primaryCompletion":9371,"start":1620,"enrollment":5770,"conditions":9638,"interventions":9639},[],[1248,9380,1916],[9331,9310,9333,9366],{"nctId":9390,"briefTitle":9391,"status":105,"phases":9641,"primaryCompletion":9393,"completion":9393,"start":9394,"enrollment":207,"conditions":9642,"interventions":9643},[],[15],[9331,9310,9366],{"nctId":9645,"briefTitle":9646,"status":105,"phases":9647,"primaryCompletion":9338,"completion":9338,"start":8558,"enrollment":207,"conditions":9648,"interventions":9649},"NCT01229124","RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia",[],[15],[9331,9350,9366],{"nctId":9651,"briefTitle":9652,"status":105,"phases":9653,"primaryCompletion":9338,"completion":9338,"start":9490,"enrollment":942,"conditions":9654,"interventions":9655},"NCT01511575","Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder",[],[15],[9331,9366],{"nctId":9413,"briefTitle":9414,"status":105,"phases":9657,"primaryCompletion":9416,"start":488,"enrollment":125,"conditions":9658,"interventions":9659},[],[1521,1523,9418,9419,9420],[9331,9310,9342,9350],{"nctId":9661,"briefTitle":9662,"status":105,"phases":9663,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":9664,"interventions":9666},"NCT01490801","Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma",[],[23,9665],"Nonneoplastic Condition",[9330,9331,9485,9667,9333,9351,9428],"in situ hybridization",{"nctId":9669,"briefTitle":9670,"status":105,"phases":9671,"primaryCompletion":9338,"completion":9338,"start":8784,"enrollment":207,"conditions":9672,"interventions":9673},"NCT01298414","Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia",[],[15],[9331],{"nctId":9675,"briefTitle":9676,"status":105,"phases":9677,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":9678,"interventions":9679},"NCT01139983","DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers",[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":9681,"briefTitle":9682,"status":105,"phases":9683,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":9685,"interventions":9686},"NCT01169376","Biomarkers in Young Patients With Neuroblastoma",[],380,[18],[9330,9365,9331,9526,9333,9403],{"nctId":9445,"briefTitle":9446,"status":105,"phases":9688,"primaryCompletion":9338,"completion":9338,"start":2107,"enrollment":9448,"conditions":9689,"interventions":9690},[],[21],[9331,9310],{"nctId":9692,"briefTitle":9693,"status":105,"phases":9694,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":9695,"interventions":9697},"NCT01433224","Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression",[],[1248,1249,1916,9696],"Testicular Germ Cell Tumor",[9365,9331,9333,9350,9351,9403],{"nctId":9487,"briefTitle":9488,"status":105,"phases":9699,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":9700,"interventions":9701},[],[168],[9365,9331,9310,9350,9403],{"nctId":9529,"briefTitle":9530,"status":105,"phases":9703,"primaryCompletion":9338,"start":1620,"enrollment":207,"conditions":9704,"interventions":9705},[],[15],[9330,9331,9310],{"nctId":9564,"briefTitle":9565,"status":105,"phases":9707,"primaryCompletion":9338,"completion":9338,"start":573,"enrollment":11,"conditions":9708,"interventions":9709},[],[18],[9331,9310],{"nctId":9570,"briefTitle":9571,"status":105,"phases":9711,"primaryCompletion":9393,"completion":9393,"start":1219,"enrollment":312,"conditions":9712,"interventions":9713},[],[15],[9331,9310,9333,9374],{"nctId":9588,"briefTitle":9589,"status":105,"phases":9715,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":9716,"interventions":9717},[],[170],[9365,9331,9593,9310,9350,9403],{"nctId":9595,"briefTitle":9596,"status":105,"phases":9719,"primaryCompletion":9598,"completion":9598,"start":1219,"enrollment":207,"conditions":9720,"interventions":9721},[],[15],[9331,9310,9366],{"nctId":9723,"briefTitle":9724,"status":105,"phases":9725,"primaryCompletion":9338,"completion":9338,"start":8628,"enrollment":207,"conditions":9726,"interventions":9727},"NCT01626183","Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia",[],[15],[9331,9343],{"intervention":9351,"totalTrials":27,"cells":9729},{"EARLY_PHASE1":9730,"PHASE1":9732,"PHASE2":9734,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9731,"activeCount":99},[],{"trials":9733,"activeCount":99},[],{"trials":9735,"activeCount":99},[],{"trials":9737,"activeCount":99},[],{"trials":9739,"activeCount":99},[],{"trials":9741,"activeCount":99},[9742,9746,9750,9756,9763,9771,9775,9779,9785,9789,9793,9799,9805,9814,9818,9826,9834,9838,9842,9849,9853,9859],{"nctId":9616,"briefTitle":9617,"status":105,"phases":9743,"primaryCompletion":9338,"start":9386,"enrollment":9619,"conditions":9744,"interventions":9745},[],[18],[9331,9351,9374,9343,9428],{"nctId":9345,"briefTitle":9346,"status":105,"phases":9747,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":9748,"interventions":9749},[],[21],[9330,9331,9310,9333,9350,9351],{"nctId":9751,"briefTitle":9752,"status":105,"phases":9753,"primaryCompletion":9338,"completion":9338,"start":573,"enrollment":125,"conditions":9754,"interventions":9755},"NCT01510600","Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma",[],[18],[9330,9351],{"nctId":9757,"briefTitle":9758,"status":105,"phases":9759,"primaryCompletion":9760,"completion":9760,"start":967,"enrollment":207,"conditions":9761,"interventions":9762},"NCT01358604","Biomarkers in Samples From Young Patients With Neuroblastoma",[],"2016-04",[18],[9351,9374,9428],{"nctId":9764,"briefTitle":9765,"status":105,"phases":9766,"primaryCompletion":9338,"start":9767,"enrollment":207,"conditions":9768,"interventions":9770},"NCT01314391","Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor",[],"2011-08",[170,9769],"Renal Failure",[9333,9351],{"nctId":9661,"briefTitle":9662,"status":105,"phases":9772,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":9773,"interventions":9774},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"nctId":9675,"briefTitle":9676,"status":105,"phases":9776,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":9777,"interventions":9778},[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":9780,"briefTitle":9781,"status":105,"phases":9782,"primaryCompletion":1255,"start":282,"enrollment":30,"conditions":9783,"interventions":9784},"NCT01138319","Biomarkers in Patients With Acute Myeloid Leukemia",[],[15],[9330,9333,9351],{"nctId":9692,"briefTitle":9693,"status":105,"phases":9786,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":9787,"interventions":9788},[],[1248,1249,1916,9696],[9365,9331,9333,9350,9351,9403],{"nctId":9479,"briefTitle":9480,"status":105,"phases":9790,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":9791,"interventions":9792},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":9794,"briefTitle":9795,"status":105,"phases":9796,"primaryCompletion":9338,"start":166,"enrollment":9619,"conditions":9797,"interventions":9798},"NCT01139320","Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin",[],[15],[9330,9351],{"nctId":9800,"briefTitle":9514,"status":105,"phases":9801,"primaryCompletion":9338,"start":9475,"enrollment":9802,"conditions":9803,"interventions":9804},"NCT01247584",[],234,[15],[9330,9333,9351],{"nctId":9806,"briefTitle":9807,"status":105,"phases":9808,"primaryCompletion":9338,"start":9809,"enrollment":9810,"conditions":9811,"interventions":9812},"NCT00088803","DNA Variations in the Gene in Young Patients With Wilms' Tumor",[],"2004-08",471,[170],[9813,9351,9403],"molecular genetic technique",{"nctId":9521,"briefTitle":9522,"status":105,"phases":9815,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":9816,"interventions":9817},[],[21],[9330,9526,9310,9333,9351,9527],{"nctId":9819,"briefTitle":9820,"status":105,"phases":9821,"primaryCompletion":4427,"completion":206,"start":9822,"enrollment":9823,"conditions":9824,"interventions":9825},"NCT00003790","Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome",[],"1995-02",496,[15,2309],[9351],{"nctId":9827,"briefTitle":9828,"status":105,"phases":9829,"primaryCompletion":9338,"completion":9338,"start":2392,"enrollment":9830,"conditions":9831,"interventions":9832},"NCT00898391","Study of DNA in Blood Samples From Patients With Neuroblastoma",[],329,[5717,128,129,32,130,132],[9351,9833,9330],"polyacrylamide gel electrophoresis",{"nctId":9542,"briefTitle":9543,"status":105,"phases":9835,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":9836,"interventions":9837},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":9556,"briefTitle":9557,"status":105,"phases":9839,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":9840,"interventions":9841},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"nctId":9843,"briefTitle":9844,"status":105,"phases":9845,"primaryCompletion":9846,"completion":9338,"start":8784,"enrollment":2268,"conditions":9847,"interventions":9848},"NCT01290107","Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia",[],"2015-01",[15],[9330,9332,9342,9351],{"nctId":9576,"briefTitle":9577,"status":105,"phases":9850,"primaryCompletion":9338,"start":8972,"enrollment":207,"conditions":9851,"interventions":9852},[],[15],[9310,9332,9351,9443,9428],{"nctId":9854,"briefTitle":9855,"status":105,"phases":9856,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":9857,"interventions":9858},"NCT01119586","Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia",[],[15],[9330,9435,9342,9350,9351,9403],{"nctId":9860,"briefTitle":9861,"status":105,"phases":9862,"primaryCompletion":9338,"completion":9338,"start":9767,"enrollment":7173,"conditions":9863,"interventions":9864},"NCT01419509","DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma",[],[21],[9365,9342,9351],{"intervention":9333,"totalTrials":27,"cells":9866},{"EARLY_PHASE1":9867,"PHASE1":9869,"PHASE2":9871,"PHASE3":9873,"PHASE4":9875,"NA":9877},{"trials":9868,"activeCount":99},[],{"trials":9870,"activeCount":99},[],{"trials":9872,"activeCount":99},[],{"trials":9874,"activeCount":99},[],{"trials":9876,"activeCount":99},[],{"trials":9878,"activeCount":99},[9879,9883,9887,9891,9895,9904,9908,9912,9919,9923,9927,9931,9935,9939,9943,9950,9954,9958,9962,9966,9972,9976],{"nctId":9325,"briefTitle":9326,"status":105,"phases":9880,"primaryCompletion":2107,"completion":2107,"start":1219,"enrollment":125,"conditions":9881,"interventions":9882},[],[21],[9330,9331,9310,9332,9333],{"nctId":9627,"briefTitle":9628,"status":105,"phases":9884,"primaryCompletion":9338,"start":967,"enrollment":207,"conditions":9885,"interventions":9886},[],[21],[9330,9331,9333,9350],{"nctId":9345,"briefTitle":9346,"status":105,"phases":9888,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":9889,"interventions":9890},[],[21],[9330,9331,9310,9333,9350,9351],{"nctId":9368,"briefTitle":9369,"status":105,"phases":9892,"primaryCompletion":9371,"start":404,"enrollment":376,"conditions":9893,"interventions":9894},[],[35,170],[9330,9310,9333,9374],{"nctId":9896,"briefTitle":9897,"status":105,"phases":9898,"primaryCompletion":108,"completion":206,"start":9899,"enrollment":9517,"conditions":9900,"interventions":9901},"NCT00899652","DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[],"1997-01",[15],[9902,9903,9485,9332,9333],"Southern blotting","chromosomal translocation analysis",{"nctId":9376,"briefTitle":9377,"status":105,"phases":9905,"primaryCompletion":9371,"start":1620,"enrollment":5770,"conditions":9906,"interventions":9907},[],[1248,9380,1916],[9331,9310,9333,9366],{"nctId":9764,"briefTitle":9765,"status":105,"phases":9909,"primaryCompletion":9338,"start":9767,"enrollment":207,"conditions":9910,"interventions":9911},[],[170,9769],[9333,9351],{"nctId":9913,"briefTitle":9914,"status":105,"phases":9915,"primaryCompletion":1038,"start":193,"enrollment":9916,"conditions":9917,"interventions":9918},"NCT00003291","Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia",[],200,[15],[9485,9333],{"nctId":9661,"briefTitle":9662,"status":105,"phases":9920,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":9921,"interventions":9922},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"nctId":9681,"briefTitle":9682,"status":105,"phases":9924,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":9925,"interventions":9926},[],[18],[9330,9365,9331,9526,9333,9403],{"nctId":9437,"briefTitle":9438,"status":105,"phases":9928,"primaryCompletion":9371,"start":8972,"enrollment":3501,"conditions":9929,"interventions":9930},[],[18],[9442,9310,9342,9333,9443],{"nctId":9780,"briefTitle":9781,"status":105,"phases":9932,"primaryCompletion":1255,"start":282,"enrollment":30,"conditions":9933,"interventions":9934},[],[15],[9330,9333,9351],{"nctId":9692,"briefTitle":9693,"status":105,"phases":9936,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":9937,"interventions":9938},[],[1248,1249,1916,9696],[9365,9331,9333,9350,9351,9403],{"nctId":9479,"briefTitle":9480,"status":105,"phases":9940,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":9941,"interventions":9942},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":9944,"briefTitle":9945,"status":105,"phases":9946,"primaryCompletion":9338,"completion":9338,"start":1620,"enrollment":9947,"conditions":9948,"interventions":9949},"NCT01585376","Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma",[],58,[21],[9333,9350],{"nctId":9800,"briefTitle":9514,"status":105,"phases":9951,"primaryCompletion":9338,"start":9475,"enrollment":9802,"conditions":9952,"interventions":9953},[],[15],[9330,9333,9351],{"nctId":9513,"briefTitle":9514,"status":105,"phases":9955,"primaryCompletion":9338,"completion":9338,"start":9516,"enrollment":9517,"conditions":9956,"interventions":9957},[],[15],[9310,9333],{"nctId":9521,"briefTitle":9522,"status":105,"phases":9959,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":9960,"interventions":9961},[],[21],[9330,9526,9310,9333,9351,9527],{"nctId":9556,"briefTitle":9557,"status":105,"phases":9963,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":9964,"interventions":9965},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"nctId":9967,"briefTitle":9968,"status":105,"phases":9969,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":9970,"interventions":9971},"NCT01507441","Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial",[],[15],[9547,9342,9333,9350],{"nctId":9570,"briefTitle":9571,"status":105,"phases":9973,"primaryCompletion":9393,"completion":9393,"start":1219,"enrollment":312,"conditions":9974,"interventions":9975},[],[15],[9331,9310,9333,9374],{"nctId":9977,"briefTitle":9978,"status":105,"phases":9979,"primaryCompletion":650,"completion":248,"start":283,"enrollment":1682,"conditions":9980,"interventions":9981},"NCT00003793","Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma",[],[15,2309,21],[9982,9983,9333],"clonality analysis","microsatellite instability analysis",{"intervention":9330,"totalTrials":9985,"cells":9986},21,{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":9991,"PHASE3":9993,"PHASE4":9995,"NA":9997},{"trials":9988,"activeCount":99},[],{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":99},[],{"trials":9994,"activeCount":99},[],{"trials":9996,"activeCount":99},[],{"trials":9998,"activeCount":99},[9999,10003,10007,10011,10015,10019,10026,10030,10034,10038,10042,10046,10050,10054,10058,10062,10066,10070,10074,10078,10082],{"nctId":9325,"briefTitle":9326,"status":105,"phases":10000,"primaryCompletion":2107,"completion":2107,"start":1219,"enrollment":125,"conditions":10001,"interventions":10002},[],[21],[9330,9331,9310,9332,9333],{"nctId":9627,"briefTitle":9628,"status":105,"phases":10004,"primaryCompletion":9338,"start":967,"enrollment":207,"conditions":10005,"interventions":10006},[],[21],[9330,9331,9333,9350],{"nctId":9345,"briefTitle":9346,"status":105,"phases":10008,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":10009,"interventions":10010},[],[21],[9330,9331,9310,9333,9350,9351],{"nctId":9368,"briefTitle":9369,"status":105,"phases":10012,"primaryCompletion":9371,"start":404,"enrollment":376,"conditions":10013,"interventions":10014},[],[35,170],[9330,9310,9333,9374],{"nctId":9751,"briefTitle":9752,"status":105,"phases":10016,"primaryCompletion":9338,"completion":9338,"start":573,"enrollment":125,"conditions":10017,"interventions":10018},[],[18],[9330,9351],{"nctId":10020,"briefTitle":10021,"status":105,"phases":10022,"primaryCompletion":9338,"completion":9338,"start":10023,"enrollment":9503,"conditions":10024,"interventions":10025},"NCT01016379","Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia",[],"2009-11",[15],[9330],{"nctId":9661,"briefTitle":9662,"status":105,"phases":10027,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":10028,"interventions":10029},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"nctId":9675,"briefTitle":9676,"status":105,"phases":10031,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":10032,"interventions":10033},[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":9681,"briefTitle":9682,"status":105,"phases":10035,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":10036,"interventions":10037},[],[18],[9330,9365,9331,9526,9333,9403],{"nctId":9780,"briefTitle":9781,"status":105,"phases":10039,"primaryCompletion":1255,"start":282,"enrollment":30,"conditions":10040,"interventions":10041},[],[15],[9330,9333,9351],{"nctId":9479,"briefTitle":9480,"status":105,"phases":10043,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":10044,"interventions":10045},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":9794,"briefTitle":9795,"status":105,"phases":10047,"primaryCompletion":9338,"start":166,"enrollment":9619,"conditions":10048,"interventions":10049},[],[15],[9330,9351],{"nctId":9800,"briefTitle":9514,"status":105,"phases":10051,"primaryCompletion":9338,"start":9475,"enrollment":9802,"conditions":10052,"interventions":10053},[],[15],[9330,9333,9351],{"nctId":9500,"briefTitle":9501,"status":105,"phases":10055,"primaryCompletion":9338,"start":9416,"enrollment":9503,"conditions":10056,"interventions":10057},[],[15],[9330,9310],{"nctId":9521,"briefTitle":9522,"status":105,"phases":10059,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":10060,"interventions":10061},[],[21],[9330,9526,9310,9333,9351,9527],{"nctId":9827,"briefTitle":9828,"status":105,"phases":10063,"primaryCompletion":9338,"completion":9338,"start":2392,"enrollment":9830,"conditions":10064,"interventions":10065},[],[5717,128,129,32,130,132],[9351,9833,9330],{"nctId":9529,"briefTitle":9530,"status":105,"phases":10067,"primaryCompletion":9338,"start":1620,"enrollment":207,"conditions":10068,"interventions":10069},[],[15],[9330,9331,9310],{"nctId":9542,"briefTitle":9543,"status":105,"phases":10071,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":10072,"interventions":10073},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":9843,"briefTitle":9844,"status":105,"phases":10075,"primaryCompletion":9846,"completion":9338,"start":8784,"enrollment":2268,"conditions":10076,"interventions":10077},[],[15],[9330,9332,9342,9351],{"nctId":9854,"briefTitle":9855,"status":105,"phases":10079,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":10080,"interventions":10081},[],[15],[9330,9435,9342,9350,9351,9403],{"nctId":10083,"briefTitle":9495,"status":105,"phases":10084,"primaryCompletion":9371,"start":1620,"enrollment":10085,"conditions":10086,"interventions":10087},"NCT01576198",[],2227,[170],[9330,10088],"nucleic acid amplification",{"intervention":9342,"totalTrials":9985,"cells":10090},{"EARLY_PHASE1":10091,"PHASE1":10093,"PHASE2":10095,"PHASE3":10097,"PHASE4":10099,"NA":10101},{"trials":10092,"activeCount":99},[],{"trials":10094,"activeCount":99},[],{"trials":10096,"activeCount":99},[],{"trials":10098,"activeCount":99},[],{"trials":10100,"activeCount":99},[],{"trials":10102,"activeCount":99},[10103,10107,10111,10117,10121,10125,10129,10133,10140,10144,10148,10156,10160,10164,10170,10174,10178,10182,10186,10190,10194],{"nctId":9335,"briefTitle":9336,"status":105,"phases":10104,"primaryCompletion":9338,"start":464,"enrollment":9339,"conditions":10105,"interventions":10106},[],[15],[9310,9342,9343],{"nctId":9353,"briefTitle":9354,"status":105,"phases":10108,"primaryCompletion":9338,"start":9356,"enrollment":9357,"conditions":10109,"interventions":10110},[],[358,5722,360,9359,9360,9361,9362,9363],[9365,9310,9342,9366],{"nctId":10112,"briefTitle":10113,"status":105,"phases":10114,"primaryCompletion":9338,"start":967,"enrollment":324,"conditions":10115,"interventions":10116},"NCT01366170","Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma",[],[23],[9342,9374,9428],{"nctId":9398,"briefTitle":9399,"status":105,"phases":10118,"primaryCompletion":9338,"start":464,"enrollment":33,"conditions":10119,"interventions":10120},[],[15],[9365,9310,9342,9403],{"nctId":9405,"briefTitle":9406,"status":105,"phases":10122,"primaryCompletion":9408,"completion":9408,"start":488,"enrollment":9409,"conditions":10123,"interventions":10124},[],[15],[9310,9342],{"nctId":9413,"briefTitle":9414,"status":105,"phases":10126,"primaryCompletion":9416,"start":488,"enrollment":125,"conditions":10127,"interventions":10128},[],[1521,1523,9418,9419,9420],[9331,9310,9342,9350],{"nctId":9675,"briefTitle":9676,"status":105,"phases":10130,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":10131,"interventions":10132},[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":10134,"briefTitle":10135,"status":105,"phases":10136,"primaryCompletion":9338,"completion":9338,"start":967,"enrollment":10137,"conditions":10138,"interventions":10139},"NCT01366157","Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma",[],23,[23],[9342,9374],{"nctId":9430,"briefTitle":9431,"status":105,"phases":10141,"primaryCompletion":9338,"start":1620,"enrollment":2452,"conditions":10142,"interventions":10143},[],[35],[9310,9435,9342],{"nctId":9437,"briefTitle":9438,"status":105,"phases":10145,"primaryCompletion":9371,"start":8972,"enrollment":3501,"conditions":10146,"interventions":10147},[],[18],[9442,9310,9342,9333,9443],{"nctId":10149,"briefTitle":10150,"status":105,"phases":10151,"primaryCompletion":9338,"completion":9338,"start":10152,"enrollment":219,"conditions":10153,"interventions":10154},"NCT00896766","Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia",[],"2006-05",[15],[9562,9342,9403,10155],"tumor replication error analysis",{"nctId":9452,"briefTitle":9453,"status":105,"phases":10157,"primaryCompletion":9338,"start":9393,"enrollment":5770,"conditions":10158,"interventions":10159},[],[15],[9310,9342,9374,9366,9428],{"nctId":9472,"briefTitle":9473,"status":105,"phases":10161,"primaryCompletion":9338,"start":9475,"enrollment":5814,"conditions":10162,"interventions":10163},[],[15],[9365,9310,9342,9366],{"nctId":10165,"briefTitle":10166,"status":105,"phases":10167,"primaryCompletion":9371,"start":967,"enrollment":9448,"conditions":10168,"interventions":10169},"NCT01365949","Biomarker in Tissue Samples From Patients With Ewing Sarcoma",[],[21],[9342,9443],{"nctId":9542,"briefTitle":9543,"status":105,"phases":10171,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":10172,"interventions":10173},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":9556,"briefTitle":9557,"status":105,"phases":10175,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":10176,"interventions":10177},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"nctId":9967,"briefTitle":9968,"status":105,"phases":10179,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10180,"interventions":10181},[],[15],[9547,9342,9333,9350],{"nctId":9843,"briefTitle":9844,"status":105,"phases":10183,"primaryCompletion":9846,"completion":9338,"start":8784,"enrollment":2268,"conditions":10184,"interventions":10185},[],[15],[9330,9332,9342,9351],{"nctId":9854,"briefTitle":9855,"status":105,"phases":10187,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":10188,"interventions":10189},[],[15],[9330,9435,9342,9350,9351,9403],{"nctId":9860,"briefTitle":9861,"status":105,"phases":10191,"primaryCompletion":9338,"completion":9338,"start":9767,"enrollment":7173,"conditions":10192,"interventions":10193},[],[21],[9365,9342,9351],{"nctId":10195,"briefTitle":10196,"status":105,"phases":10197,"primaryCompletion":10198,"completion":311,"start":10199,"enrollment":9409,"conditions":10200,"interventions":10201},"NCT00899899","Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission",[],"2005-03","1998-06",[15],[9342,9366],{"intervention":9374,"totalTrials":33,"cells":10203},{"EARLY_PHASE1":10204,"PHASE1":10206,"PHASE2":10208,"PHASE3":10210,"PHASE4":10212,"NA":10214},{"trials":10205,"activeCount":99},[],{"trials":10207,"activeCount":99},[],{"trials":10209,"activeCount":99},[],{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":99},[],{"trials":10215,"activeCount":99},[10216,10220,10224,10228,10232,10238,10242,10248,10252,10256,10263,10267,10271,10277,10281],{"nctId":9616,"briefTitle":9617,"status":105,"phases":10217,"primaryCompletion":9338,"start":9386,"enrollment":9619,"conditions":10218,"interventions":10219},[],[18],[9331,9351,9374,9343,9428],{"nctId":9368,"briefTitle":9369,"status":105,"phases":10221,"primaryCompletion":9371,"start":404,"enrollment":376,"conditions":10222,"interventions":10223},[],[35,170],[9330,9310,9333,9374],{"nctId":9757,"briefTitle":9758,"status":105,"phases":10225,"primaryCompletion":9760,"completion":9760,"start":967,"enrollment":207,"conditions":10226,"interventions":10227},[],[18],[9351,9374,9428],{"nctId":10112,"briefTitle":10113,"status":105,"phases":10229,"primaryCompletion":9338,"start":967,"enrollment":324,"conditions":10230,"interventions":10231},[],[23],[9342,9374,9428],{"nctId":10233,"briefTitle":10234,"status":105,"phases":10235,"primaryCompletion":9338,"start":2107,"enrollment":9448,"conditions":10236,"interventions":10237},"NCT01419496","Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia",[],[15],[9374],{"nctId":10134,"briefTitle":10135,"status":105,"phases":10239,"primaryCompletion":9338,"completion":9338,"start":967,"enrollment":10137,"conditions":10240,"interventions":10241},[],[23],[9342,9374],{"nctId":10243,"briefTitle":10244,"status":105,"phases":10245,"primaryCompletion":8784,"completion":8784,"start":9475,"enrollment":2452,"conditions":10246,"interventions":10247},"NCT01232855","Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia",[],[15],[9374,9428],{"nctId":9452,"briefTitle":9453,"status":105,"phases":10249,"primaryCompletion":9338,"start":9393,"enrollment":5770,"conditions":10250,"interventions":10251},[],[15],[9310,9342,9374,9366,9428],{"nctId":9458,"briefTitle":9459,"status":105,"phases":10253,"primaryCompletion":9338,"start":404,"enrollment":9461,"conditions":10254,"interventions":10255},[],[9463,18],[9310,9374],{"nctId":10257,"briefTitle":10258,"status":105,"phases":10259,"primaryCompletion":9338,"start":10260,"enrollment":585,"conditions":10261,"interventions":10262},"NCT01426945","Protein Expression in Samples From Young Patients With Rhabdomyosarcoma",[],"2011-11",[21],[9374],{"nctId":9535,"briefTitle":9536,"status":105,"phases":10264,"primaryCompletion":9338,"start":9538,"enrollment":9461,"conditions":10265,"interventions":10266},[],[15],[9310,9374],{"nctId":9542,"briefTitle":9543,"status":105,"phases":10268,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":10269,"interventions":10270},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":10272,"briefTitle":10273,"status":105,"phases":10274,"primaryCompletion":9338,"completion":9338,"start":9416,"enrollment":207,"conditions":10275,"interventions":10276},"NCT01407731","Protein Expression in Human Neuroblastoma Tumor Samples",[],[18],[9374,9428],{"nctId":9570,"briefTitle":9571,"status":105,"phases":10278,"primaryCompletion":9393,"completion":9393,"start":1219,"enrollment":312,"conditions":10279,"interventions":10280},[],[15],[9331,9310,9333,9374],{"nctId":10282,"briefTitle":10283,"status":105,"phases":10284,"primaryCompletion":9338,"start":9356,"enrollment":219,"conditions":10285,"interventions":10286},"NCT01245231","Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia",[],[15],[9374,9428],{"intervention":9428,"totalTrials":2643,"cells":10288},{"EARLY_PHASE1":10289,"PHASE1":10291,"PHASE2":10293,"PHASE3":10295,"PHASE4":10297,"NA":10299},{"trials":10290,"activeCount":99},[],{"trials":10292,"activeCount":99},[],{"trials":10294,"activeCount":99},[],{"trials":10296,"activeCount":99},[],{"trials":10298,"activeCount":99},[],{"trials":10300,"activeCount":99},[10301,10305,10312,10316,10320,10324,10328,10332,10336,10340,10344,10350,10354],{"nctId":9616,"briefTitle":9617,"status":105,"phases":10302,"primaryCompletion":9338,"start":9386,"enrollment":9619,"conditions":10303,"interventions":10304},[],[18],[9331,9351,9374,9343,9428],{"nctId":10306,"briefTitle":10307,"status":105,"phases":10308,"primaryCompletion":10309,"completion":10309,"start":9475,"enrollment":9448,"conditions":10310,"interventions":10311},"NCT01150058","Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia",[],"2012-11",[15],[9428],{"nctId":9757,"briefTitle":9758,"status":105,"phases":10313,"primaryCompletion":9760,"completion":9760,"start":967,"enrollment":207,"conditions":10314,"interventions":10315},[],[18],[9351,9374,9428],{"nctId":10112,"briefTitle":10113,"status":105,"phases":10317,"primaryCompletion":9338,"start":967,"enrollment":324,"conditions":10318,"interventions":10319},[],[23],[9342,9374,9428],{"nctId":9661,"briefTitle":9662,"status":105,"phases":10321,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":10322,"interventions":10323},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"nctId":9423,"briefTitle":9424,"status":105,"phases":10325,"primaryCompletion":9338,"start":166,"enrollment":4966,"conditions":10326,"interventions":10327},[],[15],[9310,9428],{"nctId":10243,"briefTitle":10244,"status":105,"phases":10329,"primaryCompletion":8784,"completion":8784,"start":9475,"enrollment":2452,"conditions":10330,"interventions":10331},[],[15],[9374,9428],{"nctId":9452,"briefTitle":9453,"status":105,"phases":10333,"primaryCompletion":9338,"start":9393,"enrollment":5770,"conditions":10334,"interventions":10335},[],[15],[9310,9342,9374,9366,9428],{"nctId":9494,"briefTitle":9495,"status":105,"phases":10337,"primaryCompletion":9338,"start":9490,"enrollment":207,"conditions":10338,"interventions":10339},[],[170],[9310,9343,9366,9428],{"nctId":10272,"briefTitle":10273,"status":105,"phases":10341,"primaryCompletion":9338,"completion":9338,"start":9416,"enrollment":207,"conditions":10342,"interventions":10343},[],[18],[9374,9428],{"nctId":10345,"briefTitle":10346,"status":105,"phases":10347,"primaryCompletion":1255,"completion":1255,"start":166,"enrollment":207,"conditions":10348,"interventions":10349},"NCT01138332","Biomarkers in Young Patients With Acute Myeloid Leukemia",[],[15],[9428],{"nctId":9576,"briefTitle":9577,"status":105,"phases":10351,"primaryCompletion":9338,"start":8972,"enrollment":207,"conditions":10352,"interventions":10353},[],[15],[9310,9332,9351,9443,9428],{"nctId":10282,"briefTitle":10283,"status":105,"phases":10355,"primaryCompletion":9338,"start":9356,"enrollment":219,"conditions":10356,"interventions":10357},[],[15],[9374,9428],{"intervention":9366,"totalTrials":2643,"cells":10359},{"EARLY_PHASE1":10360,"PHASE1":10362,"PHASE2":10364,"PHASE3":10366,"PHASE4":10368,"NA":10370},{"trials":10361,"activeCount":99},[],{"trials":10363,"activeCount":99},[],{"trials":10365,"activeCount":99},[],{"trials":10367,"activeCount":99},[],{"trials":10369,"activeCount":99},[],{"trials":10371,"activeCount":99},[10372,10376,10380,10384,10388,10392,10396,10400,10404,10408,10412,10416,10420],{"nctId":9353,"briefTitle":9354,"status":105,"phases":10373,"primaryCompletion":9338,"start":9356,"enrollment":9357,"conditions":10374,"interventions":10375},[],[358,5722,360,9359,9360,9361,9362,9363],[9365,9310,9342,9366],{"nctId":9376,"briefTitle":9377,"status":105,"phases":10377,"primaryCompletion":9371,"start":1620,"enrollment":5770,"conditions":10378,"interventions":10379},[],[1248,9380,1916],[9331,9310,9333,9366],{"nctId":9390,"briefTitle":9391,"status":105,"phases":10381,"primaryCompletion":9393,"completion":9393,"start":9394,"enrollment":207,"conditions":10382,"interventions":10383},[],[15],[9331,9310,9366],{"nctId":9645,"briefTitle":9646,"status":105,"phases":10385,"primaryCompletion":9338,"completion":9338,"start":8558,"enrollment":207,"conditions":10386,"interventions":10387},[],[15],[9331,9350,9366],{"nctId":9651,"briefTitle":9652,"status":105,"phases":10389,"primaryCompletion":9338,"completion":9338,"start":9490,"enrollment":942,"conditions":10390,"interventions":10391},[],[15],[9331,9366],{"nctId":9675,"briefTitle":9676,"status":105,"phases":10393,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":10394,"interventions":10395},[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":9452,"briefTitle":9453,"status":105,"phases":10397,"primaryCompletion":9338,"start":9393,"enrollment":5770,"conditions":10398,"interventions":10399},[],[15],[9310,9342,9374,9366,9428],{"nctId":9472,"briefTitle":9473,"status":105,"phases":10401,"primaryCompletion":9338,"start":9475,"enrollment":5814,"conditions":10402,"interventions":10403},[],[15],[9365,9310,9342,9366],{"nctId":9494,"briefTitle":9495,"status":105,"phases":10405,"primaryCompletion":9338,"start":9490,"enrollment":207,"conditions":10406,"interventions":10407},[],[170],[9310,9343,9366,9428],{"nctId":9556,"briefTitle":9557,"status":105,"phases":10409,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":10410,"interventions":10411},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"nctId":10195,"briefTitle":10196,"status":105,"phases":10413,"primaryCompletion":10198,"completion":311,"start":10199,"enrollment":9409,"conditions":10414,"interventions":10415},[],[15],[9342,9366],{"nctId":9582,"briefTitle":9583,"status":105,"phases":10417,"primaryCompletion":9338,"start":192,"enrollment":207,"conditions":10418,"interventions":10419},[],[21],[9365,9442,9310,9366],{"nctId":9595,"briefTitle":9596,"status":105,"phases":10421,"primaryCompletion":9598,"completion":9598,"start":1219,"enrollment":207,"conditions":10422,"interventions":10423},[],[15],[9331,9310,9366],{"intervention":9350,"totalTrials":1725,"cells":10425},{"EARLY_PHASE1":10426,"PHASE1":10428,"PHASE2":10430,"PHASE3":10432,"PHASE4":10434,"NA":10436},{"trials":10427,"activeCount":99},[],{"trials":10429,"activeCount":99},[],{"trials":10431,"activeCount":99},[],{"trials":10433,"activeCount":99},[],{"trials":10435,"activeCount":99},[],{"trials":10437,"activeCount":99},[10438,10442,10446,10450,10454,10458,10464,10468,10472,10476,10480],{"nctId":9627,"briefTitle":9628,"status":105,"phases":10439,"primaryCompletion":9338,"start":967,"enrollment":207,"conditions":10440,"interventions":10441},[],[21],[9330,9331,9333,9350],{"nctId":9345,"briefTitle":9346,"status":105,"phases":10443,"primaryCompletion":9338,"start":2107,"enrollment":207,"conditions":10444,"interventions":10445},[],[21],[9330,9331,9310,9333,9350,9351],{"nctId":9645,"briefTitle":9646,"status":105,"phases":10447,"primaryCompletion":9338,"completion":9338,"start":8558,"enrollment":207,"conditions":10448,"interventions":10449},[],[15],[9331,9350,9366],{"nctId":9413,"briefTitle":9414,"status":105,"phases":10451,"primaryCompletion":9416,"start":488,"enrollment":125,"conditions":10452,"interventions":10453},[],[1521,1523,9418,9419,9420],[9331,9310,9342,9350],{"nctId":9692,"briefTitle":9693,"status":105,"phases":10455,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":10456,"interventions":10457},[],[1248,1249,1916,9696],[9365,9331,9333,9350,9351,9403],{"nctId":10459,"briefTitle":10460,"status":105,"phases":10461,"primaryCompletion":9338,"start":9490,"enrollment":2317,"conditions":10462,"interventions":10463},"NCT01533168","Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia",[],[15],[9485,9350],{"nctId":9944,"briefTitle":9945,"status":105,"phases":10465,"primaryCompletion":9338,"completion":9338,"start":1620,"enrollment":9947,"conditions":10466,"interventions":10467},[],[21],[9333,9350],{"nctId":9487,"briefTitle":9488,"status":105,"phases":10469,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10470,"interventions":10471},[],[168],[9365,9331,9310,9350,9403],{"nctId":9967,"briefTitle":9968,"status":105,"phases":10473,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10474,"interventions":10475},[],[15],[9547,9342,9333,9350],{"nctId":9854,"briefTitle":9855,"status":105,"phases":10477,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":10478,"interventions":10479},[],[15],[9330,9435,9342,9350,9351,9403],{"nctId":9588,"briefTitle":9589,"status":105,"phases":10481,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":10482,"interventions":10483},[],[170],[9365,9331,9593,9310,9350,9403],{"intervention":9365,"totalTrials":2452,"cells":10485},{"EARLY_PHASE1":10486,"PHASE1":10488,"PHASE2":10490,"PHASE3":10492,"PHASE4":10494,"NA":10496},{"trials":10487,"activeCount":99},[],{"trials":10489,"activeCount":99},[],{"trials":10491,"activeCount":99},[],{"trials":10493,"activeCount":99},[],{"trials":10495,"activeCount":99},[],{"trials":10497,"activeCount":99},[10498,10502,10506,10510,10514,10518,10522,10526,10530,10534],{"nctId":9353,"briefTitle":9354,"status":105,"phases":10499,"primaryCompletion":9338,"start":9356,"enrollment":9357,"conditions":10500,"interventions":10501},[],[358,5722,360,9359,9360,9361,9362,9363],[9365,9310,9342,9366],{"nctId":9398,"briefTitle":9399,"status":105,"phases":10503,"primaryCompletion":9338,"start":464,"enrollment":33,"conditions":10504,"interventions":10505},[],[15],[9365,9310,9342,9403],{"nctId":9681,"briefTitle":9682,"status":105,"phases":10507,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":10508,"interventions":10509},[],[18],[9330,9365,9331,9526,9333,9403],{"nctId":9692,"briefTitle":9693,"status":105,"phases":10511,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":10512,"interventions":10513},[],[1248,1249,1916,9696],[9365,9331,9333,9350,9351,9403],{"nctId":9472,"briefTitle":9473,"status":105,"phases":10515,"primaryCompletion":9338,"start":9475,"enrollment":5814,"conditions":10516,"interventions":10517},[],[15],[9365,9310,9342,9366],{"nctId":9487,"briefTitle":9488,"status":105,"phases":10519,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10520,"interventions":10521},[],[168],[9365,9331,9310,9350,9403],{"nctId":9556,"briefTitle":9557,"status":105,"phases":10523,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":10524,"interventions":10525},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"nctId":9860,"briefTitle":9861,"status":105,"phases":10527,"primaryCompletion":9338,"completion":9338,"start":9767,"enrollment":7173,"conditions":10528,"interventions":10529},[],[21],[9365,9342,9351],{"nctId":9582,"briefTitle":9583,"status":105,"phases":10531,"primaryCompletion":9338,"start":192,"enrollment":207,"conditions":10532,"interventions":10533},[],[21],[9365,9442,9310,9366],{"nctId":9588,"briefTitle":9589,"status":105,"phases":10535,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":10536,"interventions":10537},[],[170],[9365,9331,9593,9310,9350,9403],{"intervention":9403,"totalTrials":2452,"cells":10539},{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10546,"PHASE4":10548,"NA":10550},{"trials":10541,"activeCount":99},[],{"trials":10543,"activeCount":99},[],{"trials":10545,"activeCount":99},[],{"trials":10547,"activeCount":99},[],{"trials":10549,"activeCount":99},[],{"trials":10551,"activeCount":99},[10552,10556,10560,10564,10568,10572,10576,10580,10587,10591],{"nctId":9398,"briefTitle":9399,"status":105,"phases":10553,"primaryCompletion":9338,"start":464,"enrollment":33,"conditions":10554,"interventions":10555},[],[15],[9365,9310,9342,9403],{"nctId":9681,"briefTitle":9682,"status":105,"phases":10557,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":10558,"interventions":10559},[],[18],[9330,9365,9331,9526,9333,9403],{"nctId":10149,"briefTitle":10150,"status":105,"phases":10561,"primaryCompletion":9338,"completion":9338,"start":10152,"enrollment":219,"conditions":10562,"interventions":10563},[],[15],[9562,9342,9403,10155],{"nctId":9692,"briefTitle":9693,"status":105,"phases":10565,"primaryCompletion":9338,"completion":9338,"start":192,"enrollment":9339,"conditions":10566,"interventions":10567},[],[1248,1249,1916,9696],[9365,9331,9333,9350,9351,9403],{"nctId":9479,"briefTitle":9480,"status":105,"phases":10569,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":10570,"interventions":10571},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":9487,"briefTitle":9488,"status":105,"phases":10573,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10574,"interventions":10575},[],[168],[9365,9331,9310,9350,9403],{"nctId":9806,"briefTitle":9807,"status":105,"phases":10577,"primaryCompletion":9338,"start":9809,"enrollment":9810,"conditions":10578,"interventions":10579},[],[170],[9813,9351,9403],{"nctId":10581,"briefTitle":10582,"status":105,"phases":10583,"primaryCompletion":9338,"completion":9338,"start":10198,"enrollment":10584,"conditions":10585,"interventions":10586},"NCT00898469","Identifying Risk Factors for Bone Tissue Death in Young Patients With Acute Lymphoblastic Leukemia Treated on Clinical Trial CCG-1882",[],671,[15],[9403],{"nctId":9854,"briefTitle":9855,"status":105,"phases":10588,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":10589,"interventions":10590},[],[15],[9330,9435,9342,9350,9351,9403],{"nctId":9588,"briefTitle":9589,"status":105,"phases":10592,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":10593,"interventions":10594},[],[170],[9365,9331,9593,9310,9350,9403],{"intervention":9485,"totalTrials":324,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10603,"PHASE4":10605,"NA":10607},{"trials":10598,"activeCount":99},[],{"trials":10600,"activeCount":99},[],{"trials":10602,"activeCount":99},[],{"trials":10604,"activeCount":99},[],{"trials":10606,"activeCount":99},[],{"trials":10608,"activeCount":99},[10609,10613,10617,10621,10625,10629,10637],{"nctId":9896,"briefTitle":9897,"status":105,"phases":10610,"primaryCompletion":108,"completion":206,"start":9899,"enrollment":9517,"conditions":10611,"interventions":10612},[],[15],[9902,9903,9485,9332,9333],{"nctId":9913,"briefTitle":9914,"status":105,"phases":10614,"primaryCompletion":1038,"start":193,"enrollment":9916,"conditions":10615,"interventions":10616},[],[15],[9485,9333],{"nctId":9661,"briefTitle":9662,"status":105,"phases":10618,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":10619,"interventions":10620},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"nctId":9479,"briefTitle":9480,"status":105,"phases":10622,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":10623,"interventions":10624},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":10459,"briefTitle":10460,"status":105,"phases":10626,"primaryCompletion":9338,"start":9490,"enrollment":2317,"conditions":10627,"interventions":10628},[],[15],[9485,9350],{"nctId":10630,"briefTitle":10631,"status":105,"phases":10632,"primaryCompletion":1038,"completion":248,"start":1143,"enrollment":10633,"conditions":10634,"interventions":10635},"NCT00003096","Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors",[],88,[196,197],[10636,9526,9485,9442],"DNA ploidy analysis",{"nctId":10638,"briefTitle":10639,"status":105,"phases":10640,"primaryCompletion":9371,"start":8558,"enrollment":207,"conditions":10641,"interventions":10642},"NCT01232842","Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia",[],[15],[9485],{"intervention":9343,"totalTrials":3501,"cells":10644},{"EARLY_PHASE1":10645,"PHASE1":10647,"PHASE2":10649,"PHASE3":10651,"PHASE4":10653,"NA":10655},{"trials":10646,"activeCount":99},[],{"trials":10648,"activeCount":99},[],{"trials":10650,"activeCount":99},[],{"trials":10652,"activeCount":99},[],{"trials":10654,"activeCount":99},[],{"trials":10656,"activeCount":99},[10657,10661,10665,10671,10675],{"nctId":9616,"briefTitle":9617,"status":105,"phases":10658,"primaryCompletion":9338,"start":9386,"enrollment":9619,"conditions":10659,"interventions":10660},[],[18],[9331,9351,9374,9343,9428],{"nctId":9335,"briefTitle":9336,"status":105,"phases":10662,"primaryCompletion":9338,"start":464,"enrollment":9339,"conditions":10663,"interventions":10664},[],[15],[9310,9342,9343],{"nctId":10666,"briefTitle":10667,"status":105,"phases":10668,"primaryCompletion":9371,"start":404,"enrollment":11,"conditions":10669,"interventions":10670},"NCT01550393","Biomarkers in Urine Samples From Patients With Wilms Tumor",[],[170],[9343],{"nctId":9494,"briefTitle":9495,"status":105,"phases":10672,"primaryCompletion":9338,"start":9490,"enrollment":207,"conditions":10673,"interventions":10674},[],[170],[9310,9343,9366,9428],{"nctId":9723,"briefTitle":9724,"status":105,"phases":10676,"primaryCompletion":9338,"completion":9338,"start":8628,"enrollment":207,"conditions":10677,"interventions":10678},[],[15],[9331,9343],{"intervention":9332,"totalTrials":3501,"cells":10680},{"EARLY_PHASE1":10681,"PHASE1":10683,"PHASE2":10685,"PHASE3":10687,"PHASE4":10689,"NA":10691},{"trials":10682,"activeCount":99},[],{"trials":10684,"activeCount":99},[],{"trials":10686,"activeCount":99},[],{"trials":10688,"activeCount":99},[],{"trials":10690,"activeCount":99},[],{"trials":10692,"activeCount":99},[10693,10697,10701,10705,10709],{"nctId":9325,"briefTitle":9326,"status":105,"phases":10694,"primaryCompletion":2107,"completion":2107,"start":1219,"enrollment":125,"conditions":10695,"interventions":10696},[],[21],[9330,9331,9310,9332,9333],{"nctId":9896,"briefTitle":9897,"status":105,"phases":10698,"primaryCompletion":108,"completion":206,"start":9899,"enrollment":9517,"conditions":10699,"interventions":10700},[],[15],[9902,9903,9485,9332,9333],{"nctId":9479,"briefTitle":9480,"status":105,"phases":10702,"primaryCompletion":9371,"start":967,"enrollment":235,"conditions":10703,"interventions":10704},[],[35,9483,170,6428,18,716,21],[9330,9485,9310,9332,9333,9351,9403],{"nctId":9843,"briefTitle":9844,"status":105,"phases":10706,"primaryCompletion":9846,"completion":9338,"start":8784,"enrollment":2268,"conditions":10707,"interventions":10708},[],[15],[9330,9332,9342,9351],{"nctId":9576,"briefTitle":9577,"status":105,"phases":10710,"primaryCompletion":9338,"start":8972,"enrollment":207,"conditions":10711,"interventions":10712},[],[15],[9310,9332,9351,9443,9428],{"intervention":9442,"totalTrials":3501,"cells":10714},{"EARLY_PHASE1":10715,"PHASE1":10717,"PHASE2":10719,"PHASE3":10721,"PHASE4":10723,"NA":10725},{"trials":10716,"activeCount":99},[],{"trials":10718,"activeCount":99},[],{"trials":10720,"activeCount":99},[],{"trials":10722,"activeCount":99},[],{"trials":10724,"activeCount":99},[],{"trials":10726,"activeCount":99},[10727,10731,10735,10739,10743],{"nctId":9675,"briefTitle":9676,"status":105,"phases":10728,"primaryCompletion":9338,"start":9598,"enrollment":9339,"conditions":10729,"interventions":10730},[],[21],[9330,9331,9442,9342,9351,9366],{"nctId":9437,"briefTitle":9438,"status":105,"phases":10732,"primaryCompletion":9371,"start":8972,"enrollment":3501,"conditions":10733,"interventions":10734},[],[18],[9442,9310,9342,9333,9443],{"nctId":10630,"briefTitle":10631,"status":105,"phases":10736,"primaryCompletion":1038,"completion":248,"start":1143,"enrollment":10633,"conditions":10737,"interventions":10738},[],[196,197],[10636,9526,9485,9442],{"nctId":9542,"briefTitle":9543,"status":105,"phases":10740,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":10741,"interventions":10742},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":9582,"briefTitle":9583,"status":105,"phases":10744,"primaryCompletion":9338,"start":192,"enrollment":207,"conditions":10745,"interventions":10746},[],[21],[9365,9442,9310,9366],{"intervention":9526,"totalTrials":1449,"cells":10748},{"EARLY_PHASE1":10749,"PHASE1":10751,"PHASE2":10753,"PHASE3":10755,"PHASE4":10757,"NA":10759},{"trials":10750,"activeCount":99},[],{"trials":10752,"activeCount":99},[],{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[],{"trials":10760,"activeCount":99},[10761,10765,10769],{"nctId":9681,"briefTitle":9682,"status":105,"phases":10762,"primaryCompletion":9338,"completion":9338,"start":4974,"enrollment":9684,"conditions":10763,"interventions":10764},[],[18],[9330,9365,9331,9526,9333,9403],{"nctId":10630,"briefTitle":10631,"status":105,"phases":10766,"primaryCompletion":1038,"completion":248,"start":1143,"enrollment":10633,"conditions":10767,"interventions":10768},[],[196,197],[10636,9526,9485,9442],{"nctId":9521,"briefTitle":9522,"status":105,"phases":10770,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":10771,"interventions":10772},[],[21],[9330,9526,9310,9333,9351,9527],{"intervention":9443,"totalTrials":1449,"cells":10774},{"EARLY_PHASE1":10775,"PHASE1":10777,"PHASE2":10779,"PHASE3":10781,"PHASE4":10783,"NA":10785},{"trials":10776,"activeCount":99},[],{"trials":10778,"activeCount":99},[],{"trials":10780,"activeCount":99},[],{"trials":10782,"activeCount":99},[],{"trials":10784,"activeCount":99},[],{"trials":10786,"activeCount":99},[10787,10791,10795],{"nctId":9437,"briefTitle":9438,"status":105,"phases":10788,"primaryCompletion":9371,"start":8972,"enrollment":3501,"conditions":10789,"interventions":10790},[],[18],[9442,9310,9342,9333,9443],{"nctId":10165,"briefTitle":10166,"status":105,"phases":10792,"primaryCompletion":9371,"start":967,"enrollment":9448,"conditions":10793,"interventions":10794},[],[21],[9342,9443],{"nctId":9576,"briefTitle":9577,"status":105,"phases":10796,"primaryCompletion":9338,"start":8972,"enrollment":207,"conditions":10797,"interventions":10798},[],[15],[9310,9332,9351,9443,9428],{"intervention":9435,"totalTrials":2365,"cells":10800},{"EARLY_PHASE1":10801,"PHASE1":10803,"PHASE2":10805,"PHASE3":10807,"PHASE4":10809,"NA":10811},{"trials":10802,"activeCount":99},[],{"trials":10804,"activeCount":99},[],{"trials":10806,"activeCount":99},[],{"trials":10808,"activeCount":99},[],{"trials":10810,"activeCount":99},[],{"trials":10812,"activeCount":99},[10813,10817],{"nctId":9430,"briefTitle":9431,"status":105,"phases":10814,"primaryCompletion":9338,"start":1620,"enrollment":2452,"conditions":10815,"interventions":10816},[],[35],[9310,9435,9342],{"nctId":9854,"briefTitle":9855,"status":105,"phases":10818,"primaryCompletion":352,"start":9516,"enrollment":384,"conditions":10819,"interventions":10820},[],[15],[9330,9435,9342,9350,9351,9403],{"intervention":9562,"totalTrials":2365,"cells":10822},{"EARLY_PHASE1":10823,"PHASE1":10825,"PHASE2":10827,"PHASE3":10829,"PHASE4":10831,"NA":10833},{"trials":10824,"activeCount":99},[],{"trials":10826,"activeCount":99},[],{"trials":10828,"activeCount":99},[],{"trials":10830,"activeCount":99},[],{"trials":10832,"activeCount":99},[],{"trials":10834,"activeCount":99},[10835,10839],{"nctId":10149,"briefTitle":10150,"status":105,"phases":10836,"primaryCompletion":9338,"completion":9338,"start":10152,"enrollment":219,"conditions":10837,"interventions":10838},[],[15],[9562,9342,9403,10155],{"nctId":9556,"briefTitle":9557,"status":105,"phases":10840,"primaryCompletion":9475,"completion":9475,"start":464,"enrollment":9559,"conditions":10841,"interventions":10842},[],[170],[9365,9310,9562,9342,9333,9351,9366],{"intervention":9547,"totalTrials":2365,"cells":10844},{"EARLY_PHASE1":10845,"PHASE1":10847,"PHASE2":10849,"PHASE3":10851,"PHASE4":10853,"NA":10855},{"trials":10846,"activeCount":99},[],{"trials":10848,"activeCount":99},[],{"trials":10850,"activeCount":99},[],{"trials":10852,"activeCount":99},[],{"trials":10854,"activeCount":99},[],{"trials":10856,"activeCount":99},[10857,10861],{"nctId":9542,"briefTitle":9543,"status":105,"phases":10858,"primaryCompletion":9338,"start":404,"enrollment":5770,"conditions":10859,"interventions":10860},[],[170],[9330,9442,9310,9547,9342,9351,9374],{"nctId":9967,"briefTitle":9968,"status":105,"phases":10862,"primaryCompletion":9338,"start":9490,"enrollment":2452,"conditions":10863,"interventions":10864},[],[15],[9547,9342,9333,9350],{"intervention":10866,"totalTrials":2060,"cells":10867},"in vitro sensitivity-directed chemotherapy",{"EARLY_PHASE1":10868,"PHASE1":10870,"PHASE2":10872,"PHASE3":10874,"PHASE4":10876,"NA":10878},{"trials":10869,"activeCount":99},[],{"trials":10871,"activeCount":99},[],{"trials":10873,"activeCount":99},[],{"trials":10875,"activeCount":99},[],{"trials":10877,"activeCount":99},[],{"trials":10879,"activeCount":99},[10880],{"nctId":10881,"briefTitle":10882,"status":105,"phases":10883,"primaryCompletion":9338,"start":9416,"enrollment":2452,"conditions":10884,"interventions":10885},"NCT01395628","Cell Samples From Patients With Leukemia",[],[15],[10866],{"intervention":9902,"totalTrials":2060,"cells":10887},{"EARLY_PHASE1":10888,"PHASE1":10890,"PHASE2":10892,"PHASE3":10894,"PHASE4":10896,"NA":10898},{"trials":10889,"activeCount":99},[],{"trials":10891,"activeCount":99},[],{"trials":10893,"activeCount":99},[],{"trials":10895,"activeCount":99},[],{"trials":10897,"activeCount":99},[],{"trials":10899,"activeCount":99},[10900],{"nctId":9896,"briefTitle":9897,"status":105,"phases":10901,"primaryCompletion":108,"completion":206,"start":9899,"enrollment":9517,"conditions":10902,"interventions":10903},[],[15],[9902,9903,9485,9332,9333],{"intervention":9903,"totalTrials":2060,"cells":10905},{"EARLY_PHASE1":10906,"PHASE1":10908,"PHASE2":10910,"PHASE3":10912,"PHASE4":10914,"NA":10916},{"trials":10907,"activeCount":99},[],{"trials":10909,"activeCount":99},[],{"trials":10911,"activeCount":99},[],{"trials":10913,"activeCount":99},[],{"trials":10915,"activeCount":99},[],{"trials":10917,"activeCount":99},[10918],{"nctId":9896,"briefTitle":9897,"status":105,"phases":10919,"primaryCompletion":108,"completion":206,"start":9899,"enrollment":9517,"conditions":10920,"interventions":10921},[],[15],[9902,9903,9485,9332,9333],{"intervention":10923,"totalTrials":2060,"cells":10924},"quizartinib",{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10929,"PHASE3":10931,"PHASE4":10933,"NA":10935},{"trials":10926,"activeCount":99},[],{"trials":10928,"activeCount":99},[],{"trials":10930,"activeCount":99},[],{"trials":10932,"activeCount":99},[],{"trials":10934,"activeCount":99},[],{"trials":10936,"activeCount":99},[10937],{"nctId":10938,"briefTitle":10939,"status":105,"phases":10940,"primaryCompletion":9338,"completion":9338,"start":8628,"enrollment":2452,"conditions":10941,"interventions":10943},"NCT01576185","Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia",[],[10942],"Childhood Acute Myeloid Leukemia\u002FOther Myeloid Malignancies",[10923,10944],"sorafenib tosylate",{"intervention":10944,"totalTrials":2060,"cells":10946},{"EARLY_PHASE1":10947,"PHASE1":10949,"PHASE2":10951,"PHASE3":10953,"PHASE4":10955,"NA":10957},{"trials":10948,"activeCount":99},[],{"trials":10950,"activeCount":99},[],{"trials":10952,"activeCount":99},[],{"trials":10954,"activeCount":99},[],{"trials":10956,"activeCount":99},[],{"trials":10958,"activeCount":99},[10959],{"nctId":10938,"briefTitle":10939,"status":105,"phases":10960,"primaryCompletion":9338,"completion":9338,"start":8628,"enrollment":2452,"conditions":10961,"interventions":10962},[],[10942],[10923,10944],{"intervention":9667,"totalTrials":2060,"cells":10964},{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10969,"PHASE3":10971,"PHASE4":10973,"NA":10975},{"trials":10966,"activeCount":99},[],{"trials":10968,"activeCount":99},[],{"trials":10970,"activeCount":99},[],{"trials":10972,"activeCount":99},[],{"trials":10974,"activeCount":99},[],{"trials":10976,"activeCount":99},[10977],{"nctId":9661,"briefTitle":9662,"status":105,"phases":10978,"primaryCompletion":9338,"completion":9338,"start":8972,"enrollment":5770,"conditions":10979,"interventions":10980},[],[23,9665],[9330,9331,9485,9667,9333,9351,9428],{"intervention":10155,"totalTrials":2060,"cells":10982},{"EARLY_PHASE1":10983,"PHASE1":10985,"PHASE2":10987,"PHASE3":10989,"PHASE4":10991,"NA":10993},{"trials":10984,"activeCount":99},[],{"trials":10986,"activeCount":99},[],{"trials":10988,"activeCount":99},[],{"trials":10990,"activeCount":99},[],{"trials":10992,"activeCount":99},[],{"trials":10994,"activeCount":99},[10995],{"nctId":10149,"briefTitle":10150,"status":105,"phases":10996,"primaryCompletion":9338,"completion":9338,"start":10152,"enrollment":219,"conditions":10997,"interventions":10998},[],[15],[9562,9342,9403,10155],{"intervention":11000,"totalTrials":2060,"cells":11001},"glutamine",{"EARLY_PHASE1":11002,"PHASE1":11004,"PHASE2":11006,"PHASE3":11008,"PHASE4":11010,"NA":11012},{"trials":11003,"activeCount":99},[],{"trials":11005,"activeCount":99},[],{"trials":11007,"activeCount":99},[],{"trials":11009,"activeCount":99},[],{"trials":11011,"activeCount":99},[],{"trials":11013,"activeCount":99},[11014],{"nctId":11015,"briefTitle":11016,"status":647,"phases":11017,"start":1203,"enrollment":99,"conditions":11018,"interventions":11020},"NCT00334984","Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma",[92],[11019,21],"Childhood Malignant Fibrous Histiocytoma of Bone",[11000],{"intervention":9813,"totalTrials":2060,"cells":11022},{"EARLY_PHASE1":11023,"PHASE1":11025,"PHASE2":11027,"PHASE3":11029,"PHASE4":11031,"NA":11033},{"trials":11024,"activeCount":99},[],{"trials":11026,"activeCount":99},[],{"trials":11028,"activeCount":99},[],{"trials":11030,"activeCount":99},[],{"trials":11032,"activeCount":99},[],{"trials":11034,"activeCount":99},[11035],{"nctId":9806,"briefTitle":9807,"status":105,"phases":11036,"primaryCompletion":9338,"start":9809,"enrollment":9810,"conditions":11037,"interventions":11038},[],[170],[9813,9351,9403],{"intervention":10636,"totalTrials":2060,"cells":11040},{"EARLY_PHASE1":11041,"PHASE1":11043,"PHASE2":11045,"PHASE3":11047,"PHASE4":11049,"NA":11051},{"trials":11042,"activeCount":99},[],{"trials":11044,"activeCount":99},[],{"trials":11046,"activeCount":99},[],{"trials":11048,"activeCount":99},[],{"trials":11050,"activeCount":99},[],{"trials":11052,"activeCount":99},[11053],{"nctId":10630,"briefTitle":10631,"status":105,"phases":11054,"primaryCompletion":1038,"completion":248,"start":1143,"enrollment":10633,"conditions":11055,"interventions":11056},[],[196,197],[10636,9526,9485,9442],{"intervention":9527,"totalTrials":2060,"cells":11058},{"EARLY_PHASE1":11059,"PHASE1":11061,"PHASE2":11063,"PHASE3":11065,"PHASE4":11067,"NA":11069},{"trials":11060,"activeCount":99},[],{"trials":11062,"activeCount":99},[],{"trials":11064,"activeCount":99},[],{"trials":11066,"activeCount":99},[],{"trials":11068,"activeCount":99},[],{"trials":11070,"activeCount":99},[11071],{"nctId":9521,"briefTitle":9522,"status":105,"phases":11072,"primaryCompletion":573,"completion":573,"start":8972,"enrollment":691,"conditions":11073,"interventions":11074},[],[21],[9330,9526,9310,9333,9351,9527],{"intervention":9833,"totalTrials":2060,"cells":11076},{"EARLY_PHASE1":11077,"PHASE1":11079,"PHASE2":11081,"PHASE3":11083,"PHASE4":11085,"NA":11087},{"trials":11078,"activeCount":99},[],{"trials":11080,"activeCount":99},[],{"trials":11082,"activeCount":99},[],{"trials":11084,"activeCount":99},[],{"trials":11086,"activeCount":99},[],{"trials":11088,"activeCount":99},[11089],{"nctId":9827,"briefTitle":9828,"status":105,"phases":11090,"primaryCompletion":9338,"completion":9338,"start":2392,"enrollment":9830,"conditions":11091,"interventions":11092},[],[5717,128,129,32,130,132],[9351,9833,9330],{"intervention":9982,"totalTrials":2060,"cells":11094},{"EARLY_PHASE1":11095,"PHASE1":11097,"PHASE2":11099,"PHASE3":11101,"PHASE4":11103,"NA":11105},{"trials":11096,"activeCount":99},[],{"trials":11098,"activeCount":99},[],{"trials":11100,"activeCount":99},[],{"trials":11102,"activeCount":99},[],{"trials":11104,"activeCount":99},[],{"trials":11106,"activeCount":99},[11107],{"nctId":9977,"briefTitle":9978,"status":105,"phases":11108,"primaryCompletion":650,"completion":248,"start":283,"enrollment":1682,"conditions":11109,"interventions":11110},[],[15,2309,21],[9982,9983,9333],{"intervention":9983,"totalTrials":2060,"cells":11112},{"EARLY_PHASE1":11113,"PHASE1":11115,"PHASE2":11117,"PHASE3":11119,"PHASE4":11121,"NA":11123},{"trials":11114,"activeCount":99},[],{"trials":11116,"activeCount":99},[],{"trials":11118,"activeCount":99},[],{"trials":11120,"activeCount":99},[],{"trials":11122,"activeCount":99},[],{"trials":11124,"activeCount":99},[11125],{"nctId":9977,"briefTitle":9978,"status":105,"phases":11126,"primaryCompletion":650,"completion":248,"start":283,"enrollment":1682,"conditions":11127,"interventions":11128},[],[15,2309,21],[9982,9983,9333],{"intervention":1754,"totalTrials":2060,"cells":11130},{"EARLY_PHASE1":11131,"PHASE1":11133,"PHASE2":11135,"PHASE3":11137,"PHASE4":11139,"NA":11141},{"trials":11132,"activeCount":99},[],{"trials":11134,"activeCount":99},[],{"trials":11136,"activeCount":99},[],{"trials":11138,"activeCount":99},[],{"trials":11140,"activeCount":99},[],{"trials":11142,"activeCount":99},[11143],{"nctId":1747,"briefTitle":1748,"status":105,"phases":11144,"primaryCompletion":1038,"start":1750,"enrollment":1751,"conditions":11145,"interventions":11146},[92],[15],[1754,210,288,211,212,316,305,117],{"intervention":9593,"totalTrials":2060,"cells":11148},{"EARLY_PHASE1":11149,"PHASE1":11151,"PHASE2":11153,"PHASE3":11155,"PHASE4":11157,"NA":11159},{"trials":11150,"activeCount":99},[],{"trials":11152,"activeCount":99},[],{"trials":11154,"activeCount":99},[],{"trials":11156,"activeCount":99},[],{"trials":11158,"activeCount":99},[],{"trials":11160,"activeCount":99},[11161],{"nctId":9588,"briefTitle":9589,"status":105,"phases":11162,"primaryCompletion":9338,"start":1620,"enrollment":9448,"conditions":11163,"interventions":11164},[],[170],[9365,9331,9593,9310,9350,9403],{"intervention":10088,"totalTrials":2060,"cells":11166},{"EARLY_PHASE1":11167,"PHASE1":11169,"PHASE2":11171,"PHASE3":11173,"PHASE4":11175,"NA":11177},{"trials":11168,"activeCount":99},[],{"trials":11170,"activeCount":99},[],{"trials":11172,"activeCount":99},[],{"trials":11174,"activeCount":99},[],{"trials":11176,"activeCount":99},[],{"trials":11178,"activeCount":99},[11179],{"nctId":10083,"briefTitle":9495,"status":105,"phases":11180,"primaryCompletion":9371,"start":1620,"enrollment":10085,"conditions":11181,"interventions":11182},[],[170],[9330,10088],{"intervention":11184,"totalTrials":2060,"cells":11185},"Traumeel S",{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11192,"PHASE4":11194,"NA":11196},{"trials":11187,"activeCount":99},[],{"trials":11189,"activeCount":99},[],{"trials":11191,"activeCount":99},[],{"trials":11193,"activeCount":99},[],{"trials":11195,"activeCount":99},[],{"trials":11197,"activeCount":99},[11198],{"nctId":11199,"briefTitle":11200,"status":105,"phases":11201,"primaryCompletion":11202,"completion":1029,"start":298,"enrollment":11203,"conditions":11204,"interventions":11206},"NCT00080873","Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation",[92],"2006-11",195,[170,15,23,18,11205,21],"Oral Complications",[11184]]